



JR-14,000-CON

PATENT

5 ISOLATED GENOMIC POLYNUCLEOTIDE FRAGMENTS FROM CHROMOSOME 7

PRIORITY CLAIM

This application claims priority under 35 U.S.C. §19(e) to provisional application serial no. 60/234,422, filed September 21, 2000 and is a continuation of application serial no. 09/957,956, filed
10 September 21, 2001, the contents of which are incorporated herein by reference.

FIELD OF THE INVENTION

The invention is directed to isolated genomic polynucleotide fragments that encode human SNARE YKT6, human ~~liver~~-glucokinase, human adipocyte enhancer binding protein 1 (AEBP1) and
15 DNA directed 50kD regulatory subunit (POLD2), vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain SNARE YKT6, human ~~liver~~-glucokinase, AEBP1 protein and POLD2 and to diagnose, treat, prevent and/or ameliorate a
20 pathological disorder.

BACKGROUND OF THE INVENTION

Chromosome 7 contains genes encoding, for example, epidermal growth factor receptor, collagen-1-Alpha-1-chain, SNARE YKT6, human ~~liver~~-glucokinase, human adipocyte enhancer binding protein 1 and DNA polymerase delta small subunit (POLD2). SNARE YKT6, human ~~liver~~
25 glucokinase, human adipocyte enhancer binding protein 1 and DNA polymerase delta small subunit (POLD2) are discussed in further detail below.

SNARE YKT6

SNARE YKT6, a substrate for prenylation, is essential for vesicle-associated endoplasmic
30 reticulum-Golgi transport (McNew, J.A. et al. J. Biol. Chem. 272, 17776-17783, 1997). It has been found that depletion of this function stops cell growth and manifests a transport block at the endoplasmic reticulum level.

Human ~~Liver~~-Glucokinase

35 Human ~~liver~~-glucokinase (ATP:D-hexose 6-phosphotransferase) is thought to play a major role in glucose sensing in pancreatic islet beta cells (Tanizawa et al., 1992, Mol. Endocrinol. 6:1070-1081) and in the liver. Glucokinase defects have been observed in patients with noninsulin-dependent diabetes mellitus (NIDDM) patients. Mutations in the human ~~liver~~-glucokinase gene are thought to play a role in the early onset of NIDDM. The gene has been shown by Southern Blotting to exist as a

single copy on chromosome 7. It was further found to contain 10 exons including one exon expressed in islet beta cells and the other expressed in liver.

Human Adipocyte Enhancer Binding Protein₁

The adipocyte-enhancer binding protein ₁(AEBP₁) is a transcriptional repressor having carboxypeptidase B-like activity which binds to a regulatory sequence (adipocyte enhancer 1, AE-1) located in the proximal promoter region of the adipose P2 (aP2) gene, which encodes the adipocyte fatty acid binding protein (Muisse et al., 1999, Biochem. J. 343:341-345). B-like carboxypeptidases remove C-terminal arginine and lysine residues and participate in the release of active peptides, such as insulin, alter receptor specificity for polypeptides and terminate polypeptide activity (Skidgel, 1988, Trends Pharmacol. Sci. 9:299-304). For example, they are thought to be involved in the onset of obesity (Naggert et al., 1995, Nat. Genet. 10:1335-1342). It has been reported that obese and hyperglycemic mice homozygous for the *fat* mutation contain a mutation in the CP-E gene.

Full length cDNA clones encoding AEBP₁ have been isolated from human osteoblast and adipose tissue (Ohno et al., 1996, Biochem. Biophys Res. Commun. 228:411-414). Two forms have been found to exist due to alternative splicing. This gene appears to play a significant role in regulating adipogenesis. In addition to playing a role in obesity, adipogenesis may play a role in osteopenic disorders. It has been postulated that adipogenesis inhibitors may be used to treat osteopenic disorders (Nuttall et al., 2000, Bone 27:177-184).

DNA Polymerase Delta Small Subunit (POLD2)

DNA polymerase delta core is a heterodimeric enzyme with a catalytic subunit of 125 kD and a second subunit of 50 kD and is an essential enzyme for DNA replication and DNA repair (Zhang et al., 1995, Genomics 29:179-186). cDNAs encoding the small subunit have been cloned and sequenced. The gene for the small subunit has been localized to human chromosome 7 via PCR analysis of a panel of human-hamster hybrid cell lines. However, the genomic DNA has not been isolated and the exact location on chromosome 7 has not been determined.

OBJECTS OF THE INVENTION

Although cDNAs encoding the above-disclosed proteins have been isolated, their location on chromosome 7 has not been determined. Furthermore, genomic DNA encoding these polypeptides have not been isolated. Noncoding sequences can play a significant role in regulating the expression of polypeptides as well as the processing of RNA encoding these polypeptides.

There is clearly a need for obtaining genomic polynucleotide sequences encoding these polypeptides. Therefore, it is an object of the invention to isolate such genomic polynucleotide sequences.

SUMMARY OF THE INVENTION

The invention is directed to an isolated genomic polynucleotide, said polynucleotide obtainable from human chromosome 7 having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polynucleotide encoding a polypeptide selected from the group consisting of human SNARE YKT6 depicted in SEQ ID NO:1, human ~~liver~~-glucokinase depicted in SEQ ID NO:2, human adipocyte enhancer binding protein 1 (AEBP1) depicted in SEQ ID NO:3 and DNA directed 50kD regulatory subunit (POLD2) depicted in SEQ ID NO:4;

(b) a polynucleotide selected from the group consisting of SEQ ID NO:5 which encodes human SNARE YKT6 depicted in SEQ ID NO:1, SEQ ID NO:6 which encodes human ~~liver~~ glucokinase depicted in SEQ ID NO:2, SEQ ID NO:7-8 which encodes human adipocyte enhancer binding protein 1 depicted in SEQ ID NO:3 and SEQ ID NO:8-7 which encodes DNA directed 50kD regulatory subunit (POLD2) depicted in SEQ ID NO:4;

(c) a polynucleotide which is a variant of SEQ ID NOS:5, 6, 7, or 8;

(d) a polynucleotide which is an allelic variant of SEQ ID NOS:5, 6, 7, or 8;

(e) a polynucleotide which encodes a variant of SEQ ID NOS:1, 2, 3, or 4;

(f) a polynucleotide which hybridizes to any one of the polynucleotides specified in (a)-(e);

(g) a polynucleotide that is a reverse complement to the polynucleotides specified in (a)-(f) and

(h) containing at least 10 transcription factor binding sites selected from the group consisting of AP1FJ-Q2, AP1-C, AP1-Q2, AP1-Q4, AP4-Q5, AP4-Q6, ARNT-01, CEBP-01, CETS1P54-01, CREL-01, DELTAEF1-01, FREAC7-01, GATA1-02, GATA1-03, GATA1-04, GATA1-06, GATA2-02, GATA3-02, GATA-C, GC-01, GFII-01, HFH2-01, HFH3-01, HFH8-01, IK2-01, LMO2COM-01, LMO2COM-02, LYF1-01, MAX-01, NKX25-01, NMYC-01, S8-01, SOX5-01, SP1-Q6, SAEBP1-01, SRV-02, STAT-01, TATA-01, TCF11-01, USF-01, USF-C and USF-Q6 as well as nucleic acid constructs, expression vectors and host cells containing these polynucleotide sequences.

The polynucleotides of the present invention may be used for the manufacture of a gene therapy for the prevention, treatment or amelioration of a medical condition by adding an amount of a composition comprising said polynucleotide effective to prevent, treat or ameliorate said medical condition.

The invention is further directed to obtaining these polypeptides by

(a) culturing host cells comprising these sequences under conditions that provide for the expression of said polypeptide and

(b) recovering said expressed polypeptide.

The polypeptides obtained may be used to produce antibodies by

(a) optionally conjugating said polypeptide to a carrier protein;

(b) immunizing a host animal with said polypeptide or peptide-carrier protein conjugate of step (b) with an adjuvant and

(c) obtaining antibody from said immunized host animal.

The invention is further directed to polynucleotides that hybridize to noncoding regions of said polynucleotide sequences as well as antisense oligonucleotides to these polynucleotides as well as antisense mimetics. The antisense oligonucleotides or mimetics may be used for the manufacture of a medicament for prevention, treatment or amelioration of a medical condition. The invention is further directed to kits comprising these polynucleotides and kits comprising these antisense oligonucleotides or mimetics.

In a specific embodiment, the noncoding regions are transcription regulatory regions. The transcription regulatory regions may be used to produce a heterologous peptide by expressing in a host cell, said transcription regulatory region operably linked to a polynucleotide encoding the heterologous polypeptide and recovering the expressed heterologous polypeptide.

The polynucleotides of the present invention may be used to diagnose a pathological condition in a subject comprising

(a) determining the presence or absence of a mutation in the polynucleotides of the present invention and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

DETAILED DESCRIPTION OF THE INVENTION

The invention is directed to isolated genomic polynucleotide fragments that encode human SNARE YKT6, human liver-glucokinase, human adipocyte enhancer binding protein 1 and DNA directed 50kD regulatory subunit (POLD2), which in a specific embodiment are the SNARE YKT6, human liver-glucokinase, human adipocyte enhancer binding protein 1 and DNA directed 50kD regulatory subunit (POLD2) genes, as well as vectors and hosts containing these fragments and polynucleotide fragments hybridizing to noncoding regions, as well as antisense oligonucleotides to these fragments.

As defined herein, a "gene" is the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region, as well as intervening sequences (introns) between individual coding segments (exons).

As defined herein "isolated" -refers to material removed from its original environment and is thus altered "by the hand of man" from its natural state. An isolated polynucleotide can be part of a vector, a composition of matter or could be contained within a cell as long as the cell is not the original environment of the polynucleotide.

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

The polynucleotides of the present invention may be in the form of RNA or in the form of DNA, which DNA includes genomic DNA and synthetic DNA. The DNA may be double-stranded or single-stranded and if single stranded may be the coding strand or non-coding strand. The human
5 ~~snare~~ SNARE YKT6 polypeptide has the amino acid sequence depicted in SEQ ID NO:1:-

KLYSLSVLYKGEAKVLLKAAAYDVSSSEFFQRSSVQEFMTFTSQLIVERSSSKGTRASVKEQDYLCH
VYVRNDSLAVVIADNEYPSRVAFTLLEKVLDEFKQVDRIDWPVGSPATHYPALDGHLSTRYQNP
READPMTKVQAELETKIILHNTMESLLERGEKLDDLVSKEVLGTQSKAFYKTARKQNSCCAIM

10 and is encoded by the genomic DNA sequence shown in SEQ ID NO:5:-

CCAGACATAGGCAAGGCGCAAGGTGATACAGTAGGCAGCCACCATGGGGGGCCAGGAGGCTCC
AGCAGAGGGCCACACAACCAGCCCAGAATCCAGGACAGAGAGCTGGAATGGAGACAGGGAAG
CCAGATACCAGGCCAGACTGGCCAGGTGCTACAGGCCTGTGGGCCAGGCCAGGCTTGGGGAC
15 TTCGTCTCTGGGTGTGAAGGAGACAGGCACCCCTGAGGCCTTCCCTCTGCATCTCCAGCCCAAG
CTAAGCGCAAACCTCTTAGGTTGGAGTAAGGAGTAACCCCTTGCCAAGTTTCTCCTGTCTCTCAG
GCTCCACCCACCACCTATGCTGCCTGGCCCCATGGGGCACACGCTCAGGCCCAGCCTGGGAAA
GCAACTGCACCTGCCTGTGCTATGCTGGCCCTTCTCAGCCTCAATGCCCTCCTCCCTCCCCGACG
CACCCCTCGTGGCCCCCGCTGGGCCCCCTGATGCACCTCATGTCTCCATGGCAACCTGCTCAGA
20 GTGTGGCCCTGCCCTTGGCTCCCCCTCCACACCTGTGTCCCAGGCAGTGCCACGGCACTTTCTTA
AACAGAAGGATGGGCTTCAAAACAGTCCCAGACACTAAACACACCTGCATTTTGGGTCCAAG
TAACTTCTGACAAGACGAGTGCCCCCTACACACTCTCAGTCCTATCCACTATGGGCAAGGAGCC
TGAAGGATCCCCCAGAAGTGGCTAAAGCCCTCAGTCTCCTCCTCCACCCTGAGCACCTTCACGC
GGCAGAGTGGCCCTGGATGTCAGCTTCTTGCTCCCCATGGTCTGCACCTGGACAGGTGCTCTC
25 AGGTGTGTGGGTGGGCAGGTGGCAGGTCCCAAGAGCCAGGTGCAAAGAATCTAGGCCAGTGC
CCACGAGTGTGTCAGTGTCTGTCCCCAGCATGGTATCTAGGGCTCCACTTGCCTATCAGCTGTA
ATCGGAGGAGGCTTTCCAGGCCAGGCCTCCCCCAGGAAGGCTGCAGGCACTGCGGATCGTGCG
CCCTCACATGCATTATTCCTGAGGCCCTTCTGCAGATGCCATCAGGGCAGCAACTCTGATGAG
GTATTAGGGCACAGCACACAGGGCTAAGCCACCCTGTACTGGGCCAAGCGCTACAGGCCAAAA
30 AGGACACCACCGACGGGCATTTTCATTCATCGCTTTTATTTTATATATTTTGGAGAGGGAGCC
TCACTCTGTGCCCCAGGCTGGAGTGCAGTGGCGCGATCTTGGCTCACTGCAACTTCTCCCTCCT
GGGTTCAAGTGATTCTCCTGCCTCAGCCTCCCCGAGTAGCTGAGATTACAGGTGCCCCGCCACCA
TGCCAGCTAACTTTTGTATTTTAGTAGACATGGGGTTTCACCATGTTGGTCAGGCTGGTCTC
GAACTCCCGACCTCAAATGATCTGCCTACCTCAGCCTCCCAAAGTGCTGGGATTACAGGCATG
35 AGGCACTGCACCCGGGCCATTTCATCACTTTTAAATAGCACCTCTGAACAAAGCTCCCTGGGCC
ACATGACCCTAAGGGTTACCCCATCCACCCCAACCCAGGTCGGCAGGTCTCAGAACAGGA

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

AAAGCTGAGCACTGCCCAAGGCTGCTTGCTGGGCCAGTCAGAGAGGTCTCTGCCTTCCAGGAT
CAGAAGTACAGGCTGAAAGCAGCCTTGGGCCCCGCTCCCTGGGAGGCTACAGAGGCTTCAGA
GGGTTCCCTGAACTCAAAACCAGATGTGAGACTTGAATTTGACTTACCCCTGGTTCACCTCCC
AACCAAAGCAGGGGTCAGCTTTGGCTCCTCCAGGAACCAGGAAGCTTCCAGGTACCCTGTGGA
5 GCCCCCTCTGCTCCTGAAAAGTTGCCACCTGTGCTTGGTGGGATGCCAGGTGGTCTCAGATTG
ACCCTGGGGTCAGCGGTGAGGGACAGGAAGCCTACAGCGGGATCAGGATGGGGATGGGGCCT
CCTGTCCCATGGCTCTGCAGCTATGAGGCAGCTTTCCTAGGGTGGGTCTCCTGGCTGCAGCTA
AGACCAGGCAACAGGATTCAGCAATGACAGGGCTTCTTCTACTCCAGGGCTCCCTCACCTGGT
TAACAGCAAAAAAGAAAAATACAGTTCTTGCTAGCAAGGTCTATAGAAAGGAGGTGAAGGAG
10 TCAGGCCTGCAGCTACCTCTCCTGGACAGGAGCTGGTCAGGATAACTTGGACCCTTGCATGCG
GCAGGCCACAGGCACACAGCATGAGGCCACTCTCTCCCCCGGGGAAGGGCTTGGTGAAGA
AAGGATTCCCTGAAGCACAAAGAAAGCACAGGACCACTGTGAAATTTCAAGACAACCTTTAT
CCAGACAGGCGCCTCTCAAATAGAACACAGGGGAAGTTAGGCAGCAGTTACTAAAATACAGTC
TCGCCAAATGATTTACAACAGAACACAACAGGAGCAGGGGATCTGTGGGTGGGGCTGGGCTG
15 GGCCTCTATCTCACAGGGCCTGAGTCAAGCCAGCCCGCCCTGCAAGGCAGGGGCTGACCTGC
AAGCGGAGATCTCACTTCCTCTTACCCCAAATTCATACCTCCATTTTCCCCGCCCCCATCTCTCC
CCAGGGTCCTCAAGTGGGAAAGGGAGAGGTAGCATCCCTCGGATCCAGGCCCACTCCACTCCG
TCTCCGGCACCAAGTGGGCAGGCTGAGTCTGGGCCTCAAGGGGCCCTGGGCTTAGGGTATCTAT
GGCAGTAGGAAAATGACATGGACAGGCTCTTCAGGGGTAGGCTAAAGTCCTCTGGCCAGCAG
20 TACCCAGAGAAAATGGGCAGCAGCAGGTAAACCAGCCAGGAGGTGGAGTCCTCTGAACCCAC
AGCAGACCCCAACCTCCTGCCAGCCCTGCCACATTGGGGGTGAGGACCACTGAGACTCTG
GTCAGGACAGTGGGTGCTCTCAGCAGTGTGGCAAGCTCAGAGCAGAGCTCCCAAGGACCATA
CCACACTGGTTCAAAACCCATAGGTGACACCATCCCAGCAGAAGCTTCCATGGGTGCTGGATC
CCAGGGCTGCATCCTGAGCACAGGTGGGCAGACTGGAACATAACACTAGGACCCAAGGGATC
25 CAGAACATTTTAGGCCCATCTCCTGGGCTGCTCCAGCCTGTTGCCATGACTTGGGCAGTGAGT
GGGCCTCCTGCCAGGTGGCAGGGCACAGCTTAGACCAAACCCTTGGCCTCCCCCTCTGCAGCT
ACCTCTGACCAAGAAGGAAGTCTAGCAAGCCTATGCTGGCAAGACCATAGGTGGGGTGCTGGGA
ATCCTCGGGGCCGGCTGGCACCCACTCCTGGTGTCTCAAGGGAGAGACCCACTTGTTTCAAGATGC
ATAGGCCTCAGGCGGTTCAAGGCAGTCTTAGAGCCACAGAGTCAAATAAAAAATCAATTTTGA
30 GAGACCACAGCACCTGCTGCTTTGATCGTGATGTTCAAGGCAAGTTGCAAGTCAAGGCAAGT
GTCCAGAGGCCCTGGGCAGCTGAGTGCACCTGTGTTTGTATCTTCCCTGATGATGGACACTC
CCAGCTGACCATCCAAACACCAGGAAAACATCCCCCTTTCCTGGGCTCAGTTCCTAGTCTACTT
GCTGGTACGAACCCAAACCCACACACTCCCCGCCACAATGCAGCTCCTTCCAAATCCTCCACAC
AGCCACCTTTGTGGGACTTGGAAGCTGCTTAGGATGGGCCCTGCCCTCTGCGGGAAGCCAATC
35 CTAGCAGAAAGGTAAGCTAAACAACAGTCTCAGAATCTGAGACCCAGTGACT

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

GTTCCCCCCCCGCCCCAGGCCTTGGGGCCTGAAGTGGGGGGCCTGCCTGTGGCCTCTGTGGTGGGCTC
ACTCCCACCCCCAACAGTGGCCCCAGGAGAGGCTTTCCCAAGAGTCTTCAAACCTCCACCCACCC
CAGCCCTAGCATCAGGGACTCCCCACCCCCACTGGAGTGTTAATATCATTAATGTACAAATA
AGATCCAAAGATATACCAAAGATCGAGAAACAGCTGGCTCCGACCTCCCTCCACAGAGCCTT
5 CCCAGGGTTAGCTGAAAAAGAGCCCTTTGGCATCTACAGAAGCCAGTCGGAGTTTATGGTTTC
ATTTGCCCAAAAATACACCTTTGGGGACCTCAAATTCTTTCCAAGAATCACTACCACACATAT
GAATTTGAACATTCCGCCACCCTTCCACCATCCATTTCTCGCAGGAACCTTCAAAATAAAAATGG
CCAGTCTGCCCCCACTCTGGCTCCTCGTCTATGGCTGTCTCTTCTTTTCCAGGGGGCTGCAGTTCT
GATGTGAATGATGGTGGCATTCCAGCATTGGGCCTCTGGCAGGCTGCATCACATGATGGCACA
10 GCATGAGTTTTGTTTCCGGGCCTTGGAAAAAACAAGAGGAGCTGAGAAGGAGGACTGACG
AAGTAAGGGAAGCCCCAATCCTGGCAGGCGTGGCAGAGGGAGCTCCACAGGACACAGCCAGG
CAGAGAACTAGCACTAGAACAGGGTGGGGGTGGAGGCCTTGAGGGAAGCTGTCCACAAGC
AATTC CATCACCAAGCACAAAGGCGGGCCCCGGCTTCCAAAAGTAGTCTGGGATCCTTTTTCT
TTCTTTCTCACACCCCATTAATGCTATCAAAAAGTGAGTAAAATTCTACAGTTAGGCCAGG
15 TACAAACAAAGGACCAATAATACAAATGGGATTGGCAGAATATCTTAACTTTGCCCCACTCCT
GTCTTCACACAATGCTATCTGACCACCACGGTGGTGTTCCTTCCTAGAAGATGGTCCTGAGGA
CAACAGATGTGGTTCCCACTTGGGATGTGGTTTGTGGGGACCACTGTTGCCACCTTCTCTCTTG
CTTCTGGTCACAGACTATCTTCCTAATCCACCTAGCCATCTCCCTCCAATGTGCACATGAAA
GCAAATGTGTGTGGACAGACCAAGTAAATTTGTCCCTATGACTATCCAACCATGGGGCCAACAG
20 TGCCATCTCCACATAGGAAGACATGAGCACTGACCTGAGAGAAAGCGGCAGTCAGCAGCACC
CATCCTTGTCAATTAATAATTTTCTGTCAAAGGGAAATTAAGGCTTAAGAACCTCTTCAGGA
AGGCTGAATTGCTTGCATCTTAAAGACTTATGTCTACTCAGCAGAAAGAGGAATAAGATTCA
ACAGTAAATCTCTGGTGATCAGAACTTGAACCAGCCTTCCTGGACTGGGAGTAGGAGTTCAG
AAATCAGCCAGAGCAGCAGAGGGCAGAGCAGAGGCAGGAGTGGAACAAGGCCTCGGCCCCC
25 ATCGACTCCAACGGCGCCCCAAGTGAAGTGCCTCCAACCACCTGGGCCTGAGGCGCTCACCTTA
GGCTCTTGCCGCACAAGGAATCATCCACCATGATTCAACAGTCTAAGAAAGACCCGTTTCATAG
TGGAGAGTGCCAGAAGCAGCAAGCTGCGACTGCTCTCTAGAGAGAACACCCAGGAGGCAGCA
GGTGCTGGGTACTCACAGTTTTATAGAAGGCTTTAGACTGTGTTCCAGCACCTCGGATTTGG
ACACCAAGTCATCTAGCTTCTCACCTCGCTCTAACAGAGACTCCATGGTGTGTGTGCTGGACAA
30 AAAAGAAAAGAGAATCCAGCTCTGTTACGTACGTGCCCTGACATGAGCCCCTCATATTTAGT
CATGGGGGAAAGTGCTTACCTGGGTTCCTCTCCAACACACACAACTTCACCTCTAGGTGTC
GAGACTCGGTCCAAGAATAGTTACTGTCCAAGTGGATGGAACAGAACCTGGTGACATTCCCCG
TGAAATCTAGAAGATCTAACTGGGATGTAGCAGACTTCCCAAAAAGCTGTCCCCAGCACAGG
CTTAGATAACCAGCACTCCAGGAAAACCTCATATATATATATACACACACATTTATATATACAT
35 TTGTGTGTGTGTGTGTGTGTGCACGCACATGTGCGTGTGCATGGAGCTTTGGAAAAAAGAGT
AGCTGGGCACTATATGATTGTACTGGGTTGGAGAGTGACCCACACCGCACCCCCCAACCCCAA

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

CCGCATCCCAGAAATTAACATCCCCAGAATCTCTGAATGTGACCATATTTAGAAATAGGGTCT
TGGCAGATGTAACTAGTTAGGAAGAGGTAATACTGGATTAGGGTGGCATCTAATTCATGAC
TGATGTCCTGGTAAGAAACGGAAACACACACACAGAAGGTCACGTGACGGCAGAGGCAGAGC
CTGAAGTGATGCACCTCTAATCCAAGGAATGCCAAGGATGGCCAGCAGCCACCAGAGGCTGG
5 AGAGAGGCCTGGGACAGACACTCAGAGCCCCAAAAGACACCAGCCAGGCCACAGAGCTATC
TGTTAAAAGCAAATATTTGAGGGGTTTCTGTTGACAGCAGCCACAGGAAACAAAAGGCGGTGG
GAAATGGCTATTGAGCACTTGATGTGAGGCAAGTCCAAACTGAGCAGCGCTCTGAGTACAGA
CACACCAGATTTTCAGATGCCAACTCACACATGCTTCATTAGTAAGTTTTATACTGAAAAAAA
ACAAGTTTTATACCGATTACATGTTGGAAAAATTGTATTTGGATATACTGCGTTAAGTAAAT
10 ATATAATTAAATTAATTTCTACCTATTTTCTTTTATCATTTTAAAAATATGGCTCCTAGAAAAT
TCTAAGTTACACACATGCCCCAAATATATACCAGACAGCACTATGACAGAACATGTCCTGCCT
TCTAAATGGGCTATGTCCTAAATGTCATCACTACAACTCTGACTTAGGAAATGAAAACACTG
ACCCCATGGGAAGGGGTCTAGAGATGGAGACCTCACAAGAGCCAGCAGCTCTGCTGCCAGGG
CCCTCAGGAAGCAGCAGCTCGCTTCTCTCCTCAGATGGCCACTGCTGCAGCAGCTAGATGCAC
15 ACATGAAGCGCCATAGAACAAGGAGCCAGCAAGAATGTCCTTCATCCCTACACACAGCTGAG
CGACTCAAATTTTTAACACAGAAAGTTAACTGATTCAGATATGCACACCAATCATCTAGATTT
TACAACTGCAGCTAGATGAGGCTGGGTGAATAGGACTCATCCACTCCCCACCGTGGGGAGAG
GAGAAACAGCGGGGTGTCCCAGGTGTCATGGTACTCAGACTAGGACTTGAGCAACAGAAAGAG
ATGGCTTGAGGAGAAAACGGAGAAATGCCACCTAGGTGGTAAGAAAGCTCACAAGGTTTCAA
20 AAGACACAGATACCATGAGACTTTCACATCTATCGTTTCATTCCAAAGCCACGTTATTTGGAGT
GCAGTCAGCACACCTGTGTTTGAAGCCCCTGGGATGCTTTTTATAAAATGCAGGTTCCCAGGC
TCCATCGCAGGCCAACAACCTCCAACCCCAGGAGACGCTGATGTACACACTAAAGCTATGCCTG
TGTAATGGTAAAGCTTTGTATGTGGGTTTCAATCCACTCCAGGTATCTATCAACTGCTGAGC
ATGGTATAAACTAGGCACTGTATCATGAGCAGGATGGAAAGATGTCCCAGTGCTCATAACGCT
25 GGTGAGGGAGACATGTAAACAAGCAGTGACAAAACCTGTGACATCTGGTCAGAAAGGCCCAAC
CTTCAGGCGCCTGTGTGTGAGCTGGGCAAGAAAGGGTATAAGAGAGAAACAGGGCCCAGTCAG
GAGACTGTGAGTTAGTTTGCACTTTATCCTGGGGCGGATCTGAGAGCTGCTGAAGGGTTCTAA
GTTGTGCAGATCAATGACTACTCTCTGGTGGACAGACTGGAGGTGAGCAGGAGGCAAGGGGA
CCACTTAGAGGCCAAAGGCTGTAAGAGAAAAACCTGAGAAAAACAGATAGCTGCTTACATTCC
30 ACTTGTATGCAAAAATTTAAAAAAAAGAGTTGAAGCAACAGTTACAAATCAGGAGATTTCA
GCTCAAAATGCAGGGTTCTGGCTCTTTTCAAAGGGGCCCTATGTGACAACCTGGGGCCCATATT
CCAGAAGCTGCCCTGTGGTCAGTGCACGGTGCTTCAATCTGTTACCTTCAATGCAAACGCTG
CAAGGGGAGGCACCTGTGGGGTGTGGAGGCACCCGAAACCTAACAAGGCACCAGGGTGGG
AATCCAGGTCTTCAGAAGCCAAACCTAGGAACCCAGTAAATGGTCAGACAGGCAGTAGCCA
35 TGAGGAAGGGAGACTTGAGGGTTCCACTGGTTCCAGCTTGGTCCCCTAGAAACAATGGGTG
CCATTAACCAAGAGAAGGGTATAGGAAAGACAGTCTGATGCCCGGGGTGGGGGAAGGGGTG

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

GGCAATCCCACCTTGCTGGAGAGTGCCGTGGTTACTATTATATTTAAAACGAGGATGGATCTGTG
CATGCCTGGCCAGTGGAAATCGCACCCCCGCCTCAGTTCTTGGGCTTGCTCTCCATCTTCCTGC
TTACCAGAATGATTTTGGTCTCATCTAGTTCGGCCTGCACTTTAGTCATGGGATCAGCTTCTCG
TGGGTTCTAGGAAAGAGTGAAAAATAATAAAGTCAGGACTGGAGTGGCTACCTGCAAAACAA
5 AACCTAAAACTGAGGAAGCTGGACAAACTTTCACAGGTAAAAAACACAGCCTGGGCCGGGC
ACAGTGGCTCACGCCTGTAATCCCAGCATTTTGGGAGGATGAGGCGGGTGGATCACCAGAGA
TCAAGAGTTCGAGACCAGCCTGACCAACATGGTGAAACCGTCTCTACTAAAAATACAAAAAT
TAGCCAGGCGTGGTGGCACATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAAT
CGCTTGAACCCAGGAGGTGCAGGTGAGTGAGCCGAGATTGCGCCACTGCACTCCAGCCTGGG
10 AAACAGAGTGAGACTCCAACCTCAAAAAACAAAAACAAAAACAAAAACCCACAGCCTGTTTA
ACATGTAACAGAAACCCAAAGCCTGCCTAGAGCTTGGGTTCCCCGGTCTGAACGTAGATTCTC
TGTTTTCCAAACAGTAAGGCTTGAGAGAGGACACCAGCATCAGAAGCTGTCAGAAGTAATT
GACCAGAACTATCAGGGCAGTTGGCTTTTTTCAGTTTCACATGGATTCTGGGCCACATGGTGT
TGCTGAAGCTTCCTTTAACCTAGCTGGTATCTACTGAGGTGACCATCCAGGGCTGGGTAATG
15 GATTGTAGCAGGGGATCCTACTGGCCAGTCTATCCTGTGCACTTGCTTGGAGAATTCATCTAG
TACCTGCAAGACAAAGGAGACTCAACAAGCCTCCCACTGTGCACTCACCAGTGGTCTCAATGA
CAGGGCTTCACCCCTGAGCACCTCACCTGAATGAGGCTCCTTGGCCTTCACAGCCCAGGAAG
GAGGAATGAGGGGGACATATAATGGCAACAGAGAAAATCTAGGCTAAAGTTCTTTCCAAATT
TTTATCATTTAAACATATCCTAAATATTCTGAGAATCAAAAGTATGCCCAGCCCCGAGATGAAC
20 CTCACTTGGGGAGTAATAAAGGTATTTGAATTTTAAACTACAGATTTCCAGAAAAAAGGGGC
ACTGGTCTCTAATTTTCCAAAGCAATTTTTTAAAAAAGAGAATTAGGTCCCCTAGATTTAAG
AAACCACCAGATTCCATGTGTTTGGAGGTATTTTGGTGCTCTGGGGTATAGGATGAAGCCTCT
GACTTCAAAGAGTTAATATTAGTAATTAGCACCGTACGCAAAAAAATTTAAAGAATGCTTAG
GTGCTAAGCTCTGTGGTGCAACTGACTGACATCAAGGTAGAGGGATGCAGCAACTGCAGGAG
25 GCAATGGGGAGAGTGAAAGGCATTCAAGAGGGAGACTCCTTGAGCAGAAGCACAGGGGGCGA
GAACACAAGGCACAGCTGTCTCCGAGGGTCCCATCCAGAGAATAGATGCTATGACTCAGTG
GCCTAGACCCAGCTCACATGAGGGACAGCACCGGGGAGGAAACCCATACAGGGATGCCAAAT
TGTCTCTTGGGTTGCAGGGAAGGGGGCTGAAAAATGTGTTGACTTTGGACACATCATTTATC
CCTTATGTCTCAGGGACTGCCATCAACCCCTGTCCCAGTCCATAAATGTGCCCATTTCATCATCC
30 AAGTCCAGGAGAGGCAAATAAAAAACTCACCTTCTCCAGCAAGGTAAAGGCCACCCGGGATG
GGTATTTCATTGTCAGCAATGACCACACCTGCAAGACTATCATTCGGACGTAGACGTGGCACA
GATAGTCTAAGGAGACAAGAGATCAGACACATGGATGCTGACATGAGGGCTTCAGACTTCTT
TTAATCCCCCAAATCAAAGCATCCAATGTTAGGCCAAATGAAGCCACTCGGAAGCTCAATAG
CTCTGGGCAAGTCTTGTGGAGAGGCTTAGCAGCACAGCCCAATGGGCCACACACAGGAGCTT
35 GGCCCAACGCCTGCTTTAGGACCAGTAAATACCCAGAGGCCAGTATGCAAAGCCAGGGCTTA
AAGAAACAGCCAGTGGTGCAGAAAACACACCCTTGACAACATGGCCCCAGGAGCATTTCCAA

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

GTGTATTCCTTAAGCTCGGGTCAGGCCAAGCTATATCTTAGGGATCTGGAGCCCTTGGGGCTC
TGTGCTGCTCCCAAACCTTAGGGAACCTGGACAAGCCAAGAGGCCTCTGCTTTCTTAAAAAAT
CTTTTCAGAGCAGCCAAAAGACAGGAAATTACCCCCAGGGCCTCAGTCTTCCATATTATAGC
AACCTGCTGGGTTTGCTCCACTCTGGTGGGTGACTGGGAGTAGGGGGGTAGTCTAGAAAAA
5 GATTAGCTACTGCCAGCTAAGGCCTCCAGAGCACTGTGCTAAAAATCCTCATATGATTGAAAGG
TACAGTTGTACAGGTCTTCCGCAAAATATTCACAATCCACAGGATTGTTCAATTCATCACTTT
GAAAGGATTTCAGAGTTGATACAGCTAACCATATCCCCAAGGAAAGAGAAATGTAAGGATTAC
AGCTTACAAATAAGAACCTTCTTGTCTTAAGGATCTGACCCAGAAGATTCCAATGCTAAACA
ACAGAAAAACAAATAAAAGAGGAGGGAATGATGGTGAGCCCCTGAAATCAGAAAAAGAGCAG
10 AGATAAATGAGAACAAGAATGAGGAGGAGGAAGAGGACAGGGGGTTGTCACCAATGCTCTC
CAGATTTTGTATACCATCCCCAATTAAGATTCAAACATGGGGTCAAAGTGCATACCCTCCAAA
GAAACTGAGAACCTGGTCAGTGGAGGAATTGTCTTTAAGTAATAAACGTGGGAAGGGCAGGC
ACAGTTTGAAGAACAGAGCAAGAACACTGAAATATTTGTGATGCGATTTCACTTCTATGATG
TTAATAGCACAGAGATCCACATAAAGTGTATATAGTCAATCCTGCCTGTATCATAACTGACA
15 TTTATATCATCAATTCAGTAACTCTATGTCACGTGACTTGAGGTTAGCATAAGTGTGAGATGA
TCTTTGTCCCTACCTGATGAAACTCATGTAACCTTTTCCTGATCTGTCTGTATAACATACACAT
CTAAATAAATGCCTAAACCTGAATTATCAGAAAGAAAAAATAGTTTTTTCAGATTCCTGATCA
AAAAATCTACGATGCACAGAATACATATAGTACCTCAACAGTGCTAGCTGGAAATCCTTTTTT
GAGGGGTCTGCAACTCTGAAGAGGATAGGGAAGAATACGATATGAAGGCTGCTTACTGCTCC
20 AAAAGAGTCAGACCCTAATCTTAAATGAGTCTAAGTTTGAGGGCAATTTTATCTGGGAAGCT
CAGACTTCAACAGTGGGCACAGAATTCTGCATAAATAGGAAAAGGAAGAGGTGGGAAAGAG
AGAACAAGCTAGAGGAGGAGTAGGGTCCCAGTAGAAAGGAGAAAGCTGGGTGCTATGTGAG
GTGAGGCATGGCAGCCAGGCCAGCACACGCACAGAAGTTGGAGGGTCTTCTTACCTTGTCTT
TGACAGAAGCTCTAGTGCCTTTCGATGAGCGCTCCACAATCAGTTGACTCGTGAAGGTCATGA
25 ATTCCTGAACGCTAAGAAACACAAAATGTATTTATTGCCTACTTCTTATCACCTTGTCCCCAAC
ACAGTGGAAAGTGACCTCTGGGCTTATACATTAAGTAGACATTGCTTCTTGGTTTCATTCTT
TCCCTCCCATCCCTAGTAACAAACACTCTATAAATGAGCACAAATACTGATAATTATGAATTA
TCATCACCATGAAAGCTCCATCTGTTTGCTACCTGGCTCACCAAAACAGGTGAATTTTCTGGG
GGGTTTTTCCACAGGATACAGTCAATTTTACATTTTGGTGAATGCATAATTTGGAATGCAATG
30 GAAAAACAAGAGGCAGGTCCTGCTCTCAAGGTCCCAATAACTTCCAAGAAGCAGGACATTTA
TAAGAACTGCACTAGAAGAATAGTGTGCAAAAACCTGTCAGGCAGAAATGCACAACCATTTAT
GGCTGTGTCCACATGACAGACCCTCGCAATGCCACATACACCCATAGTGAGTGCTGGCTCAGG
TCTGCTGGGGCTCGTCCACAGAACGAGCGCAAGACACTCTGGATGGAACAAAAGGAAAACTG
CTCATCCAAGACAAAGAAGTGGGAAATGGCTCATACAAAGGGTGAAAGGGAGAAGGTCCAT
35 CATGGGCTCAACAGAGAGATCTATCCAGAACAGAACAGTCACAGGAGATGGTACAGCCAGAG
GAAGAGGTGCTGACAAGGAGCCTCCAACCTGAGGATGTGATATAAAGGGCAACCAGGGCCATC

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

AAAGCAGGGTGCTCAAATGGGAGTCTGCAGCAGGCTCCAGCAGAGCCATATAGGTAAGTCAA
GGCCTGACTCTGGGCCTGTGTGCTGTGCCTCCACATTAATAAATAAATCAAGATTGTGCAACAGT
TAAACGAGGTAATACGTGTAAAGCACTTGGAACAATGCCTGCACACACAGTATTACTTGTTA
ATATCTTGAGGGACTGAAGTGATCAAAATAACCCCTCAGAAAAGAAGACCTCAAACAAGGAA
5 GGCTTTGCAGTAAACCTAGAGACAGCATTTGAGACACGGCTATAAAGAGACAAAGGAAGAAC
TGCATTGTGACAGCATGTATACAAAGACCAAAAAAGCTGGGAAACTACTTTTTCAACTTTGG
AATCGGGTAATTATAGGGCACAAAGGACGTAAGTAAAGCGGTCTTATAAGAAAACAAGCTCA
GGCCGGACGTGGTGGCTCAAGCCTGTAATCCTAGCACTTTGGGAGGCCAAGGCAGGCGGATC
ACTTGAGCTCAGGAGTTCGAGACCAGCCTGGCTAACATGGTAAAAACCCCATCTCTACTAAAAA
10 TACAAAAATTAGCCGGGTGTGGTGGTGCAGCGCCTGTAATCCCAGCTACTTGGGAGGCTGAGG
CAGGAGAATCACTTGAACCCAGGAGGCGGAGGTTGCAGTGAGCTGACACTGTGCCACTGCAC
TCCAGCCTGGGTGACAGAGCAAGACTCCATCTAAAAATAAAATAAATAAATAAATCAGC
TGGGACATGTGTTGTTTTAAGACATATTAGTAGAGATGTCCCTTTAGTGTTGCAGCTGTTAGT
CATTGGAACTAGTGTTGGCATCCCAAGCAGGTGAGGTATAAGTCCTACAAGTGAAATCTCT
15 GAGAATCTTAAGTACTAATGGGAAGGAAAAAGGAAAAAGAATCAGAGCCAAGTTGGCACCA
AAAGTTCCATCTGAGAAAAGCAACAACACAGAGCAGTGAATGTAGGCCATGGTAAAGACTGC
AAAGACCAAGAACCCCAAGAAGGAGCTAAAAGATAATGCAGCAATTCCGCTTCTGGGTAAAT
ACCAAAAAAATGCGAGCAGGGTCTTGAAGAGATATTTGTACATCCATGTTTCATAGCAGTATC
ATTACAAATGGCTGAAATGTGGAAGCAACCCAGGTGTCCACTGACAGATGAACAGATAAGCA
20 AAATGTGGTGAATAATACAATGGATTATTCAGCCTTAAAAAGGAAAGAAATTCTGATATATG
CAACAAGATGCATGAGCCTTGAGGACATTATGCTACATGAAATAAGCCAGACACACAAAAAC
TATATGATTCCATTTATCTAAGGTCGCCAGAAAAGTCAAAATCACAGAGACAAATTAGAATG
GCAGTTGCCATGGGCTGGGGGAGAAGGGAATGTGTTTAATAGACACGAATTTGATAAAAAAG
GAGTTCTGGAGACGATTGACAGTGATGGCTGCACAACACTATCAATCTATTTCATATCAATGC
25 ACTCACTACACGCTTAAAGATAGTGAAGATAAATTTTGTGTACCATTTTACCACAATTAATAA
TATTTTTTTTAAAAAGAACTCAAAGAAGCAGAAAGTTTCAACAAAAATAACATTTTTTTTTTTTA
CATCCAGCAAGTCCTTGGCAAAGAACTCTCATCAAGAACCAGCTGCACTGAAGCAGGGAAAA
CAGAATCCAAACGGCAGATTCCATCAGATTTTGAGACAAGATGACCATAGATACCGACCATG
TAGGGTCCTCCTTCTTTTCGTGCCTGAGTCACCCCAATCCCTCCACGAATGGTCTGGAAGTGTC
30 TGTGTTACTTCTAACACGTTCCAGCAATTAAGCGCCCCAGAAACAAGTAAAAGCCTGTAAGC
CCTACAGATCCCATGCTTCATTTGCATCTTCGGTGTGGAATCCTTTTGTACCACTAGTGTCCAA
CTAAAAAGCGTTAAACCTGGCTTTTCAAGTTCTAGCTGGTTGTGATATAACCTCTTGGTACCTCA
GTGACTTCACCCATTAAAAACAAACAAAAAAGTATATCACTATCTCTCATACAGAATTGTT
GGGAAGCCCCGCAAGAAAATCAAAATATGGCTCTCAAGATGCGGCACCCAAGCTCCCAGAGT
35 CAGAATCACTGGGTGGGAAGTGTTGGTCTAAAAATATAAATACCGAGGCCTCAATCTACTAAT
TCAGAACATCTTGGCATGAAGCTTGGAAATCTGCACTACTTCACAGTCTCCTTAAAAATTTTA

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

CACGACAGAAATTTGAAAAACACTGAGTAGAGAACTATATTCTAGAATGGTATAAGCTCTTA
 AAGAGCTAATGTTGGTTCCTCAAAGGTAGAGTCCACGGCCAGATTCCATTATAGGAGACCAA
 GCGCGGACAGCAGACCCCGGGCCCTCCCCACCCCGCCCCGCTCTGACTCGGACACCAGCCTTC
 TCAGACCCCGGGCACTCGGCCACCCCGCCCTGCCCTACCCCTGGCCCTCCTCCACCCTCCCCCTCA
 5 TCCCTCCGCGGACCCCAAGGCCACTCCGACTCGGACCCCAACCCAGTCCTCTCCGCGCGACCGC
 CACGGCCCCACCAGCCTGTGCCGCTCACCTGGATCTCTGGAAAAAGCTGAAGGAAGACACATCG
 TATGCGGCTTTGAGCAGCACCACCTTGGCCCTCGCCCTTGTAGAGGACGCTGAGGCTGTACAGC
 TTCATGGTCCCGGCCCTCAGGCCCGCCCGCCTGCCAGCTGCGGGACCCGTTCTCAGGGAGCAGC
 GCGGCCGCGCCCTCGGGACCGCCGCGCCCTACCGGCCTCTCAGCAGCCGGCTGCTGACGGG
 10 GCCACCGCGCGCTTCCTCCTCCTGGCTCGCAATCCACTTCCGGATCCGGTCAGCCTGGTTGAGG
 GTTCTCATACTCCGGATGCAGAAATGTGAGCCCCGGAAGTACAATGCAGCGAGGGGCGGGATG
 CCACGCCTCGCGTAAGCTTGGCCCCCTCCCTGCTCGCCAGGTGGAGTCGGGCGCGCGGGCGGGAT
 ACCGTA CTGTCTTGTGCTGGGTGGTGGTGGGCTCCACAGCGGCCTGAACCCCTTCTTTTTTTT
 TTTTTCTTTTCTTTCTTTTTTTTAAAGTAAGCATTTTTTTTTTATTATTATACTTTAAGTTTTAGGG
 15 TACATGTGCACAACGTGCAGGTTTGTTACATATGTATACATGTGCCATGTTGGTGTGCTGCAC
 CCATTA ACTCGTCATTTAGCATTAAGTATATCTCCTAATGCTATCCCTCCCCCTCCCCCACCC
 CACAACAGTCCCCGGTGTGTGATGTTCCGCTTCCTGTGTCCATGTGTTCTTATTGTTCAATTCC
 CACCTATGAGTGAGAACATGCGGTGTTTGGTTTTTTTGTCTTGCAATAGTTTGCTGAGAATGA
 TGGTTTTCCAGCTTCATCCATGTCCCTACAAAGGACATGAACTCATCATTTTTTTATGGCTGCATA
 20 GTATTCCATGGTGTATATGTGCCACATTTTAGGAGGAGCTTGTACCATTCTTCTGAAACTAT
 TCCAATCAAAAAGAAAAAGAGAGAATCCTCCCTAACTCATTTTTATGAGGCCAGCATCATCTGA
 TACCAAAGGGTGGCAGAGAGAGACACAACAAAAAAGAATTTTAGACCAATATCCTTGATGA
 ACATTGAAGCAAAAATCCTCAGTAAAATACTGGCAAACCGAATCCAGCAACACATCAAAAAG
 CTTATCCACCATGATCAAGTGGGCTTCATCCCTGGGATGCAAGGCTGGTTCAACATACGAAAA
 25 TCAGTAAACGTAATCCAGCATATAAACAGAACCAAGACAAAAACCACATGATTATCTCAAT
 AGATGCAGAAAAAGGCCTTTGACAAAAATTCACAACCCTCATGCTAAAAA ACTCTCAATAAATF
 AGGTATTGATGGGACGTATCTCAAAATAATAAGAGCTATCTATGACAAACCCACAGCCAATA
 TCATACTGAATGGACAAAAA ACTGGAAGCATTCCTTTGAAAAA ACTGGCACAAGACTGGGATGC
 CCTCTCTCACC ACTCTTTTCAACATAGTGTTGGAAGTCTGGCCAGGGCAATCAGGTAGGAG
 30 AAGGAAATAAAGGGTATTCAATTAAGAAAAGAGGAAGTCAAATTGTCCCTGTTTGCAGATGA
 CATGATTGTATATCTAGAAAACCCCATCGTCTCAGCCCAAAATCTCCTTAAGCTGATAAGCAA
 CTTCAGCAAAGTCTCAGGATACAAAATCAATGTGCAAAAATCACAAGCAGTCTTATACACCA
 ATAACAGACAGAGAGCCAAATCATGAGTGA ACTCCCATTCACAATTGCTTCAAAGAGAATAA
 AATACCTAGGAATCCA ACTTACAAGGGATGTGAAGGACCTCTTCAAGGAGAACTACAAACGA
 35 CTGCTCAATGAAATAAAAGAGGATACAAACAAATGGAAGAACATTCCATGCTCATGGGTAGG
 AAGAATCAGTATCGTGAAAATGGCCATACTGCCCAAGGTAATTTATAGATTCAATGCCATCCC

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

TATCAAGCTACCAATGACTTTCTTCACAGAATTGGAAAAAACTAAAGTTCATATGGAACCAA
 AAAAGAGCCCGCATTGCCAAGTCAATCCTAAGCCAAAAAGAACAAAGCTGGAGGCATCACACT
 ACCTGACTTCTAACTATACTACAAGGCTACAGTAACCAAAACAGCATGCTACTGGTACCAAAA
 CAGAGATATAGAGCAATGGAACAGAACAGAGCCCTCAGAAATAATGCCGCATATCTACAAGC
 5 ATCTGATCTTTGACAAACCTGACAAAAACAAGCAATGGGGAAAGGATTCCCTATTTAATAAA
 TGGTGCTGGGAAAACTGGCTAGCCATATGTAGAAAAGCTGAAACTGGATCCCTTCCTTACACCT
 TATACAAAAATTAATTCAAGATGGATTAAAGACTTACATGTTAGACCTAAAACCATAAAAAAC
 CCTAGAAGAAAACCTAGGCAATACCATTACAGGACATAGGCATGGGCAAGGACTTCATGTCTA
 AAACACCAAAAAGCAATGGCAACAAAAAGCCAAAATTGACAAATGGGATCTAATTTAAACTAAA
 10 GAGCTTCTGCACAGCAAAAAGAACTACCATCAGAGTGAACAGGCAACCTACAGAATGGGAGA
 AAATTTTGTCAACCTACTCATCTGACAAAGGGCTAATATCCAGAATCTACAATGAACTCAAAC
 AAATTTACAAGAAAAAAAACAACAACCCCATCAACAAATGGGGCGAAGGATATGAACAGACA
 CTCTCAAAAAGAAGACATTTATGTAGCCAAAAAACACATGAAAAAATGCTCATCATCACTGG
 CCATCAGAGAAATGCAAATCAAAACCACAATGAGATACCATCTCACACCAGTTAGAATGGTG
 15 ATCATTAAAAAGTCAGGAAACAACAGGTGCTGGAGAGGATGTGGAGAAATAGGAACACTTT
 TACACTGTTCTGGGACTGTAAACTAGTTCAACCATTGTGGAAGTCAGTGTGGCGATTCTCTCA
 GGGATCTAGAACTGGAAATACCATTGTGACCCAGCCATCCCATTACTAGGTATATACCCAAAGG
 ATTATAAATCATGCTGCTATAAGGACACATGCACACGTATGTTTATTGTGGCACTGTTTCAAA
 TAGCAAAGACTTGGAACCAACCCAAATGAACCCCTTCTTTTTTGCTTGCGTTGTTGAAAGAAGGC
 20 AAGTCTATGGATAGGAATGAGTGAGGCACAGCTCCCTGAGGATGCCATATCTTGCCCGTTTCT
 TGTGTATTAAGTGACATCACGTGTTACCAAACCTAAACCGGCTGCATTTGCCTGCGCACAAACAT
 AAAACCAAACACCCAAGCATTGGATTTTTGTAGCAAGAAAGATGTATTGCCAAGCAGCCTTG
 CAAGGGGACAGAAGACGGGCTCAAATCTGTCTCCCAATACTTGCTTCCGACGAGTAGATTAA
 GGGAGAGATTTTGGAAAGTGGAGTTTCCGGGCTGGACGGTGATTGGCTGAAACGAAGAAGTGTT
 25 TAGAAAATCTCTTGGTCATGAGCTGTTGCTTCTTCATGCTGCTTCAAGGGTCACATGCAGATT
 CAGGAGGTGGTATAAAACAAGCTGTGGGAATTTGGGCTGTGACATCAAAGGGCCGCTCCTCG
 GGCTAGTAAGTCTATTTTGCACAGGCTCCAGTCAGCCATATTGGTTCCAACCTGTTCCAGCAA
 GTTGTATAAGCAGAGGGGATTATAGCAAACCTGTTTCCTTATCGGGCTGCCCTGCAAGACAAGCT
 CAAGATTTCTGTTAGTTACCAGTTTCTTTAACCCTGTGCGGGCACAGTTTCACATGTAATCAGA
 30 AAGGAACTTGCAAGACACATACAACTGAAAGAACTTGGTCTTTGGAAGTTGTCAGTAAGGT
 CACAAAGTTGTGATGCTAGAAGCAGCCGTATCTGAGATTATGGGAAAGAGATGATATATTGG
 AAAAACAACAGCATCACTTTAAACATTACTCTAAATCAAGGTTTCTCAACCTTGGCACTATTG
 ACATTTTGGGTTAGATAGTTCTTTCTTGTGGGAGACTGCCCTGTACATTGTGTAGGCAGCAT
 CTCAGGCCTTTGTAGAAATGTCAGTACCAACCCACCCCTCCCCACTGCACAATCAAAAACGTC
 35 AAAATGTCCTTTGGGAGCAGTAGTTTTGAGAAACATTGCTTTGCAGATATATATGTTTGTGTTG
 TTTGTTTGTCTTTGTGACAGGGTCTTACTCTGTGCCCCAGGCAGAAAGTGCAATGGTGTGATCC

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

CACTCACTGCAACCTCTGCCTCCCAGGTTCAAGCGATTCTCATGCCTCAGCCTCCCGAGTAGCT
GGGATTACAGGAATGCATCCATACACGCGGCTAATTTTTTGTATTTTTTAATAGAGATGGGATTT
CACCATGTTGGCCAGGCTGGTCTGAAACTCCTGGCCTCATGTGATCCACCCACCTCGACCTCCC
AAATTGCTGGGATTACAAGCTTAAGCCACTGCGCCCAGCTGAGAAACATTGCTTTAAATAATC
5 TGTGGTGAAGGAAGTTCCCACCACCTGCCCACCTCACTCAGTACCTCTGTACCAACCCCTCTTC
CCTGGGTGTTTCCAAGTACAGAGGGTGGAAAGGGCTTTTCCACATTTCCTCTGTTTTGGTAGT
AAACATTAGGAACAGCCATTGGCCGTGGCTAGGCTCAGCCACCCACAGATATGGACACAGTA
GTCTGACAAGCTGGGTGCTGGGTGCTATCAGTCCAGGCTCAACTGCTTGCCTGACACCATT
TCCCTATAGGAGGCAGGTGAGAGCCATTCTGAGGAAAGTCTCTGGAGCCCCCTCTTCCTTCCA
10 CTGAAAGTTGTGCAAAAAGATCAGGAAGACAGCGCTTGGATGGAATAAATTTTCACTGTATCC
ACTTGACACATTATAGTGGCTGTCCCAAAGTTTACCTTATGCCAAGTACTTTCCATGTGCCACA
TCATTTAATCCTCACA AAAACAGGGGAAAAATATTATTGCCACCCTACAGACATAGAGACTGA
GATTCAATTTAAGGAGATGGTTGGTAAGGGACAGAGTTGGGGTTCAGATGTCAACAGTGAAA
TGCTTAACAAACTGTCATGCAGCCCACTCCTGGCAACTCTTCCTGCTCCTCTCTGGCCTCACTC
15 AGCCTCTACTGTTCCAGGAAGCCTCATTATAGTCATGTGGTTGCAGACTTCCCAAGCTCACTG
TGTTACCAAAAAGCAAGACCTGCCTTCTGCTGCATCGCCCCAGCTGTACCCCACTTGGATTCA
GTCCCAGCACTGACACATCACA AAAATCACA AAAAGTGAGCAAACCATTACCTCCCTGAGTCTCC
TTTTGTTTTTATCTATAAAACTAGAAAAATATTCTTTCCATAGGAATGTTGTTGGAAATAATA
AAACATTATATTACAAGCTCTAGTCATTGTTGATGTTTAAACAGGTAACAGTGATAATTATTG
20 TCTTCTCATTAAATGAAGAAAAGGATTATTAATCATAGAGGGTGGAAAGGCATCTATGGGAAGT
AGAGATTTGAAGATAGGCTAAAACCCAAGTAAGGCCTCTAGATTAGATAAATAGTATTGTATC
TATTTTAATTTCTGCTTTCCATCACTGTGCCATGGTTATATAAGAGAAGTCTTTGTTTATAGG
AAATATACACAAGAATTTAGAAGTAAAGGGACATTGTGTCTGCAACTTACTCTTACAGGGTG
TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAGAGAGAGAGAGAGACAGAGAGAGAGAGACA
25 GAGAGAAAAGAGAATGATAAAGCAAATACAGGAATCAGGATGAAGCGTATCTGTTTGTTTTGT
TTGCTTTGTGATAGGGTCTTGCTCTGTTGCCCAGGCAGGAGTGCAATGGTGTGATCCCCGCTCA
CTGCAACCTCTGCCTCCCAGGTTCAAGCGATTCTCATGCTTGTAATTGTTCTTGCACCTGTTCTG
CAAGTACAACATTGTGGGAATGGAAAATGCAGGAAATGGGCAGTAAGGCTATGAACGAAGC
CCGCACAGGAGTGTGGGTAGCAGAGTTCTCTAGTCCAGGCTCCCACCTGAGGTGCTGGGACCT
30 AGAAGAAAAGCCTCTCTGCAGACAGAACTGGAGTTAACGCTGTCCACGATAAATGGCCCAGG
CCCTGTAAAGTTTGCCCCATTGAGCAAAACAAGTACCCACCCGCTTTTGACGCTTGCCTAGCT
CACATAAGGTGCCAGCCCTTGCTGTACAGCAGAACCTTTGGGGAGCTGGACAAAAGCCTATCA
AGGAGCATACCCCCAGGAAGCCCAGTCCAGGTGGGGAGCCCAGCCACACAATGGCCCTTGCCC
CCACACCTCCTCATTCACTCAGCTAAGGCCATGGCAGCTGAGCTGCCTCCACAGCTCATATAG
35 GAAAAGGGTGTGGAAAGGGGGCCACCAATGTGGTCAAGGCCTCCATGGCCTGAGTAGGTCACCA
AGCCTCAGGTGCACAGACTTGATGTATCAATCAGGGTCTGTGAGCAGACACCTAGCCCTCAGGA

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

ACACTGCTCCCCACTGCAACCCACACCAAGGCATCCTGGGCTCCCTCTGGGTTCCTCCAGGCC
CAGGGAAGACAGACAGAGTCTGCCACCAAAGGTTTGAGCTCTGCCACTGGCTACGAAGCAAT
AGGGGATGTCAGAGCAAGGGAGGAACAGGACAGGAGTATACGTGGGCAGGAAGGGATTACA
GCCAAGGAAGACAGGAGGCAGGTGCCCTGATTTTGAGGCTGTGCCCCAGCAGGGGCTTCCCA
5 GAAGCTGTATTTGTCCTAAGACACCCCTCTGCAGCTGAGGGGCTAGAGATGGATATGTAGCTG
TGTTAGGCCATTCTTGCATTGCTATAAAGAAATACCTGAGACCAGGTAATTTATAAAGAAAA
GAGGTTCATIGGTTACAGTTCTGCTGGCTTTGCAAGAGGCATGGTGCTGGCATCTGCTCAG
CCTTTGAGGAGGCTCAGGAACTTACAGTCATGGCGGAAGGCCAAAGGGGAAGCAGGCACAT
CACACAGTGGAAGCAGGAGTGAGAGAGAGAGAGGCACTGGGAGGTGCCACACTTTTAAACA
10 ACCAGATCTCGTGTGAACTCAGAGCAAGAGCTGACTCATCACAAGGGGATGGCCCAAGCCA
TTCATGAGGGATCCACCCCCATGACTCAGACACCTCCCACCAGGCCCCACCTCCAATATTGGGG
ATTACAATTCAGATGAGATTGGTGGGGACACATATCCAAACCATATCAGTTATCAGTAGCCA
TACTGGATGAATGCCAGGAACTTAGAATTAGGACACATGGTCATTTAGGCAAGTGGCTTGTG
CTGTCAATGGTACCCTGATAGTCGTGGGGTTGCCCCGTACAAAAAGCGAGAGGAAGTCTACA
15 GAGCTGTCAAAGAGGGGCAGGTGGAAAGGCCTGCAGAGGAGTCCCCTGCTCCACAACCAGGC
GTGCACCTCCCACATCCTCGGGGCTGTAGGCCCCACATGAGAGCAGAAAGAAGGATGCAGAG
GAAGGCC
AAGAACACAAGGTGTGCCCTTGGAAAGGCTGGGCACACCAAACACAACCTAATAAACAAACAG
CAATGAGCACACAGGGAAAGTACTCACAGGGAAACCATCATGAACTAGAGGGCTGATCCCACA
20 CCCTGCCACATGGGGCCCCAGGCCCCAGCCTATCAACCAGTGGTCCTTATTGCCACAGCGATTG
GTCTTTGGATAGGCACCTGATGCAAGCTTCAGCCAATCAACAGGCCACTCAGCTGGCCATCAG
TAGGCCATCCAATCAGAGCAAAGCCCAGGACTTTCTTCGACTCTTAAGAAAAGAGAAGCAAA
GTAACCTGGCACAGATTGGAGAGGATCAAGGAACCCCGAGCTGGATACATACAAACCTTTGGGT
TAACATGGATGATTAAATACATATGTTTATGTGAACCACCTCCCAAATATGCTCCACTATAAT
25 GACACAAGACAAAGGGCAGGGGGAGACCAATTGCAAGGTGGCGCAAATGAGAGATGCTACC
AAGGGTGGCGGGGGAGAGAGGGGAGCAGTTGTCAAGTTAGGAGGCAACAGGCTGAGGGACA
GGGACCAGCAGACGGGGAGGGAGGGGCTGAAGCAGAAGTGTCCAGTGTCTGGAGGGATGGG
GCCAGAAAGGCAAGGGGCATCCTGAAGAAGCTATACCTGGGGAGGGCAGCTCTCTCCCCACC
TGCTCCCCAATTCATCAGCCAGGAATGCCCCATCCACCCCACCCCAGGGAGGAGGACAGAGGA
30 CTTTCGTTTGGGAGCATTGAATGGTTCAGAGATTCTGCAACTCTGCGGTCCCCAACTAAACTG
CTCATTGTTTCAAGCAGTCCCTGTTGGGTAAATGTCCCCCATTTGTAACCGGACTCGGATTCCAC
CGCTTGAAAGCCAAATACAAGAGGAGAGGTTTGGTGGGAGGAAAAGTGGTTTTAACTAGAG
CCAGCAAACCAAGAAGATGGTGAATTGTTGTTTTAAAGCATTCAATTATCTCAAATTTTAAAA
TTTATCATAGGATTCTGAAAGGAAAACTTGGTATGGGACATACGTGGGAGCAGTGCAGGGTA
35 CAGGGTCTATGTGTCTTGATCCAATGGCTGTCTTGAGTATCACCTATCCTGAGGTCTGGTTGG
TGTTATCTTTCCTTCGGCCAGATGGTGGTGGGTGAATTGTTTCGACTCCCCCTAAGTTGGAGG

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

ATTC CGCAGGGGTTCCGTGTCTGGTTTTTTGTTTCAAGATTAGCCCCTGGAATTCCCAAATAAG
CATAGAGTTAGATAAGCGGGCATGGTGCAAAGGAGTGTCTAGTGGGAAAGGGAGAGAAGCA
GAGTTTCAAAGTACATTTCAAGGTTACATTTTAAAGACTAAAGAAAAAGCCTTAAAAATGCATT
TTTAAAGCTGATTTAATGCTTGGCTACACTAGGCTGTGGCCAGTGTGCAGTGTGGCTGCTCTT
5 GGATCAGGTGATGTTTCATCAGCTGTGTCCAGGGAGGGCAGGGCCATGTGGCAGAACCTGGG
ACCTCTGTGTGAGGGACTACCTTGGCCCCCTGTCTTAGCAGGAAGCTATGGTAAGGAACCTT
AGGGAGACATTAAATTGGGGAGACCGTCCCTGCCAATCCTTTAACCTCCCCAGCCTCAGCGAC
CTCAGTTGGAAAGTGGTGGTAATAATACTACCAGGTGTGGTGGCCAGACATTCCAC
ACTTTGGCTTCAGCCGCTCCCTCCCCACTCTACTGTAATCCCAGCACTTTGGGAGGAAGAGGTA
10 GCGGGAACCTGAGGTCTGGAGTTGAGACCAGCCTGGTCAACATGGTGAAACCCCATATCTACT
AAAAAGAAAGTACAAAAAATTAGCCAGGTGCAGTGGCACACGCTGTGTGGTCCCAGCTACTCG
TGGGTCTGAGGCATGAAAAATTGTTTGAGCCTGGGAGGCAGAGGTTCCATTGAGTGGAGATCG
AGCCACTGCACTCCAGCCTGGGTGATAGAACGAGATTCTGTCTCAAAAAAATAAAAAATAAAA
TAATAATAATAATACCAGTGCCTGCCACACTAAGATTGTCTGATTAGATGACAGAATGAATGC
15 AAAAGTACTTTGTGAATCATAAATGTTTTCATCAATATTAGTTATAATGACAATTGCTCCTTC
TCCTAATAAATGTATTGCCTTTCTTTAGGAATAAATATAACAAGAAATGTGTAAGATATATAT
GAGAAAAATAATAAAATTCACCTGAAGGACATAAAAGAAGACCAAAATAAATGAAACAACA
CATACTTCTAGATGAGAAAACCTCAATATTATAAAGAGGTTAGTTCTCTAAAATGAATCCCTAA
ACCCACAAAGTCAATGTATTTCCAATGAAATGTCAACAGCATTATTTTCCGAAGTGGGATGA
20 GTAGTGCTAAGATTTATAAGAAAGCCAACATTCAGAGCAGTGGGGAAGGGATTGCTTCACC
ACCAAATAGCCATATTAGAGATTCCCTTGCAACCATACCCAAACCACCATCTCCAGGACCCGG
GAGAGCAGAAAAGAGGAATGAGAAGAAAGGCGAGGATGTGAGGTGTGCCCTCATAATGGCG
GTGCACGCAGCACAAAGCAATTGCAGAAAGACTAAAGTACTGAACAAATAGAAAACCTTGGA
AAATATTAGAAGGAAATGTGGGAGAACATTTTTGCAATTTGGGGATTGGAAACGGTTTTCTT
25 AACAAGATATAAAAACCCCAAAACAAGAAAACAAAGGTTGAAATTCATAAAAACCTAGATAC
TTCTGTATGATGAAAGACACGATTAATCAAGTTGTAAAGTTTAGCAATAGACTAGGGGAGAT
ATCATAGTATATTTAACAGACAAAGGATTAATAGATACTACAGATGAAATATAAAATAGTTT
CTCCAAGTCCATAGGCAGAAGATAATCCAATAGCAACATAGTTAAGTAATGTAAACAAATCA
TCTTAGAAGAAGAAATGCAATCACCAAGAAACACATGAAAAGGTGTCCAGCATTTTGCAAT
30 TCAAGCAACAATGAGGTGACAGATCGGCAAAAAACCTCATAAAGATTTATCATCTGAAGGATT
GGCCAAGATAAAGCCAAACTTCTCGTGTGGCAGAAAGAACTGGTGAAGCCATGTGAAGAGG
CCACGTGGTCTCTGCCTACCAAGATGTAATAATGTGTACAGCATTTGAACTAGCAATTCAGCCTC
CAGGAGCCATCCAGAAGAAACACTGACACACACTTAGACTCCGGTGAAATTC AAGGACTTCT
GCCACAGCCTGCTTCGTAATAGTGAAAATCTGAAACTGCCTCAATGACCGTCAATAGGAAGTT
35 GATTTTAAAGTGTTACAGCACATCTGTCTGGAGAGATCGCACTGGCCACTCCTCCTCACCCTCCT
CTGCTGGACCTCTGAGCGTAGGTGGCCTGGAGCTGGGTCTTGAGCCCTCTTTGGTCTATACCG

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

ACACTACCCAATATGGTAGCCACCAGTCACGCTGGACACTTGAAAAAGTGGCCGATCCTGACTG
AGAAGGGGCCACGAGTGGGAAAAACACACCAGACCTCAGTGACTTAGGCAGAAGTATGTTTTG
TTCCAGACTATTGACTGAGCCCCGAGCTGAGTTGGCTCCAGCACCCCTGGCCCCCTGCTCCATCC
ACTCACTGGGACTCCCCACTGCACAGGGGCAACCTCTCCAGGGGCACTTGGGGCTGCGAAGGGGA
5 GAGTGGGTGGCATCCAGGCTGAAGCTTCCTGAGCAGGGCCAGAGGAGGAGCCAGTCCCTGT
GGGCCTCTGTTCTGACAGTGTCAACCTCAGCCAGGCTTGTGTGGGGCCAGGTGTACTGTTCTGG
TTCAGATTTC AAGGAGATAGTCAGGGCAGGGCCGCGCCAAAGCCCTCCGATGGGGCTCCCCTACT
GCCTGGCAGACCTGTCCAGCTTTGGACTCTGGCCCTGCGACCTGGAAGTCAGGCTGCCAAGAG
GTCCAGGCAGTGGCCTCCACTGTGGAGGGTCTCTGGAGAGTTTACAGCCCTAGATAGGGGGG
10 TTAGGGATGTGAGATGGTCCCAGGGGCTGCTCCTGAGCCACGCCAAGCTGCCTGCTCCCTTT
CCTCTGCTTCCAGACTCACGGGATCCTCTGCTCATCAGAACAGGAGTGTGGGAGACCCTGAGA
CACTGCCCCAGGATCTGAACAGGTGGCAAAGGCTTAACAGGCTAGCGGTCACTGTAGTGACA
AGGCGATTGAGTGGTCACCATGGTGATGGGGATGGAGGCTCTTTGCCACCAGTCCCAGTTTTA
TGCATGGCAGCTCTAATGACAGGATGGTCAGCCCTGCTGAGGGCACTCCTGGTCACCATGACA
15 ACCACAGGCCCTCTCAGGAGCACAGTAAGCCCTGGCAGGAGAATCCCCCACTCCACACCTGGC
TGGAGCAGGAAATGCCGAGCGGCGCCTGAGCCCCAGGGAAGCAGGCTAGGATGTGAGAGAC
ACAGTCACCTGCAGCCTAATTACTCAAAAAGCTGTCCCCAGGTCACAGAAGGGAGAGGACATTT
CCCCTGAATCTGTCTGAAGGACACTAAGCCCCACAGCTCAACACAACCAGGAGAGAAAAGCG
CTGAGGACGCCACCCAAGCGCCCGAGCAATGGCCCTGCCTGGAGAACATCCAGGCTCAGTGAGG
20 AAGGGTCCAGAAGGGAATGCTTGCCGACTCGTTGGAGAACAAATGAAAAGGAGGAAACTGTG
ACTGAACCTCAAACCCCAAACCAGCCCGAGGAGAACCACATTCTCCAGGGACCCAGGGCGGG
CCGTGACCCCTGCGGCGGAGAAGCCTTGGATATTTCCACTTCAGAAGCCTACTGGGGAAAGGCT
GAGGGGTCCCAGCTCCCCACGCTGGCTGCTGTGCAGATGCTGGACGACAGAGCCAGGATGGA
GGCCGCCAAGAAGGAGAAGGTATCTCGCCCTCCATTGGGCATTCTGGGAGTGTGTTGCTTGCCT
25 GTCCCCAACATTCCATGGTTTTGTTTGAGCCTCAGAATCTGATTTTATGCACAGGCTCTTTGAGA
AGGGTCTTGCCAGGGGTGCCTTCTGGGGCAGGAAGGCCCTACTGCCTGGCAGACCCATCCAG
CTTTGGACTCTGGTCTGCGACCCGGAAGTCAGGCTGCCAAGAGGTCCAGGCAGTGGCCTCCA
CTGGGGAGGGGCTCTGGAGAGTTTAGAGCCCTAGATGTGGGGGTTAGGGACATGAGGTCTTG
TGGACAAAGCCCACTACCTGATTTTGAGACAACACTCACTAGACATGGTGACAAGTCAAAGA
30 TGCCTTGCCTCCTACCAGGAATCACTTCGCAGGGAGCCCGAGGGCTGCTGTGGCCTGCTGAGG
AGTGCAGGGCAGTTACTTTTTCCAAAAACAAAGAGAAATCCAGGCATGCTCTGAGCCAGCCCT
GAGCCCAGCAGTGAGCAAGGAGAGAGCTGGAGACAGGGGACTTTGCTGTGAAACACTGGGG
GGAATGTGCCTGCATCACCCAGCTGGGGGGCCAGGCAGAGTGGGGGAGAAGGGGTAAGTGG
GCAGAGCCAGTCACTTTGGGCATGCTTCCCTCTCGCCTCTGTGTGAAATGACCAGGTGAGCAT
35 AAACCCCGGGCTGGCTGTGCTTCTGGCAGAGCTAATGATGTTAGGAGGAAAAACAACCAACCC
AAGTGAGAGGGTGGCGAGCCAGACAGCTGGACCGGCCGAGGCCCAACCAAGTCCCAGATCT

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

GCCTGTCACTGGTGCTATGGCAGCAATTTGGATGAGAAATCCTGCCCAAAGGGCCCCCTTCAGG
 CCACCCGGGGAGAAAGGAAGCGGCTGTCTTTGGCATGACCAGAAAGATGGCTCGGAGCTAGGG
 AGAGGTGGACATGTGGGCTGTGGAGATCTGGCACTTTCCCCAAACAAGGAGAGAAAGCATAG
 TGTGCCTATGTGTGAATGTGCTATGTGTGCATGTTTGTGCCTGTGCATACCTGCATGTGTACA
 5 TGCATGTGCACATATGTGTGCACAGGGAATCACTTTAATAAAGGCCACAGCAGAGCTGTCCCT
 GAGCCCCCTTGCATTACAGTGGCATGTGAGTGAACCACCTTCTTAGGCTGGGCATCCAGTCTC
 AGACTCTGGGGCTGCCCATGCCCCATCCTTTATCTGCTCCACGTGTGAGGGGTTGCTGGTCCTG
 ACCAGGGGCCAGCTGTGAACCCCAAGAATCCTGGGAAGTCACTGACATTCTTGTGAGGGCCAAGA
 GTGGAGCAAGGCAATGCCTCGGGCACAACTTTAAGGGGTCAACCAGAAACATCAATCATCAA
 10 GATATATGCTATTTTAAATAATCAAAATGAATGCAAAAAAATTTATGATGGACAACATACC
 AAATTCTAAACAAAGGCAGGATGAGTATCACTGGCTTCTGCACTTTTCTCCACCCAGTCTACC
 CCTCTTCTAGTGCCTGGATCGCAGGGTGGCAAGGCCTGGATGAGGGAAGCGTGGAGCTGCAA
 TGGCCACTCCTGTCTGCCTGTTCTGGCTGCACAGAGGACTCAGTCCTTGTCTTGGGGGAACCTA
 TCTTGGTTTTAGGGTCATCCTAAGGATCTGATGTTTTCCAAGTGAGCTGGCTGTCCAGGCCCA
 15 CCCAGGTTCACTCCAGTCTGTGTCTCTGGGAAGTGCTGCCCTACCCCAAGCCAGTGTGTTGAC
 CTTGGAGCAATGAGCAATGCCCTCCTTCCACTTTCAAAGTTGTCCCAAGACGTGAGCTGTGG
 TTGTCTCTGTGCAGACACCGAGGAGGAACTGTCTTCTTTCTCCTTTTGGTTGCTTTGGAGGAA
 AGTAAAGTGTTGCTGGTTTTCCCTCTTTCTACTTCTTTGATTGAGAGCAGCCGTCTTGCCGGTAC
 CAACCTTCCAGATCTTACCTGTGGTTGCAGGAGCCTGTGGCCTCAGTCCTGTGCCCAGTGACTT
 20 CTCCATGTGGATGTCAGCTCCTTAGGGGCAAGCCTGATTCCACTGACACTACTCCCACCCCTCA
 TAAGCCCCCTTCTTACCAGCTGCAGTTGCCTGGTACCCACCATCGCTGACTCATTCCTTTGGCA
 TCAAGGTTCACTCCCTTACTGGGCCACCACTTCTGGGTGGCCTGAAATAGGGCCCCTGGGCATCC
 CTCTTGGGGACCTTTTGGTCTATATTTTCACTCTCACCTCACTAAGGACAGATGAGTAAATCTG
 GTTAACTTTGCCTGATAGATTTGGTGACCTTTTTTCAGGAAGGAGCCTGGAAAGATGAGATTG
 25 AGGTGTATTGGTCAGCTTAGACTGCCATAAGAGAATACCATCCACTGATGGCTTAGAAACAA
 CAGAAATCTATTTCTCACTATTCTAGAGGCTGGACGTCCAAGATCAGATGCCAGCATGGTCAG
 GTTGCAGGGAGGGCTCTCTTCTGACTTGCAGACCGCCACCTTCTTGCTGTGTCTCACATCGT
 GGAGAGAGAGTGAAAACAAGCTCTCTGGTGTCTCTTCTTATAAGAATGCTAATCCTATGATG
 GGGGCTCCCCCTCCTTACCTCATCTAAACCTAATTATCTCCCAAAGGTCTCATCTCCAGATACC
 30 ATCACACTGGGGTTAGGGCTTTGACATATGAATCTGGGGGGACACAATTCAATCTGTAACACC
 AGGAGGGCATGCCGGGAGGAAGTGAACCTTCTCCCTCCAGCTGCCCTGGACACCTTTGCCCCA
 TTGAAGGAGCAGGCTCAGAAGTGGAATGAGGATGGAATAAGGTGCACTCCATCATGCTTACC
 CACATCCCTGGCAGGAATTGTCTGGGCCCCAGCAGGAGAGATGCCCCCCCCATACTGCCATGG
 CACCTGCTCTGAGACAGGTGTGCAGAGTGCAAAGCTCCAGGTGGCCCCCAAGCAGGTGTGCTG
 35 GGAGGAGGGGGCCCGTGTGGGAGGAGCAGGCAGCGCCAAGGCCTAGCGGAGCAGTGACAGGT
 CCCTGACTTCAGGGAATGGGCACGCTGTGGGCAGGCAGCTGGTGTGGGGGTGAGGGCTGGGG

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

CTGCATCTGTGGGACCAGGGCTGGGGCCATCCTCATATGCCGTGTCACAACCCCAGTGCCCCCTGC
TGTAGCCAGGACAGGAGGGCTGGGGCCAGGCTGGGAGGTGACAAGAGTGGGGGCTGTCCCCAGG
AGAAGCACTCTGCTGCCTGTGCCCAGGCCTCTGGGGATGAGGACCCCTCAGAAGGAGTAGCTA
TGTCTAGGAAGCCCCAGGGCAGGAGCAAGCCAAAGGGGACATCATTAGTGAGATCCAGGGGA
5 TCAGTGGGGCCACAGAAGCCCCAGCGTGAGCCCCCTCTGACTGATGCAGCTAGGCCCCACACCTGC
ACCTGCCCCACAGCAAGACCCCCAGGAGGAGAGGGGACAGATGGAGAGAGGCACAAAGTGCCC
CTGGCCTCTGCCTTGAAGCCACCCCAAGGCAAGAGAGATTGAGCCCCCTGTTTAGTGACCTCC
AGGGGAACATTCTGGCCCATCTGATGTGGGAAGCCCCTTGTGGAGTCTGTCAATTCCTCAGCTG
AGCCAGGCCTTTGGAGGCAGCCAGGCATGTCCCCTGTGTGCTCCTATCCCTGTGTGGGACA
10 CCTGGCCCCAGCCCCCTCCTTCTGCCTTTCTCTTCCCTTCCCTTCTCAGGAGTGGACACTTCCTCCT
TTAGCCCCCTCACAGCTGTGTGAACCTCTCTGTATCTCTCTCTTTCTGTCTCTTTCTCCCCCTCTC
TCTCTGTCTCATTTGTCTCTCTGTGTGTCTGTCTGTAGTATTCTCTCTCTGTCTCTGTCACTCTGT
CTCTCTCTCTCTGTGTCTACCTTCTGTATTTCTGCTTTGTTTCTTTTCTCTGTGTGTGTGTGT
GTGTATCTGTTTTTCTCACTCTCTCTCTGTGTCTATCTTTCTGTATTTCTGCTTTGTTTCTTTTCT
15 GTGTGTGTGTGTGTGTATATCTGTTTTTCTCACTCTCTCAATCTCTCTCTCTCTTTCTGTCTCTC
TTTTGCTGGCCTGAGCAAAGAGGGAGCCCCATCCTGATGCTACATAACCG
TGAACCAGCACAGACAGAATTGTAGGAAAGTCCTGCAAGTAGAAGGATAGAAGGATGAGGG
AAGAAACGCCATGTGAGTCATGACAGATCCCTTTCCAGGAGCCACTGACTCACCCCTGCCTCCT
GCCCTCCCACTGTGACACTATTACTCACAGACAGGCCCGGATTAAACCTATGTTCCAGGTGCCC
20 TGTGGTTCCACAGTGTGGCTCCCTGGGTCTGGCCTCAGGCTCCACAGGTGCCCAGCCCTGCCA
AAGTCTCCAGAGCAGCTGTCCAGCTGGGGAGCTGCGGGGGCCCTTCACAGAGCGCATGGGAA
GAAGTTCCATCCTACACATTACATCGAGAGGGACGTGCCTGAGAAGGGGAGCTGGAGCCCGT
GCAGCCCCCTGCTTGCCTGCAGAACATAGTGTACCCTGAGCATGCCATGAAAAACACAAACGC
ACAAAGTTGTAAAGAAAAAAGAAATGACAGGTGGCTGTAAATCAGTTATAGCCCACGAGA
25 GGCCCACTAATGAGTGGTGATTTCAGCTGATTACAAAGAAATGATGGTGTTTTCTGTAATGAA
CTAAACATGCACTCGTGCCTGCACACACGCGCACGTATAGTCACATAACTGACCAGCCCTATG
CATCACTTGTTAATTACTTAGTAAGTGTAAACAATAATAGTTTCCAATAAGTGAGCCTTAGTCT
CTGCGCAAGGGTCAGTTTATTGAGCACACGGGGGGCCTTGCAGTGGGGGCAGGTGATCTGTCTCC
TGGGAGCCGCCAGCCTCTCCTCTCCTGCTCTTCATCTTCCTCCGTGGTGGGAAATTGTCTCACT
30 GCTTCTACACCTGAGGCTGAACATCTCCCTTTATTTCACTCTGAAACACATGTAAAAATATAG
TGGAATGAATTAAGGTGCAATTATTGATATCAGGCAGTGAGTACATCAGGGTTTATTATAC
TATCTCCTTTACTTACTTCGAAGTTCTCTATTACCAAAAAATTAATAAACTATAAAAGAAAGAA
AAAGGAAATGAGGCTAGATTCAACACAGATTACTCTTACCAAAACCCCTTCGTAGTCCCAGGAGT
CCCCTAACACAAGCACTTGTGACCTGGAGTGATATTCACAGCATTTCCTTACCTGGCAATACCT
35 GAGTATTAGCCCCCCCCAGTGGGATCTTTGTTGTAGACAACCAGCAACTATCAGCCCAGCCAAT
AAACAAGTAGGAAAGGGGAGTGCTGGAGAGGCCAAGAAGTGGGATTTTCCATGCTCCTGGGC

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

TGTGATCCAGAGGGCAGGGCTGTGAGGCTGATCTCAATGAACACTCTGTCTTGGAAGTACAG
GGATCCTCTGCTACCTGAAAACGTTCTGAGTATTCACCTTCATGGATTGCAAAAGTCATTTACCC
AAAATTCACCTCTCCAATGAAAAGTGAGTATGATGAATCAGTATTCAAGTTCCACCTGGGTCC
TGGGAGAGGGCATGGACATCATATCCCAGCTGTTCCGACAGGAGGACCCAATCTGAGTCTCAC
5 TGCCTGCCTGCATCGTTTTGTCTGCTGCCAGCCTGCACAGTAGGAAGGGAAAACATGATTTGTA
TCTGTTTTAGGTCAGGTTCCCAAGAAGTAGAGCCTGAGATTGGAATTCTTGGAATAATGGTGT
TGCGGGAGCGCTGTCAGCAGAAGCTATAAGGAAGTTGGGGGGACAGAAAACGAGAGGTAAG
AAGCCAGTCAAAAAGGCAGGTCCAGCTTAAGTCCGCCTCAGTCTGGTTCCACAAGGGCTCTGA
TGCATGAAGAATATCACAGGGTTGTCCCTCCTGGGAGAGGGGCCAGCCTATTGTACCTGTATC
10 AAAGCCACCAGCTGAGGGCCAGTGGGGAGGGAAGATCTTCCAGGCATTTCCAGGAAACTCTC
AGGAGAAGGGTGTAGCTGTGAGCAGTCTGCAGCTGCTGCTCACTGCGGCTAAAGGCTGGGTG
TGCAGGCCAGTCAGCCAGTGAGGTGCCAACAGCAGGCACTACAGTCCACCCCTTGACTGCTCA
GACCTACTGCTTTCCACTTTAAGCTCTCTCCATCCAGGCACAGCTTCAGGGGAAAACTTACAATT
GGAGAAACAGAGGGATGAACTACAATGCCCACTTCTGCATGTGATTGTAAGACTGTCACTGA
15 TACTCACCATCATGCCCCATCCCCACCATCCATTCTAGTGTCCCCCTTCCCCTTGGCTAACACTGC
TGGTCTAGGTGACTTCCCTAGAGCAGGAGCCAAACCCCTTATCCCTGAGGCATCTGAATCCTGG
ATTCCTTTATCAGGCTATTGTTGTTGTAAGTTGTCCATTCCCAATTACAACCTGGACATGAGACT
ACCAAGAAACACCCTGGCAAATCATCTGAGTGCAAGCCATATTCTTCCCTGCTCCATTATGTAG
CGGTAGTCCTACCTCCTAATGACAAGGGTAAATTGCCACATTTTGCTCCTTGTGCCAGGATGG
20 TAATACCTTTCTCTACCTGCTTGGCTACTGGCACAAGGAAGCACAGCATGACCAGGAGGCAAT
TGTAGCTGTACATTTAGTGAATGTGTTAATGTATCACCTGGTGGAAGGACCCCCCTCTGAGAAC
CAGGACTTCTAGACCCACAAAACCTAAAGTTGTGAATGGCGGAAGCACAAATTTCCCAAGTG
GATCATGGAGAGTGATGAAGAGTTCTTGGTTCCCAAACCCACATATTTTACCTTTCAGGAACA
TGGCCTCATCCCATAGCCATTAGAGTGCATATTGCATTCTGGAGGAGACTGGGCCCTCCTCAT
25 GGGTGTATCTTCAAGATGACAGCTCCACTGTGCCTCCAAGAGGATGCTCCACCACCCTATCT
GTGATTCCTTGGTTAGCAGGACAGGCTGCTGCACTGAGGGTAGGAAAGGCAAGTCCATTGAT
GGCTGGAATACATGTCAATCCAAGTCAAGAGAAAAATGCCGCCCTTTCCAGGTTGGAAGGGGC
CCGATTTAGCCAACTTGTACCCAGTAGTGGCTGGTTGGTCTCCTCCAGGAGCAGTGTTATAC
CAGGAATTCAGCACCAGTCGCTATTGCTGGCAGTTCTTACATTCAACAGCAGCAAAACTAGGT
30 CAGCCTTGATGAGAGGGAATGTATGCTTCTGGGCACAGGCATGGCTTCCTTCTCTGACTCCAT
GACTATCTATTCTGAGTGCATGGTGGCCGACATTCAGCTGCCTGCCCATCCTATCCACTTGGT
TATTATTGCCTCTTCCACAAGAAGTGGTTTCTGGCTGTCATTAATGTCTCATACTTTGTGCCCA
CTCACACAGGTTTAGCTCTACAACTTTTCCCATGCCACCACTTTTCCACAATCTTCTAATGTT
GCTCCTTCCAAGCTACTGAAGAACGAGCTAAGCTATTCACCAATGTCCATGAGTCTATATTTA
35 CCTTAGGCCACATCTCTCTCCACACAAAGTGAATAAGCAGGTGCACCCTCCAAAACCTCTACTA
AGAGGATTTCTTCTCCCCAGTGTCTTTCAGGGCCACCTTGAGTGGGGCTGAAGTACAGCAGAA

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

GTCCATTTCCAGCTTGCATCAACATTCCAAACTAACCTATCCATGATCAATGCATAGATGGGT
TTTTCCCTCCTCCAGCAGCTAGACAAAAGACACCCCCCACCAGGAGGCCATATTTGCATGTGG
GTGAAAGAGAGGGCACAGGGGCCAATATTTCGTGCAACAGTGGTAGATGGCAGGTGGGTCTGG
GCCACCTGTCCCTGCAGCTTATCTGTGCCATCTGGACCTGCTCAAGCCTGATTCCAGATATAACC
5 ATTTCCATCTTATGATGGATGGCTTATGACCTAGTGGGTCTGACAGCACCAAACTCATAATGG
GCAGTTATGGCCACATGGTCACTTAATGTCTATGGTCAGACACTCTGCTGAGTGGCATGCCA
GGAAATGCTTTACAAGTGGTGTTTGGTTCTCTGCTGCAGATGGCATGACCTTGGTCCGGAGCC
CTAGGGGTTTGGACAGTGACTCCTGTTGGGGCCTAATCTCACATTCCATGCAGAGTATCATCA
GATTTGCCAATCACATAGCCTAAGGGTCAGGACTGATCCAACCAGTTTTTGCAGAGATCAAAC
10 TGGAGAATGAAAGGTTGATATGATGTGACCATCATATCACGTTTTTCTCTCTTGAAAAGTATG
CAGATGTCTGAAAGAGACAAGTGGCCCAAGGAGAAAATGCATGCCTTCCTCAGGATCGGCCCCC
ACCTCCCCCTCCTGGCCACAAGGAGGGTCAAATCTCAGCATGGCCCAACTTGGACCTGTCAAGG
AAGAAGAAAAAAATTGTATGCCAAAGGAACTCAGTCTTTGGCTAACAAGTACTAGACATCCT
TTAAGTCTTTGAGAATGGTAATAATTTCTGCCATCCCTCCAGATTTGTGTTTTTCTGTTTTGGC
15 TGGGTGGGAATGCAGCATTTTCACTTTGCCTTTGTTATTACAAATGTTGCTTATTCTATAAATC
AAGGAACCATTTGTAAGGGGCTCTTCTGATGGTTAAGTATATCCATTCCAATGATTTATTCGGGA
TCCAAGGAAATGATTTCTGGGTGAATACACAGAACTAGTGGATCCAATTTGAGACATACCTG
GGCCAGAACTATATTTGTCTCTTACCCCAATAAGCCTGCACCTCTACTAGGACAGCCATGACA
GCACTTTGGGACCTAGATATAAGTGTGAATTGCTGGCTGGGCATGGTGGCTCACGCCTGTAA
20 TCCAGCATTTTGGGAGGCTGAGGCAGGTAGATCACCTGAGGTCAGGAGTTGAAGACCAGCC
TGGCCAACACGGTGAAACCCCATCTCTACTAAAAAATACAAAAATTAGCTGGGCGTGGTGGT
GGGTGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGGAGAATTGCTTGAACCCAGGAG
GCGGAGGTTGCAGTGAGCCAAAATCACACCACTGCACCTCCAGCCTGGGTGACAGAGCGAGAT
TCCATCTCAAAAAAAGAAAAAAGTGTGAATTGCTATGAAATCACTATCAAAAAGATCTG
25 AGTGTACCCCTTACTCAGTGTGGTCTGAATATAAATAGCCATAGGTTCCCTGTTATACACACTTG
CTGTGGTGCTACAGAGTCTTTCCTCATGGGAACCCAGTCCCTCTTTCAGTCAATGGGTTCTGGT
TCGAGAACTGGCTGAGGTTTGGAACTGTGCCTTTCCATCATAACTTTCCACTGGGGTGACTG
ACCTTGGCCTTCTGTTTCATCCTTTCTAGCCCCTAAGAATCCAACACTCTATTAGCCTTCTCCTTA
GACCCCTATAAGCTAATCCCTTCTAGTTGTTAGTCTGACCTTGGTGCCCAATATGATAATTATT
30 CCCACTTTGCTTCTGATATGCTTCTAAGTGCTGCCCCCTGGTCTCTGCCCTTAAGTGATCTATCA
TCCCCACTGCCATTAGGGGGAGAAAGCTCTGAAAAAGAGTTGTCTCCCATCAACTCTGGTCTAC
AAAGGACAGCCCTACTGAGCCTCAGCCATGTGCCCCGACACCAGCAGATTCTTTACAGCCTGGG
AAGCAGAGTGTCTTCCCTGCCTTTCCAGGGAACATAGCCAGCTTACAGGCTTTTTGATCTTAT
AGAGTAGGTCAGTTATATTTTGGCCCATTTCTTTTATCCTTTTGATCACTTCCTCTTGGCCCCACC
35 ATGTAAACTCAAGCATCCCTGCTTTCATTTAATCGAGCTGTTGCTTTTTCTAAGCTACCAAGAGC
AACCCAGCAATATATCAGAGCCCTCTCTTGGGACCCCTTGCTAGGGTGTTAAATCCTGCATCA

TAGGAGAATGCCCCACATCAGCAAAGTCCCCTTATCCTCTTGATATCCCACCTGCCCCAGTCC
 AGCACCTTCAGGATCTGGTCTCAATCACAGGATCCAGCACCTTTGGGACTGTTGCAAGCATAA
 GATCCAGCACTTTTGGGATCTAGTCTCCCACTTCCTGCTAGTACTTGTTAGCCAAAGACTGAGT
 TCCTTTGGCATAACAATTTTTTCTTCTTCCTTGACAGGTCCAAGTTGGGCCATGCTGAGATTTG
 5 ACCCTCCTTGTTGGCCAGGAGGGGAGGTAGGGGCCGATCCTGAGGAAGGCACTCATTITCTCCT
 GGGGCACTTGTCTCTTTCAGACATCTGCATACTTTTCAAGAGAGAAAAGGCCTCCTTCTCACA
 GCAAGACTACTTCTGTAGATGCAGGTGGCTCGTGGGAATCTGGCAATTCAAAATTCTCAAGTG
 TACTCACTAGCACATTAGAAAACCAGTAGTACACATCTCTTTCCAAATCTTCATTCACTGACA
 CTATGTCAGTAGCTGGAAATGGGCCATGGTGGGTGTATTTAAACCATGAAAATCAGAAAATG
 10 CTACAAACCAGGGCATCCCCGCATCTCTAGACAGCAGATTGTTGGCCATTTCCAGCATACCAT
 TGTGTATACTCCTTCCCATCAGGGCCGTGGCTTGCTTGGTGGAGGACTCAGCCCTTGCTGAA
 GTTCTGCTACTGCTCTTACAATTGAGTCCATATGCCTGGTCTCCAGCTCTGCCTGCCTCACTACA
 GGAGACAAGCATCTCTTTGAACACTGCCGAGAAGACCCTCTGGCTCTCAGGCTTGGCTTTAAA
 TCGATAGACCTGAGCCTGCCATTTTCTCTTTTCCATGCATCACTCCACTGATCCACAGGTCTCA
 15 GTGGCATAGTCCTTCGGGTTAGCATCTCCCCCACACCCTCGGTGCCAGAGACACTGAGTAAGA
 AAGTACCTCCCTGTCTACCCCCATCCCCGCTCCCCACAGGCAGGGCCTTGGCGATCCACTGCTG
 CAATGTGCCAGAGACTGTCAGTACTCCTACCACCAGTGAGGTGGCAACCAGCTGGGAAGTGA
 TCCAACCTCCAGAGTCCCCGCCCTCATAGGCTGATTTCTAGGACCACCCCTGGTATACTGTGTTAG
 GTTCTTGAAGCAGAGCCTGAGATAAGGATTCTGGCACCTGTGATTGAGTGGGAGGGGTGCTCT
 20 CAGGATGAGATGGGGTAGAAATAGGCAAAGGTACAGATTCAGCAGCAGTTGAGCCTCAGTCT
 GACCCAGCAGGGAGCTCTCAAATGTGAATGACATCACAGAGTTGTCCCTCTGAGGCAGGGGC
 CAGCCTTTGTGCTCCTACATGAGTCAGTCACTGGCTGGAGGCCCTGGGGAAAGGCTAGGGCT
 GCCAGCTTTAGCAAATAAAAAAATTAGGGCACTCAGTTAAATTGAATTCAGATAAACACA

25 The genomic DNA ~~or for~~ YKT6-SNARE YKT6 gene is 39,000 base pairs in length and contains seven exons (see Table-14 below for location of exons). As will be discussed in further detail below, the ~~YKT6-SNARE~~ YKT6 gene is situated in genomic clone AC006454 at nucleotides 36,001-75,000.

The human liver-glucokinase is depicted in SEQ ID NO:2:-

30 MPRPRSQLPQPNSQVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRST
 PEGSEVGDFLSLDLGGTNFRVMLVKVGEEGEQWSVKTKHQTYSHIPEDAMTGTAEMLFDYISECI
 SDFLDKHQMKHKKLPLGFTFSPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDF
 EMDVVAMVNDTVATMISCYIEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTE
 WGAFGDSGELDEFLLDYDRLVDESSANPGQQLYEKLIGGKYMGEVLRLVLLRLVDENLLFHGEA
 35 SEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGL

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

AGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRRLTPSCEITFIESEEGSGRGAALVS
AVACKKACMLGQ

and is encoded by the genomic DNA sequence shown in SEQ ID NO:6:-

5 ACTAGCACATTAGAAAACCACTAGTACACATCTCTTTCCAAATCTTCATTTCAGTGACACTATG
TCAGTAGCTGGAAATGGGCCATGGTGGGTGTATTTAAACCATGAAAATCAGAAAATGCTACA
AACCAGGGCATCCCGCATCTCTAGA
AGCAGATTGTTGGCCATTTCCCAGCATACCATTTGTGTATACTCCTTCCCATCAGGGCCGTGGCT
TGCCTTGGTGGAGGACTCAGCCCTTGCTGAAGTTCTGCTACTGCTCTTACAATTGAGTCCTATG
10 CCTGGTCTCCAGCTCTGCCTGCCTCACTACAGGAGACAAGCATCTCTTTGAACACTGCCGAGA
AGACCCCTC TGGCTCTCAGGCTTGGCTTTAAATCGATAGACCTGAGCCTGCCATTTTCT
CTTTTCCATGCATCACTCCACTGATCCACAGGTCTCAGTGGCATAGTCCTTCGGGTTAGCATCT
CCCCCACACCCCTCGGTGCCAGAGACACTGAGTAAGAAAGTACCTCCCTGTCTACCCCCATCCCC
GCTCCCCACAGGCAGGGCCTTGGCGATCCACTGCTGCAATGTGCCAGAGACTGTCAGTACTCC
15 TACCACCAGTGAGGTGGCAACCAGCTGGGAAGTGATCCAACCTCCAGAGTCCCGCCCTCATAGG
CTGATTTC TAGGACCACCCCTGGTATACTGTGTTAGGTTCTTGAAGCAGAGCCTGAGATAAGG
ATTCTGGCACCTGTGATTGAGTGGGAGGGTGCTCTCAGGATGAGATGGGGTAGAAAATAGGCA
AAGGTACAGATTCAGCAGCAGTTGAGCCTCAGTCTGACCCAGCAGGGAGCTCTCAAATGTGA
ATGACATCACAGAGTTGTCCCTCTGAGGCAGGGGCCAGCCTTTGTGCTCCTACATGAGTCAGT
20 CACTGGCTGGAGGCCCTGGGGAAAGGCTAGGGCTGCCAGCTTTAGCAAATAAAAAATTAGG
GCACTCAGTTAAATTGAATTTAGATAAAACAACAAATTATTTTTTAGTATATGTCCCAAATTG
TGCATAACATAATGTGTTTTCTCCGCCAGCCCTGGGAAGGGCGTAACTTCCCAGGTATTTCTA
GGTGAAGTAACTTTGTAGATCAGGAGTAAGTCCCAGGAAAGAAGTCCAGCTCTTCTCT
TCAGCCCTGGGCAGCTGGGGGTAGGCACAGGGGCCAGCAGGCACCCATA
25 GCATCTCCTACAGCATCTGAAATGAACAGGGTCATCACGTA CTACATACAAATGTACCCACTG
CTGAGTTCTTCAGGGATTATATCATTAGGTACTTGGTATTTTAAATACATTACATTATGCAGA
AGTCCTTTGTGGATTGCTATATTTGGAGAGTTTTGTGATATTGGGGGGATTAGATGGAGTTTT
CAGATGGGCAT CATA CGGTTTTTCATTTAAACCCCTAGAGTATTGTAATCCTAGGGAGTGA
TCCTGCGATTAGTAAATTAGCTCTCCAATAGATTTTCAATGTGGTTGCAAAGGACATGCATGT
30 GGTTCACCCCTCCCAGGAAATCCAGAAGGGCAGCATTGGCCTGAGTGGCCTGAGTTTGGCTGGT
TGGGCTGGTAATGCTGGACAAAGA
CAATGGGTGGAATGGTTTGCTTCCCTCAGTCCTTTT CAGACACAGCCCAGC
CCACCACGTCAAGCCAGTGGGTGCATCTGCAACCAATCCCCATGAGAACT
GCAGCCTCTCAGAGGTGGGCAAGTTGGCCCCGGGTGGGTCAGGAGGATCAG
35 ATGTTGAGGAAATCTTTGGATTGGAGGCAGGCAGAGCAGGGAAGCATCGG
GTGATTCTATGACAGACCCAGGGCTCCAAGCTGCAGTTCAGGAGGGGCAC

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

TGGCACGGCCTCTGCTCAACTCCCCCTTGAGTGACATCAGGTGAAGTGCC
 GACAACACAGAAGGCAGCAAATGCTGCCAGTCAGGTCTGCTTCCCAGGAC
 AGCCAGTTGCTAACCCTTCTCCAGCACAGCACTGGATTTTGGTCACCTGG
 CTGGGAGCTCCACCTCCCCAGCTGCTGCCTCACCTGCTTTTCCAAACCCC
 5 ACCCTGTAAACGGTAACTACATTTTGTGCCCACTACGCCTCGTTTCCATC
 TCTTTGGAGCACCTCTCACGTGGAGCTGAACAGAACGACCTGTTAAGCCC
 ACCGTGTCTGTTAGGGTTGTCTAGGCTGTATCAGATACCCAATAAACT
 GGATTACCAACAGGTATTGTCAAAGCACATAAGAAAGAGTCCAGAGGCA
 GGCAGCTCTCAGCCTGGTGTGAGGCTCTGGGTGAGCTTTCCAGATTCTCT
 10 TAACCTTCCCCACATCTGCCAGATGCCGCCACAGGCACAGGAGGTACAAA
 CAAACCCAAAAATGTTCTGGAAACAAGAAGGGAAGGGGATCCCCACCATA
 TCTCCCCAGAGGCCTTCCTTCTCACATCTCACTGTACTGAAGCCAGCTCT
 AGCAGAAGACAGCAGGGTGAATTTGTCCAGGGTATTACAGCCCCCAGTGCT
 GGGTCCATTACTACTTGACCCCTGAATAAAACAGAGGTTCCATGAGCAAG
 15 AAGGAAGGGGAAGTGGATGTTAGAGGGCAAGAATGTATCCATCCCACCCC
 TAGGAGCACGCATGGACAAGTCCCCATTTTTGCTCCTATTGCAGCCCAG
 GGGCTAGCCCAGAGACCTTGCCAGTGCTGAGTCACAAGATGCTGGGAAAG
 TGAGACCAGAGCCTGGTCTTGGGGAACAGCTCAAGGCCGCATTGGTCTGC
 AGGTCATAGAGCAGCTGCTGAGCAGTGAGAGCCCACGATGGGGCCAGGCCC
 20 TGGGTCTTGGAGACCTGAATGAGATAGACTGGGTTCCTGTTCTCCTGGGC
 ATTGCCTCTTAGAGGGCAAAGACAATTAACAATAAAACAAATAGAACATGA
 AGTGTTTTCCGATAGTGACTGATATACTTTGGATATTTGTCTCTCCAAA
 TCTCATGTTGAAATGTAATTCCTTATGTTGGAGGTGGGGCCTGGAAGGAG
 GTGTCTGGGTCATGGGGGCAGATCCCTCATGAATGGTTTAGTGCCATCCC
 25 CTGGGTGATGAGTGAGTTCAGGTGAGAGCTGGTTGTTTGAAAGAGCCTGG
 CCCCCTCTCATTCTCCTGCTCCCACTCTTGTCATGAGACACCTGCTCCCCC
 TTCTCCTTCTGCCATGATTTTAAGATTCCAGGGACTTCACAAGAAGCAAA
 TGCTAACGCCATGCTTCTTGTCTGTCTGCAAAACTGTAAGCCAATTA
 CCTCTTTTCTTTGTAATTTATCCAGTCTTGGGTATTTCTTTATAACAGCA
 30 CAAGAACAGCCTAATACAGTGATGCTCTCCAAGTGACCTTTGGGCTGAGA
 CCTGAAGAAGAAGGGGAAGCAGTTAGGTCTGATAGCTCATGCCTGTAATC
 CCAGCTCTTTAGGAGGCTGAAGTGGGAGGACTGCTTGAGCCTAGGAGTTG
 AAGACCAGCTTGGAACACATAGCAAGACCCTGGCTCTACAAAAATATTTT
 TTAATTGGCCAGGTGTGGTGGTGCACACCTGTAGTCCCACCTACTTGGAA
 35 GGCTGAGGCAGGAGCATCTCTTGAGCCCAGGAGGTTGAGACTGCAGTGAG
 TCATGTTACACCACTGCACTCCAGCTTGGGTGACAGAGCAAGACCTGTC

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

TCGAAAAAGAAGAAAGAAGAAAGTAGGAAGAAGAAGAAGAAGAAGAAGAA
GAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAGGAAGA
GGAACAAGAACAAGAAGAAGAACAAGAAGAACAAGAAGAAGAACAAGGAG
AACAAAGAAGAAGAATAAGAAGAAGAAGGAGAAGAAGAAGAAGGAGAGGAA
5 GAAGAAGAAGAGGAAGAGGAGGAAGAGGAGGAGGAGGAAGATGAGGAGGA
GGAAGCAGAAGCAGAAGAAAAAGAAAAGAAAAGAAAAGAGAAAAGAAAG
AAAAGGGAAGGAGGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGGAAGGGA
AGGAGAGGGAGAGGGAGAAGGAAGAACAAGAAGAAGAAGGAGAAGCAG
AGGCTTGCTGCTGGATAGCCTTGCTTTTGCCAATGACCTTGCTGATTTTCA
10 GGGGGTCCTGGTGTCTTAGTCCATTTGTGTTGCTGTAAAGGCATACCTGA
GGCTGGATAATTTACAGAGAAAAGAGGTTTATTTGGCTGAGAGTTCTGCA
GGCTCTACAAGAAGCATGGCACCAATGCCTACTTCTGATGAGGGCCTCAG
TCTGCTTCCACTCATGGCAGAAGGTGAAGCAGAGCCTGCATGTGCAGATA
TCACATGGTGAGAGAGGAAGCACGAGGGGGCAGGGAGGTGCCAGCCTCTT
15 CCTAATAGTAAGCTGTCTTGAGAACTAATAGAGTAAGAAAATAACTCACAC
CCTGCCCCCAAGGAAGGGCATTAATCTATTCATGAAGTATCTGCCCCCAT
GACCCAAACATCTCCCATTAGGCCCCCACCTCCAACATTGAGGATCAAA
TTTCAACATGAGGTTCCGGTGGGGCAAACATCCAGCTATAATACTGGGCAA
TGCTGACCAGACTCTTCCCCCTCTCAGGCCCAGAGCTCCTTGGCCCTGTAA
20 CAACAGAAAATTGCGTTTGAGTGTCAAGATTTTTCCTTTAGTCCCCATGC
AGCTCCTTAGAATGAGGTGGCATCTTCTCCCTTTTCATAGGTGAAGAAAC
AGAAGCTCTGGAGGAACGAATCATTTCATCCAAGGTCAGGTAGCTAGTAAG
CGTCCCACCAGCTCCCCAGATCTCCTGTTTCCCTGTCCCAAGTCCCCTGA
GTGAGCTGGAACAATGGCTTCACTGGCACCTGCCGGGAATGGTGGCAGGT
25 GCCTATAATCCCAGCTACTCGGGAGGCTGAGGCATGAGAATCACTTGAAC
CCGGGAGGCAGAGGTTGCAGCGAGCCAAGATCACACCACTGCACTCCAGC
CTGGATAACAAACGGAGATTCCATTTAAAAAAATTAACATATAATATACA
TACAGTAACATTCACTTTTTTAAGTGTACAGTTTGATGAGTTTTATCAAAT
GTATATGGTTATATAACCACCATCACCATTAAAGGCAGAATCTTCCCATCA
30 CTCAAATAATTCCTCAGCCCCACCTCTTGCTGTCAATCACTTCTCCAC
CCTAGCCACTGGAAATCATTTCATCTGTTTTCTGTCCCCCTTGGTTTTGCCT
TTTCTAGAATGTTCTATACATGAGACCACTGAGAATATAGTCTTCTGTGT
CTGGCTTCTTTCACTTAACATAATGCCTAGCTCAGCAGTGTGTCAATCCT
CCCTCCCTTGCCATTGCTGAGCAGTGAGTATTCCACTGTATGGCTGTGCT
35 ACGGTGTGTTTCATCCATTATTCATTACACAGCTAATGGGCATTTGGATT
GTTTCCAGGCTTTGGCTATGATGAGTGAAGCTGCTGTGAATGTTCAAGTA

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

CAAGTCTTTGTGTAGACAGGGGTTTTCAATTGGCGGGATAAAATACCTAGG
AGTAGTATCGTGTGGTTAAGCGTACGTTTAAACTTAGAAAACTGTCAAA
CTGTTTTCCAATGTGGCCTGTACCATGTTGCATTTCCATCAGCAGTGT
GAGAATTCCAATTGCTCCACATCCTCCTCCCGACACTTGGTTTCACCCAT
5 CTTTTAAATATTAGCCACTCTGGTGACTGTGTAGTGATATGTCAGTGTGG
TTGTAATTTGCATTTCTATGATTGACTAATAATAATGTTGCAGATATTT
TGTATGCTTAGTGGGCATTTTTGGTGAGTTTTTAAAAATTGGGTTGTTGT
CACCGTCTTATTGAGTTGGAAGAATTCTTTATATGTTCTGGATGTTTATT
CATGTGTGTCTGCTAAGAGGTGAGACTGGTCTACCCTGGTCCTAACA
10 AGCACCCCTGGGCCTGCATCCCTTTTTGTGTCTGTGAGCTGGGTCTGCAGC
CCTCTCCTCCCACTACCTACTGCCCAGCAGTACCCCTCACCCATCACTGT
GGCTCCTGCAATGACATCTCAGCCTGTCTCTCCCTCCCTCCAGCTAGCCA
GAGGCAGGATGGCTCAGTGACACAGGGTGGGCCCTGAAGACAGAGTGCCA
GGGTTTGACCTTGTATTAGCAAGAGTCACAAGGGAACTTACTTTATCT
15 CTCCATAGCTCTGTTGTGAGGATCCAATAAAATTAATCCATAGAAGAGCTT
AGGACAGCACCTGGCACAAAGTATACATGAGCTATTATGATGTTATTCTT
CCAACCCATTGTTTTCTGTGTGTGCATAAACATGAATGCAGGACTCAGTGT
CCCAGCTCTGTGTCCCTCGCATACATTCCCTAACAGCCCACAGGTCTTGC
CTGTACACCGCTCATTCAATAAGTGATGACTCTGCCTCTTCTTGGCTGG
20 GGCCTTGCAATTGGACATTTCTGTATCCATATTTGTTTTTTAAAACTAGC
TGTGGCCGGGCGCGGTGGCTCACATCTCTAATCCCAGCACTTGGGAGGC
AGAGACAGGTGGATCATGAGGTCAGGAGTTCAAGGCCAGCCTGGCCAACA
TGGTGAAACCCCATCTGTACAAAAAATACGAAAATTAGCTGGGCGTGGTG
GCATGCACCTGTAATCCCAGCTACTTGGGAGGCTGAAGCAGGAGAATCGC
25 TTGAACCTGGGAGGCAGAGGTTGTAGTGAGCCAATATAGCGCCACTGCAC
TCCAGCCTGGGCAACACAGCAAACTCCATCTCAAAAAAAAAAAAAACAA
AAAACAACCTAGCTGGACTTGACACTCTTGTTAGAGGAAGATTTTTCCAC
ATCTGTTAACTTTTCTTCTATGTATCCATCTGTGCAGGTTTTTCTGTC
CTCCTGAGTCATTTTGATAATTTATATTATTTTGAATAATCATCCATTT
30 CCTATAGTTGTTTATTAGTGTCTTCTCTGTTATATTTGATCAGATTACCA
AATCTTGCTCAATTGATTGCCCATTTATTTTATTGTGTTTATTTTTTTGAG
ACAGGGTCTCACTCGACAGCCCAGGCTGAAGTGCAGTGGTGCAATCATGG
CTCACTGCAGCCTTGACCTCCTGGGCTCAAGCAATTCTCCACCTCAGCC
TCCTGAGTAGCTGGGACCTCAGGCACACGCCACCACAGCTGGCTAATATT
35 TTATTTATTTATTTATTTATTTATTTTGTAGAGATGGGGTCTCACTATG
TTGCCAGGCTGGTTTCAAACCTCCTTGGTTCAAGTGATCCTCCTGCCTCA

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

GCTTCCCAAAGTACTGGGATTACAGGAGTGAGCCACCATGCCCAGCCCCCT
ATTTACTTTATAGTAAGTGCCTTCATGGGCATAAATGTTCCCTCTGAGACA
GCTTTGGCTATTAGCCATACTTTTAATATTTTGTACATTTCATGGTTATTG
ATTTATAAATGGTCTGTAATGCAATGCAGATTTCCCCTTTGGCCCAAATG
5 CCATTTACAGCAGCACTTTTCTCTTTCTGAGCAGACAGAATATTTTGGTT
TCCCCTCTGTTGTTTATTTCTCGTCTGCCTCGCCTCATTGCTAGGTGTT
CCCTTGGTGTGCCTTAAGTATGAGCCACTCAAATATTTGTGTTTCTCTAA
ACACCCCTGACACTGTCCCTGCTGGTTTCTCTATCTGGAATATCCTTCCCT
TCTTGGCCAGTTCCCCCTAGTGCATCAAAGAAATCCTGCTCTTTTGCCTT
10 CAGAAAACAAAACAAAACGAAACCTATCAGTCTCCTTATGTCCCCAAAGA
CATAGCTTTGCTGGTATCTGGTTGTATTGAGCTGTTTCATTGTCTCTTCT
GCTAGATGGTAAGCTCCTTGGAACTAAAACTAATCACTTTTCTAACTT
CAGACTGAGCACAAATTAGGTTCTCAAGAAACATTGAATAATGAGTGATC
CGGTATCCCCCTTCCAACATATTTTTGGTCATTGATACCATCATTCTGAGT
15 AGTTACTAGGGAACACTTCCTGCGAGTAACCAATACAGCAAAACGTGAAA
TACAGTTACATAGTAGAATTGTATTTCTTGCCCATATAATAGTCAAGTGC
AGTTCTTCATCAGCTGGGAGGTTCTCCTCCACACAGTCATTTAGGAATCC
AGGGAACATAGCAGAGGTTGCTAGCTCTAGACCCAAACCCATGTCTCTT
TGTCACAGTGAGGACAATGCCAGCAACAGCTGGCCAGCTGTTCTGTAGT
20 TCTCAGCCTCCCTCGCAGTGAGATGTCTCCATGCAATTTTCAGTGGAGCAA
CATATACCATTTCCATTTCCAGGTGTAGGCTCCTAAGAAGAGGGTGGCTT
CTTCATGTTCTTTCTCACCTTTCCGTAGGCTAGCTGCAGATAATGATGAG
GCTTTAGGGAGTGGGTGGAGCCATAAAGTAGAAGCCTGGATTCCCTAAATG
ACGGTGTGAAGTGTTCCTTAAATTTACGTAATTGTTTCTTAATTTCTGT
25 TTGGGTATTGTGTTGCTAAGGTATAAAAAACCCTGATTTTTGTGTGTTG
ATATTTGTGTGCTGCAACTTTGCTGAATTAGCTTATTAGCTCAATTTGAT
CTCAGATATTAGCTCAAATATTTTGGGAGATTATTTATGGTTATCTACAT
AAGATCATGTCATCTGAAATAAAGATAGTTCTATTTCTTCTTTCTATCT
TAGTCCATTTGGGCTGCTGTAACAAAATGCCATAAATTGGAGGCTGAGAA
30 GTCCAAGATCAAGGCCCAAGCTAATTCAGTGTCTGATGAAGGCCTGCTTT
CTGGTTCATACATGGCACCTTCTAGCTGTGTCCTCACATGGTGGAAAAGG
CAAGGTAGCTCTCTGGGATTCTTTTTGTTTGTGTTGTTTGTGTTGTT
TTTGTGTTGATTTTTTGTGAGACAGAGTCTCACTCTGTCACCAGGCTGGAGTG
CAGTGGCACAATCTCGGCTCATTTGCAACCTCTGACTCCCTGGTTCAAACG
35 ATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGGTACCCATCAC
CATGTCCAGCTACTTTTTGTATTTTTAGTAGAGACAGGGTTTCACCATGT

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

TGGCCAGGATGGTCTCGATCTCTTGACCTCGTGATCTGCCCACCTTGGCC
TCCCAAAGTGCTGGGATTACAGGCATGAGCCACCGTGCCTGTCCTCCGGT
ATTCTTTTTATAAGGGCTCTTTTTCTTTTTATGTGGGCTCTACCCTCATG
ACCTAGCACCTTCTAAGGCCCCACCTCTTAATATCATCACACAGCAGATT
5 TAATATATGAATTTTGAGGGGACACATTCTTTCCATAGCACTTTCCAGTA
TGGATACCTTTTATTTATTTTTCTTCCCTAATTGCTTTGGTTAGAAATGT
CTTCCCTAATTGCTCCACTACTATGTTGAAAAGAAGTGGCAAAAGTGGGT
ATTCTTGTCTTGCTCCTCTCTTAGGAAGAAAGTTTAAGTCTTTTGCCATT
AAATATGACGTTAGCTATGGGGTTTTCATATATGACATTTATCATGTTGA
10 GGAAATTTTCTTCTTGTTTCAATGATGACAGGGTGTTGAGTTTTGTCAGA
TGCTTTTTCTGCATCAATCAATATGACCATGTAGTTTCTTTGTTTTATTG
CATTATTGTAGTACATTACATTAATTTTTGCATGTTGAACTATTCTTGTG
TTCTTGGGATAAAATTTCACTTGGTTATGGTGTATAATCCATAACCATAAC
CTGAAGATATGCTGAAGAGGCTAAGTGCCATGGCTCATGCCTGTAATTCG
15 AACACTTTGGGAGGCTGGTGTGGGAGGATCACCTGAAATCAGGAGTTTTA
GAAGAGCCTGGGCAAGTAAACAAGATCCCATCTCTACAAAAAATTGAAAA
TTACCGCTGGGCATGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGTGG
CCGAGGCAGGCAGATCACCTGAGGTGCGGAGTTCTAGACCAGCCTGACCA
ACATAGAAAAACCCCGTCTCTACTGAAAATACAGAATTAGCCAGGCGTGG
20 TGGCACATGCCTGTAATCCCAGCTACTCAGGAGGCTGAGGCAGGAAAATC
ACTTGAACCTGGGAGACGGAGGTTGCAGCGAGCCAAGATCATGCCATTGC
ACTCCAGCCTGGGCAACAAGAGCAAATCTCCGTCTCAAAAAAAAAAAAAA
GAAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAATTAGCTTGATGTGG
TGGTTGTGCACCTTTAGTCCTAGCTACTCAGGAGGCTGAGGCAGGAGGAT
25 TGTTTGAGCCCAGGAGGTTGAGGCTGCAGTGAGCCATGATTGCACCACTG
CACTCCAGCCTGAGCAACAAAGTAAGACCTCATCACTAAAAACAAATTTT
TTAATACTGAAGAATTTTATTTGCTGGTATTTTGTGAGGATTTTGCATC
TATATTCACAAGAAATATTACTCTGTAGTTTTTCTTCTTGTAGTATCTTT
GTCTGGTTTCAGTATCAAGGCAATGCTGGCCTCATGAGATCAATCAGGAA
30 GTGTTACTTCCTCTTTTATTTTTTGGAAGAATTTGAGAGAATTGGTGTTA
ATTCTTCTTTAAATGGTTGGTAGAATTACCAGTGTAGACATCTGGTCCTG
GGATTTTCTTTGTTGGGAGGTTTTTTAGTACTAATTCATTTCTTACTT
GTTATTAGTCTAATGAGATTTTCTGTTTCTTCTTGAGCTAGTTGTAGTAG
CTCATGTGTGGAATTTTCTATTTTCATCTAAGTTATCCAAGTTTACCTAA
35 GTTAAAGTTCCATTTTATCTAAGTTGGGTAAGCCAACAAACAATACTAAA
TTGTTCATAGTATTCTCTCATAGTCCTTTTTTTCTCTAAAGTCAGTAATA

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

ACGTTCACTCTTTCATTTTTTCATTCCCTGATTTTAATAATCTGAGTTCTT
TCTCTCCCCCTCCCTGCAATTGAGAGTCATTTAAAAGTGTCTTGATTA
TTTTATATATCTGTGAGTTTTCCAGTTTTCCCTCTGTTATTCTCTTCTAG
TTTTATTTTCATGTGATCCAAAAAGATACTTTATATGATTTCAATTTTTT
5 ACATTTACTAAGACTTGTTTTGTGACTAAAAATATCCTTGAGAATTTCCAT
GCACATTTGAGAAAAATGCACATTCCTGCTGTTGTTGGACAGAGTGTTCG
TATATGTCTGTTAGGTCTAATTGGTTTAGAGTATTGTTCTAGTCCTCTCT
TTCCTTATTGATCTTCTGTCTAGTTGTTTTAATCCATTATTCAAAGTAGTG
GCCGGGCACGGTGGCTCACACCTGTAATCCCAGCACTTTGGGAGGCCGAG
10 GAGGGTGGATCACAATGTCAGGAGGTTGAGACCAGCCTGGCCAACATGGT
GAAACTCCGTCTCTACTGAAAAATACAAAAAATTTGCTGGACATGGTGGCA
CACGCCTGTAATCCCAGCTACTCAGGAGGCCAAGGCAGGAGAATCACTTG
AACCAGGAGGCAGAAAGTTGCAGTGAGCTGAGATCGCACCATTGCACTGC
AGCCTGGGCAACAGAGCAAGACTCTGTCTCGAGAAACAACAAAAACAAAA
15 AAAAAAACAAAGTAGTGTACTAAAGTCTCCAACACTACTATTGTAGAACTC
TATTTCTCCCTTCAATGTTGCAAAATTTTGTTCATGTATTTTGGTGTTT
TGTTCCTTATAATTTTTATATCTTCTTAATGGATGAAAACCTTTATCAAC
ATATAATGTTCTTTGTCTCTTGAGACTTTTTTTTTTAACTTAAAATCTAT
TTGGGCTGATAATACAGCCACCACAACCTCTCATATTGGTTGTTATTTTCA
20 TAGAATATCTTCTCCATCCTTCTACTTTAAAATCTTCTATCTTTATAT
CTAAAGTGAGCCTCTTGTAAGATAGCATATAGGTGGATAATGTTCTCTTTA
TTCACCTCTGCCAATATCTGCCTTTTAACTGGAGTTTAATCTATTTATATA
TAAAATAATTACTGATTAGGAAGGACTTACTTCTACCACTCAGCTATTTT
TTTTCTGTGTGTCTTATACATTTTTAAGTTTCTCAATTCCCTCCATTACTG
25 GATTTTTTTTTTTTACTTCTTGATTTTGTGTCTGTGTTGTTACATTTTGAT
TATTTTCTCCTTTTGATAGCGGCAGGAGGCAGCCAAATGCCTGGCAGATA
GAAGCTTGTCCCCCATGAAACCCACCTTCAAGCCAAAAAATAGCCTGAA
GGCTGAAAGACCGGACTGCTGGTCCAGATGAAACCCATGATCCAGAGTG
AGAACTTCCATTCCTGTTTGCCTGCCCTCTAAATAATCCCTTTTAAACCA
30 TCGAATGTTGCCTTTTCCAATACTACCTATGGCCTGCCCTCCCCCATTC
TGAGCCCATAAAAGCCCTGGAATCAGCCACATTGGGGGCACTTTGCCAAC
TTCAGGTAGGGGGACCACCTCTGTATCCCTTCTCTGCTGAAAGCTGTTTT
CATCACTCAATGAAACTCTCACCTTGCTCCCTCTTTGATTGTCAGCGTAT
CCTCATTTTTCTTGGGTGTGGTACAAGAACTCGGGAACCAGTGCACAAGC
35 CAGACTTGGTCTGGGCAGCACGGGTTAGTGGGCCATCTCCCACAGCAGGT
AGCATGGCCAAGTGAGGCCTGGGCAGGGCATCACCAAGGTCCCTGGCTTG

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

CAAAGTGACCAAGGAAAAAATCCTGTGTCACCTTCCTTTCTCATATTTT
TTAGTTATTTTCCTAATGATTGCCTTGAGGATGGCAATTAACATCTTACA
CTTATAAGAAGCTAGTTTGAATAATAGTTCCAATAGTACATGAACACTCT
ACTCCTATATATCTCCATCCTTCTTCTTTATATTGTTATTCACACAAAT
5 TATGTTTTTATACATTATATCCTCACTAACATAAACTTATTATTATTTT
TGCATTTGCCTTTTAAATCATAACAGGAAAAACAAGAATCACAAAGAAAAAC
TACATTAATATTTGCTGTTATATTTACCTATATAGTGACATTTAACAGTG
TATTTTTATGTCTTCAGATGTCTTTGAATTACTACTTAGTGTCTTTTCAT
TTTAGCCTCAATGTTTCCCTTTAGCATTTCCTATAGGGCAGGCCTGCCGG
10 TAATTAATTCCTTTTGGTTTTCTTTATCTGAAATGTCTAATTTCTTTTT
ATTCTTGAAGAATAGTTTTGCTGGCTATAAGATTCTTAGTTAATAGTTTT
TTTCCCAGCACCTCAATTATTATTAAAGTGTTATTATTATTATTATT
ATTTTGAGATGGAGTCTCCCTCTGTCACTCAGGCTGGAGTGCAGTGGCGC
AATCTCTGCTCACTGCAACCTCCGCCTCCCAGGTTCAAGCAATTCTCCTG
15 CCTCAGCCTCCCGAGTTAGCTGGGATTACAGGTGCCCCGCCACCATGCCCA
GCTAATTTTTGTATTTTTAGTAGAGACGGGGTTTCACCATGTTGGTCAGG
CTGATCTTGAACCTCCTGACCTCAAGTGATACACCCACCTTGGCCTCCCAA
AGTGCTGGGATTAGAGGCATGAGCCACCATGCCTGGTCTAAAGTGTAATT
ATTATTACAGCTGCCATTTGGCCTCCTTGGTTTCTAATGAGAAATCATCT
20 GTTAAACTTATTGCAAATCCTTGGTATGTATGCTATGTGTCAATTTCTCTC
TTGCTGCTTCCAAGATTCTCTCTGTCTTTGTCTTTTGACAATTTGACT
ATAATGTGTTTCAGTGTGAATTTCTTAGAGTTTATCCCACTTGGATTTC
TTGAGCTTCTTGGATGTGTACGTTTGTCTTTCACCAAATCTGGGAAATTA
TTTCACCATTTCTCAAATATCTTTTTCTTCCCCTTTCCATCTCTCTCTT
25 CTGGAGCTCCCGTATACTTAGTTGGCATGACTGATGGTATCCTACTGGTC
CCTCAGGTTCTGTTCAATTTTCTTCTTTCTTTTTTCTGCTCTGCAGACT
GGATAACTTCAATCGCCTTTTCTTCAAGTTCAATGATTATTTCTTCTGCC
TGCTCAAATTGGCCATTTAACCCCTCCAGTGACTTTTTCATTTCAGTATT
GTACTTTTCAGATCCAGAATTTCTATTTGGTTCTCTTTAATAAAATTCTT
30 TTTATTGTCAATCCCCATCTGTTACATATGCTCTCCCAATTTCTGTGA
GTTCTTTGTCCATGGTTTTCTTTAGTTAATTAAGCATATTTAAGACAGTT
GACTTAATGTCTTTGACTAGTAATTTCCAATGTCTAAAATTCCTTATGGAT
AGCTTCTTTTAAATTATTTTTGTCTGTAGAGAGTCATATCTTCCTCTT
TATTTGCTTTGTAATACTTTGTTGAAACTTAACATTTTGAGTAGTAAAA
35 TGTGGTAATTCTGAAGCCAGATTCTCCCCCTCCTTTGAGATTGGTTTTGT
TGTTTGTGAGGGCTGCAGTTGTCCATTTGTATAGTGACTTTTCCAAACG

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

ATTTTTGCAAAGTATGTATTCTCTCTTGTGTCTGGTCACTGACGTTTCTG
TTCTGGTGCCTCTGCAGTCAGCCTATGACCTGGAAGAGCATTTCCTTAAAT
GCATAGATTTTTTTTAAAACCCAAGAAACAAAAACCTAGCATGTATGTAG
CTTTTTAAAAATCTTCTGATAGATGCCACCTGGAAGGCTGCTGCTGCCTG
5 AAGGGGCAGAAACAAAGGCAAGCTCTACTCTGAGCCCTCAGGGAACCAACC
AGATAAACAAAAGAAATTTGATTCTCCAAATTTCTGGAAGACAAGGTCCCT
TTCTGCCCCTCTCTGCTCCAGCCAGCTGCTCTAGGAACACAATTACTGTC
CACATGGCCACAGGAATGTTGAAGAATGCAGGATGGTAGCTGGTTTGCCC
ACACCACTCACTTATGAGCCATCAGCATGCCTCTCCCTTCATCGAGCACT
10 CCCATGGTTGCTGTAAGTGTCCAATCAGGTTCCAGAATTCTGAAAGAGTT
GACTCTTACAGGATTTTTTTTCTTTTCTAACTTGCTGGTTGTTTAGATAGA
GGAACCAATTCCCTGAAGTTTCCCTACGTTGCCAGCTTCATGAGGATCATT
CCTAGTAACTCTTTTCAGACAAAAAGCTTCATTGATTTACTGTAGGACTA
GCATCAAAGAGTCTATGCCACCTAGTCTGTCTCCTTAAAAACACAGAAATA
15 ATCAGTATGCATTGGGGTAGGAGTTTGGCATTAGATCTGCCGTAAATCAA
GAGCTGGGGACAGCCCATGTCTTAAACTCTGACCCAAGGGCTAAAAATATC
CTTTGGTAGCAACAACAGCTACAACTATTGAACAACCTTGTATGTGCCAA
GAGCCTTACCTGCATTATCCCATTTGAATCCTCTCAACAGCCCTGTGAGGT
AGTAGAATTGTTGCCTGCCCCCTTACTGAGGCCTAGAAACATTAAGGAATT
20 TGCCCGAGGCCCTAGAGCCAGTGAGTGGCAAAGCCAGTCTCCAGACTCAG
GCTGGAGATCCTACAGTTCTGTGTTACCCCAGTGTTATCCTGCCTCTCAG
CACAGAGTCTTGGATGATTCTCCTAACCCCTCCCTAGGCAATGCACAGGG
CTGCTCCCTGCACCCCTTACTCATGCTCTGCTCTTCAACCCCAACAGTGCT
GGCCTTAGGCCTTATCCCTGACACCCAGCCCCAGGCTCCATTCCATCTGT
25 TGACAGAGGCAAACACTGGGGCAAACTGACCTCTGTGGATACCACTGTG
TCCACCTCCACCAGCTTCAGCTGAAGCCTCTGAACATCTCCAGCATGGAA
GAAGCCCCAAAGGATATTTCCCTGTCCCCCAGCATATGCTTGACCCTGAAG
CCCTCCCCATCTAGTCAAGAAGACCAAACCTGTAAACAATCCTGGAGTCAG
AGTGACCCATGGGTGAATCTTAGCCAAGTCACTCATAGCTGTTGCATCCT
30 AGTAAATCCCTTAACTCCCATAGGCTTCAGTTTCCCTGCATATAAAATGA
CAGCCTTCAGCTCATCGGCCAGTTTCAATCCATCTAAAGGGTCTAGCACA
TCCCCTGGCATGTGGAAGCCACAGGGCACACACTAGTTGTGGTCATTTGA
TCCTGGCATGCTCTGCTGTCTCTCGGCTCTCCCCTTGCCTCTTTCCCTGA
TGTCTGGCCATCAGCCACTGCCTAACACCCTCCCACTCACCAGGCCCTT
35 AGCCTGCCCCCTTAGCACAAGAGCACAGCCGGTCTCAAGTCTACCCTGCTG
TAAGCAAACACTTGCAACATCATGCTGACCTCCAGGCCCTGTGTCATCAG

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

CGTGCCACACTTGGTGCCAGCTGGTACTGAGGGTATCAGGGAACAGGC
 CAGTGGTGGAAGGGCGGACACTTTGGGTTCCCTGGTTTCCTGGCTCCCAA
 TATCTTTCCCAATGGCATATGGGGTCTAGCAGCTTGGCTCATTAACTGT
 GAACCTCTACCCTTTAGAATCTGGGCCCTCCAGGCTTGCTTCTGTGCAAAA
 5 TGGCAGATAAGGCTCAACCTTTCTTTTTTTAACTTCATTGTAAATATTAA
 CTCCATTAATACCCATTTACTGCAGAAAAGGTAGGAAATACAGATAAGCA
 AAAAGGAAAAATAAATTTAAATCCTCATACCACCATCATCAAGATAATTAC
 TGTACCATTTTGGTATATTTCTCCCAATACATATATTATCTATATCGT
 ATATACGACAAAAATGGATCATACTATGTTTCCTGTTCTTCCCCTGTGTT
 10 AGTCATCTATTGCTGTATAACAACTGCCTCAAACTTAGTGGCTTCACC
 TTTCCGTGTATTATGATGACAAGAATGTGGTATGACACTGTCTTATATCT
 GGATCATATGCTAAAAGATAGAAAAATGGTTTCTAAACTTATTTGTTCTGT
 AATAACAAAAATTTTATTTTATAAAGTGTTTTTAAAAAAAACCATAGTAGC
 TTGAAACAACAAACCTTTGTTATCTTCACACAGTTTCTGTAGGTCAAGAATTCAGAAGCAGCTT
 15 AGCTGGGTGGTCTGGCTTGGTGTCTCTCCTGAGGTCAGGGTTTTGGCTGGGGCTGCATCACCT
 GAAGGCTTGACTGGGGCCAGAGGA
 CTGCTTCCAAAGTGGTCCACTCACATGGCTGGCAAGTTGGAGTTGCGTATTGGCAAGAGACTT
 CGCTTCTTCTCAATGGATCTTCCCAGAGTTCTTGTAGGCAACCTCATAGCATAGCAGTTGGCTT
 CCCCCAGAGGGAACAGTCCAGGAGAGAAACAAGGCAGAAACCACAGGGTCTTTTCTGGCTTAG
 20 GCTCCAAAGT CATACTCCACCATTCTGCAATTATCATATTAGTTACACAGGCTAGACCTA
 TTCTGCATGGAAGAGACTATACCATGGGGTGAATACCAGAAGCAGGGCTATTGAAGGCCAGC
 TTCAAGGGCGGCTACACATTCCCTTTCAACAGTATGTCATGAACATCTTTCCATGCCAATAGA
 GCAGATGAATCTTACCATTTTTAATGACTACATGTAAGTGTAGCATAATTTATTTAACCAACC
 TCCTGTAGTTG GGTATGTGGGTTGTGTCTCGTTTTTTGATAGTAGAATTAATCATCTTGAA
 25 TATCCATCACCAAACCTTGTATATTATTTCTTTTGATGAATGAAAAAGAAAATCAAGTCATG
 TCTGTCAATCAGAACCCTGAGCAACTAAGAAATGGGGGTACCACTGGGACATAGAGCAAGGT
 CCCTTCTGATTCTGTCTTTGTCTTTCTCTCCCCATGAAATGGGGAGTTCACTATCTACTGAGAC
 ATCCTAGCCCA CAGCTGCACAGTTCTGTCTTTTTAGAAAGCTCTAAGCAGAAACAATGTTT
 ATCCATCCTCCTCGGGACAGCCCTTGAGCTACTGAAGACTCTAAGCATGTCTGGTCATCCTCC
 30 ATGAGCCATCATCTCTGAGGCCCTCCCCCTTCTTGGCCCCCTCTTCTCTGGACAGGTTCTGGACAG
 TCTTGGCCCTTCCAAAATTCCTGAAAGCAGGAAGTTCCTGCTACAATGACTCTCAACTCCAGT
 GCAGTAC AGACTGTTGGTGTACCCCTTATCCTGAAGAAGAGGCACTGAGACAGGAC
 AAGGGTGGGTGCCCAGGAGGGCTGGCATGAGTCATGAGAATCTGGTCCCGGAGAATTAGACG
 GTGTGGGGAAAGTAGGGGTGTTGGGCCGCTTTCTGGCCTCATGGATGCCAATGAATATCAGCA
 35 GGTGGCTCCCAGAAAGGAACTCTAGGGGATGCCTGTTGCTCTAAATAGAGGCTAGAGAGGGC
 ACTGGCAGTTCAGT

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

CAACCAAGAAAGGGGGCCCACTTGCCTCAGCTTCAGGCTTTGTACACATC
CTCAGCCTTTCTTGAGAACTGAATTTAGATTCTCCTCCCCTGTGCTGTGTGCTTGGCCCAGAAG
AAGGGCAAGTCTCGCTGGGTGGCTGCTTCTTGGCCTGGCTGAACCAGAAGGCCCCCAGTGCCAC
TCCAAACCTGGGTGTGAGCCCTGCCCCCATGAGCAAACAGTAGCTCAGAGCTGGGGGCTGTGG
5 GGGTCAGTGG CCTGTACATGAGATCTGATGAGGCCATCTCTGCTCTATATTGGGAAAGG
GATCAATTGTATCAAGGGCTTTCTTGGGAGTGATCACTCTGGCCATTGGCGAGAGACCTGGCA
TTCTGACAAGGCACCCTCCATACCCTGACCCACTTGCCAGCTCCAGCTAATTTTAGCAGGCTTT
GGCAGGTGCCAGCAAGTACATAGCATGTGGATGTCACTCCCAGGTGAGCCCAAGGAGAGGCC
TGGGCCAGAGC CTGGAAGTCATGGTCTATGCCCATGGAGGCACCCAAAGCAAGCCTGAGGC
10 CTGGACTTTGCAGTCACAAAATTAAGAATGATACCCCTGTTTTTTGTTTG
TTTTGATCAGTTGGCCACCTTCCTCCACCACCCCTTCCCCAAGTCCAT
CAGACCCCTGGATTGTATGAAATGCAAATCGAACCTCTCTGCAGATGAA
AATCCACTGGGGATCCCCCTTGCCCTCCAAGAGCAAGTCCAGACCTGCACCA
GCGCGGGGCCAGGCCCCCTTAGGACCCCTCCCTGTCCAAGGGCATTTCAG
15 TAAGTGTTCTGTGGCCAAGGCAGCCTGGTGACTTTCTGCCCCGACAAGGC
TGAGGAATGGAAGATGGGTAGGCTGGCTCTGCACACCCCTCCTGCTGGG
CAGCAATCCCTACCCCATGTTACAGAGTGTGGCCGGCTGCCCCATGGCT
CTGTCCCCGTGGCCCTGTCAACTGTTACCCACATGGCCTACCCTCCCTTT
CTGCCCTGCCTCTGACCCCATGGCAGGGGGCAGAGTATTTGAGCAGCCGC
20 CAGGCTGAGCCCTTTCAGTGCGAGAAGCCCTGGGCTGCCAGCCTCAGGCAG
CTCTCCATCCAAGCAGCCGTGCTGCCACAGGCGGGCCTTACGCTCCAAG
GCTACAGCATGTGCTAGGCCTCAGCAGGCAGGAGCATCTCTGCCTCCCAA
AGCATCTACCTCTTAGCCCCCTCGGAGAGATGGCGATGGATGTCACAAGGA
GCCAGGCCCCAGACAGCCTTGACTCTGGTAAGGGTCACACCAAAGTTAGGG
25 ACTTTGCACTGGGAGAGCAGCACCCAGGGCAGGGGCCCTTGGTTTTGCAGA
TTACCAAAAGTAAGGCTGGGGGCAGGGAAGGCGAGCAGGCTTGGGGGCACC
TTGGAAGGAGGCACATGGGCCTTGGGGGTCTGGCTAGGGCAGCTGTGCCTGCCACTGGCCCT
CTGCCCACCACCCCTCCTCACTGTGGCTATCCAGTGTCAGCCTCTCGAGGGGTCTAGGGTAC
TTATTCCTGGAGCTAACGGTGACCCAGGACACCAGTGTCGGGGGCTGGCCTGGGGCTTTTAT
30 GGGGGGAGCT GGCTGGCTGCCCAGGGCTGTCTGGCTCTCTGGGGGCTCTGCATGGCATT
CCAGGGGTGGGTGGATCAGGGATTCTGTCCCTCAGGAGAAATGTGGGCACTAGCCCAAGGCCA
CTCACTTCTGTGTACATAGCCACCTGAGGGCCCAGGAATGGAGGGGGCCAGGCTACAGCTGG
ACATCTGGCACTCGGATGGGCTCTGGAGCCCCCAGGCCTGCAGCATCTGCCAGGGACTGCCC
TGGCCCTTGGCCA TTCTCTCAGGGACCCACAGCTCCACCAGCCGGCCCCCTCCCAGTGCTGGAA
35 TAGACAGTTCTCAGTCCACATCTGCCAAAGGCGGCACTAGAAAGGCATCCTGCCTTTTTTACT
GCGTTCTGGAGGTGGGGTCACAAAGCACTGCTCACTGCATAAAAGGGACAGCATCCTGCCCCCT

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

GGCAGCCCTGCCTGACCAGCTCCGCCTCTCCCCTGCTATCCAACCTGTACACCCTGGTGACCA
 TGTCCAGGCC AGTGGCCTTAAGGACTGTCTCTGTACTGATGGCTCCACATCTACCTCTCC
 AGCCAGACTCTCCTCTGAACTCGGGCCTCACATGGCCAACTGCTACTTGGAACAAATCGCCCCCT
 TGGCTGGCAGATGTGTAAACATGCCAGACCAAGATCCCAACTCCCACAACCCAACTCCCAGG
 5 TCAGATGGAACCTCTTCTTCCCAGGCCCTTCTGTTCCTCTCCTCAGCCCCCTCCACCTCCCTTCA
 GAATAAGT CTAGACTCTTATCGCTTTCACCAAGCCTGCGCCCAGCATCCCTGCACAGG
 GATTGTTAGGACAGCCTGACGCCCTGCTTCCACCCTGCCCCAAGATGCCCCCTGCTCTGCAGCCC
 GCGCCTCCAGGCTTCTCACCTCCTGCTGCTCACAGCTCAGCCTCACTCCCTCCCTCCCCGCCTC
 TGCTCCAGCCTCAGTGCAGGT
 10 CCCTGCTCCCATCTTCTGGCAGCAGCTGCCCCGACCTGGTCCCTCTTCATCTGTCCCCATTCTCTC
 ACCCCCCAGCCTGTCCCCAACTTGACTGAGGTTCTTTCTCTGCAGATCCCCGCCCTTGAGAGGGG
 TTGGTCCCCTGTCAACTCTGCTTCTGTGCCCTGTGCCGCACCTGGCATTGAGTGAGCATCTGC
 TGAAGA GATGAGGGTCAGATGCCCTGCAGGGAGTGTGGGGGGCGTCCCTCAGGCAAGA
 AAAGTTGTACGTTTGGCTGTGGGGCCCTGATTATGTGTCTGTGACCTCTTGGGTGAGGTGAGC
 15 AAGAGAAACCTCTGCAAGCTGGCTGGGGCTGCCTCCCAGAGGCTGCCAGGGGGAGGGACAGG
 CTCTGTCTGTGCTCTTCTTCCGAGGCTACACCTGGGGCGCCAGGCTCTCAGGGCTCCCCAGGTA
 CCACCACATTT CCTACACTGCTTGGGAAAGCCCTGTAAGTTTGCACAGACACCCAGCATGA
 GGCTCGCCAGAGAGATACTTGTAGCTGGGGTCTGGGGCACCAGGAACAGCTTGGTGCTGGGGC
 TGAAGTCGGGCAGGATGCAGCCTGGCCAGGTGAGAGGAAAGCTTGGAGCCAGTGCCTGGGTT
 20 CAAACTCCTCTGTGGCCTATGGTTCTGTGGGCTTGGGGAAGGGTTTGTACCTCTGTGTCCAGT
 TTCCTCACTTATA
 AAAAAAGGAGATAATAAAAAGTACCCATGTCCCAGGGTGGCTGTAGCAATA
 ATAGGGAGGGGTGCCCAGAGCAGGTCTGGCACACAGGAAGTGTGCATCAG
 CCTCAGTCCCTGCCATTGGGCTTGTCTCTGGGAGTCTGTGAAGCCAACCTC
 25 TGCTCCACAATGTGACCCCCAGGCTTGTGAGACCAAGCTGGGTGAGAGCT
 TCCTCCTCTGGGGTTGCACCAGGAGGGGAACCTTCTGCAGGCCCAGATGCA
 CCCTGAGGAAAGGGCTTGTTCACCAAGAACAAGGCTCACCTTTGGAGG
 ATGCTCCCCACATGAGAGGTGAACCCCCAGGTCTACTGGTGACTGCAGCC
 TCGGAAGCTGACAGCATCTATCCTCCAACCCATGCCCCACTGGGAAGTGTG
 30 TGAGGGGTCTCATAGGCCCTGCGGTGTGGACAATGCAGAGACCCTGTAG
 CATCTGGCTAGGGCGGGGCCAGATAAGAGCCCTGTGCCAGGAGAGCCTG
 GCCGGTTCTGCCACTGTGGGGAGACAGGCTCCCCCACCCCATGTCCCCTG
 CTTCCTGCAGCCCACAGAGAATACAGACCTACTTTTACAGAAATCCAGA
 TTTTGTGTAAAAGTGTCTCTATTTTAAGTAGATTTTAAGTGGTGGCAGC
 35 AAATTTAAGCTTTTGAGAATATTATACAGAAACAAATCAGATTCACAGGCC
 AGATGCAACTTTATTTACAGAAATGGGATCAGGTCTACCTCAGGTCCCA

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

TCTCACGTTTTCACTTATGCCTATACGTCTCCTTCACGGGAAAGGCCACA
AGAGGCCCTGCGGTAAGTGTCCCGGTGTTGATTAAAGTCCCCAACAGTG
AATATGAGGGTCCTCACTGTTGCAGCAAGAGGATACCCCCCTGTGTATCT
TGGAAATGCCTGCAGCCCTCTTGCTGCAGAACAGATTCTTAGGAGAGAAA
5 CTGTCAGATCAAAGTTAAACITAGAGAAACTCCAAATTGCCCTCTGAACA
GACGGTATCAGTTTGACATCATCCAATACCGGGATTCTCGGGGAGAACT
TTCTGGCCTAGAAGGCAGTAGAGCCAGGACTTCACCCAGTCAGTGGCAGG
GCCACACGTGGGCCTTGATACAGAGGGGGAAGACTTGAGCCTCCTCGACA
CCCTACAGGGCCCAGCCTCCCAACATGTGATAAGAGAAAACAACAGCCAAC
10 TTGTACCTAGCTCTCCTTATTCTCCAAGGGCTGGGCCAGTICTCCCCACA
GCCCTGCAAGGGAGGATCACTCAAGGGCCCCCAACTGTCTGACAATAACAGC
CACACTCTGATCAGCCACCTGGGCATAGGCTCCATGCCATTGTCTCCGC
CAAGACCTCAGACTGAAATGTTGGCTCCTCCCATGAAGAACCTGGGGCCA
AAGGACCAGAGTCCAGGTCCGTGGCTGCCAGGATGGGCCACTTGGAGAGA
15 GGCACAAGGGTGGTGGCAGGCAGGTGTGAGGGCTGGACCTTTGCAAGAGC
AGCATCACTTTTGTGAGAGCCACAGGTATCTTATAATTGGGTCTTAGG
ACTTCTGCCAGTAGCCATTGTGTGCATGGATTTGGGTGCTGGCCTCACC
ATGGTGTGCTGGCTGCCCATGCCTGCAATAATGACTTCTGTAAGCCTTTC
TTCATCTGCAAGATGGGTGCTGCTGGCACCTCCTCCCCGGTGCTGTGGTG
20 ACAGGGCATAGTGTGTGAGGCTGCTATGTGAAGCACCTAATGCAGGGCCT
GGCATATGGAGGAATTCAGCAAATGACAGATGCCTTCACAGTTAGTTCCT
GGCATCCTCTACATTGGTGGGTGTAGGAAAGAAAGACAGAGGAGGCCAAAA
GTGTAGCTGTGGGGCATTGAGGACAGCCTGGATTGTTCCACAGAGCCCT
GAGGACATCTCCAGGGGTGTGCTCTGCAGGGGCAGCTGGATTGGAGGGTT
25 AGGGGTGGGGGAGGGCGTGCACCTCCACCCATGCTCACAGCCTCGGAACA
GTGCCTGCTCAGCCAACATGGGTGTTTGATTCTGTGTCTTTTGTACAGA
CTTTATCAGCCCCATCCCTTTCTGACCTTGCTCAGTTTAAATTTTACAT
GTGGGGCCTCATTAAGAGACATGGTTCCTTAACATAAGATCTGTATCCATT
AGGAATGCTTTGGGCTGCAGGAAGACAAACACCTGACTCACTGTGGCATA
30 AGTGGTTTTCGTCTGCTCCCATAGCTGCACGTGGAGGGTGGATCTGGCA
TFACTCTCTCTCCCTACATTTGCAGTATGCTAACAGCTTTAACCTCCAG
CCTTGTTTCTTCATGGTTGCAGGGTGGCTATCACAGCGCTGGCCATCACA
TCCTTACACAGCTGTGTTTACAAATTTAGGGGGACATTGAAGCTCCTCCC
CTGCTAAAATCAGGCTTCCCTTCACCTGTCATTGGCCAGAACTGGGTGAA
35 ATGCCCAACTCTAGACCGATCATCAGTAAGAGGAGTATAGAATTGCTGTG
CCCACCTTAGATTAATCATGGCGCAATGTGCTCCCCATACCAACAAAATC

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

TGAGTTCTAGAACTGAGGAAGAAGAGGAAAATGGCCGTCTTGCCCTCCTG
GCTGGGATTCAGAGCATCTCCAACCCTCTGAGCTTATGTGTAAAGACTGTG
GGCAAAAGTGTGTGAGTTTTTGTGGAATGGATCCACGGCTTTTATCAGAG
CATCTTTCCTTTTTCTTTTTTGATTCAAGATGAAAATATTCTTATGATTAT
5 TTTTCTCACCCTGCCCAGAGATAACCAGCACATTAACATGGCCCTTTTCT
CCATGAATAGCACTAGGGTGCCCACTGGACAGACACATAGCTGTCCACAC
ACCAGCTTGCTGGGGATGCATAGGCAGAGTCACATCTGCACTCACGGCCT
GTCCTCACACTGCCATGTGGAGAGCCAGCAGCCACACCATGGGCCGTCCA
TGCTCACGGGAGTGGCAGTATCAGATCTGAGCTTCGTGTGCCCAGGCGTG
10 TCTCACATCAGTGCATAGGGACCCTCTTTGTTCTGTGGCCCACTGTGCC
ATGCCACAGATGGCTTCAGTCAGCAGACACCTCCTTCTAGACACTCACAC
TCACTCCTGGCTGGCCCTTAGCACACCTGTGCAGACAGGCCCATTTATTT
TCTTGTGTAAATCCCAAGTAGGAGGACTGGGTCTCTCTGACAGCAATGCC
AGCTGCCTGGCACCCTCCAGACAGGTGGCTCAAGCCCCACCTCGCCAGCT
15 CTCCCAGTTAGCCCCCTCCTTTCCTGGCTCTGACCTGAGGGACGAAGCAG
GGTGCTACAGGACGCTGTGCCACAGGGATATCGTCAGGGACAGAAGCTAC
TCTGCCCTCTGCTGCTCACCCCTCCAACACGCTGTGGGCTGCATTTGTTG
AGTGGCTGGTACCAGACTCTGCTCTTCTGACTTTCCAGCTGGTTTTACCT
GTAGTAAAGTTTGAGAAGATGGGTCTATCCTGACCCCGGGGTGAGAAGACA
20 GAAGGAGGCCCATGGCGTGTGGGGGAGATGCCCCGTGAGGCCCTCGGTGT
GCAGATGCCTGGTGACAGCCCCACCCTGAGGTCCCCAGCCTACCCCTCC
CCAGCCCCGACTGCTCCCATCCCCCTCCCTGTGCAGGTAGAGCAGATCCTG
GCAGAGTTCCAGCTGCAGGAGGAGGACCTGAAGAAGGTGATGAGACGGAT
GCAGAAGGAGATGGACCGCGGCCTGAGGCTGGAGACCCATGAAGAGGCCA
25 GTGTGAAGATGCTGCCCCACCTACGTGCGCTCCACCCCAGAAGGCTCAGGT
ACCACATGGTAACCGGCTCCTCATCCAGAAGCAGCTGTGGGCTCAGCCCT
AGCTGGGAGAAGCACCCCAGGCACTCCCAGACTCACAGCCAGCCCCGAGAC
AGAATCTCCTGGGGAGCAATGAAGTCCTCGACTTGGGCCAGTTCTCACCC
TTGGCTCCTCTGGTCCGGCCCTGGGGCACTCGGGCTCACCCCTGGAGCTGG
30 CAAACCTCAGGAAAACCTGGCGTTTTTAAATCTCACTCCTGGCCAGGTGCAG
TGGCTCACCCCTGTAACTTCAACACTTTGGGAGGCCAAAGCAGGCGGATC
TCTTGAGGCCAGGAGTTTGAGACCAGCCTGCCCAACATGGTGAAACCCCG
TCTCTACTAAAAATACAAAAATTATCCAGGCATGGTGGCACATTCTGTGA
GTTCCAGCTACTCGGGAGGCTGAGGCATAAGAATTGCTTGAACCCGGGAG
35 GCCGAGGTTGCAGTGAGCCAAAATCGCGCCACTGCACTCCAGCCTGGGGT
GACAGGGTGAGACACCATCTCAAAAAAAAAAAAAAAAAAAGACCTCACTG

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

CTCCCCATGGGCACTTAGGGAACTCTCCCAGCCCAGTTCTGCAGCTGGGC
CATTGCACTAGATCCTCAGTTGGTCCCTGGGCTCTCGGTGACTGTCCAGG
GCAGGAGTTTCCCATTTGACTTTTCCCTGGTTGACCTTTGACCCCTTCCAC
AGTTGACACTGGTGTCCCCAGGTGTCTGGTGGCCCCCTTGTCCAGCTCCCT
5 TAGTCCCTTGTGCCTTCCCTCCTCCTCTTTGTAATATCCGGGCTCAGTCA
CCTGGGGCCCCACCCAGCCCAAGGCCAGCCTGTGGGTGTCCCTGAGGCTGA
CACACTTCTCTCTGTGCCTTTAGAAAGTCGGGGGACTTCCTCTCCCTGGACC
TGGGTGGCACTAACTTCAGGGTGATGCTGGTGAAGGTGGGAGAAGGTGAG
GAGGGGCAGTGGAGCGTGAAGACCAAACACCAGATGTACTCCATCCCCGA
10 GGACGCCATGACCGGCACTGCTGAGATGGTGAGCAGCGCAGGGGGCCGGGG
CAGGGGGCCAAGGCCATGCAGGATCTCAGGGGCCAGCTAGTCCTGACGGG
AGGTGCCACCTGTCTACCAGGGGTGGGGAGAGCGGGGGCTGGAGGACCAC
CCAGCCTCAGAGGCAGCTGGAGGCCTGGGTGAACAGGACTGGCCAACATG
TCCCCAAGTCCCACAGTCACCATCTGGCCAGCATTGAGAGGGGAACGGGG
15 TGAGGAAGAGTTAGTGGCAAGAGGAACCCAGCCAGTCACACCTTGTCCA
GTTTACCAGAGGAAAAACCAATGTGTAAGAACAGAAATGTGACCCGGCAG
CCAGTGCCTGCCCCCTCTCCAAAGGCCACCCCTCACCTCCACCAGCA
TGCACAGAAAAGTGGGGTGACAGCAATCACAATGTCTACCCAGGCAGCAAG
GACCCCTGACCATGGGGAGGACTGGGGTGAGGGAACATAGAAGCAGAAT
20 GAGGCCTAGGGGGAGTTGGGCAAGGCCAGAGCCCTAGCTGCAGCCAAGCA
CATGGCCAAGGCCAGCTCCTGGAAGGGCAGGGCTCCGAGGCAGGAGGCAG
GAGGCTGCCCCGTGGCTACCCGTCCTCACACCCCTGCAGCTTGCTAGTCTG
TCTGTGGGCTGGGTGTGAATCAAGGCAGTGGGATGGTGTGGGGACCTCCC
TGGCCCCAGCAGCCAGTGAGGAGCCTGGTCAGTCAGCAGAGCATTACAGCA
25 GTATCCAGTTCATGGAGAGGCCCGTGTGAGGGGAGTCGGGGCTGGTCTT
CAGTAAGGATGGGTGGCCAGGGCCCCCTAGAAAGTAGAAAAGGAGACTCCGG
GTGCTGGAGACAGAAATCAAGGATGTGCCTCCATGTGGAGCCTCAGGAAT
AGCTGGCCAGGCCTGAGGCTGAACCTCACAAGGTTTCAGCTGGGAGGGCTA
GGCTGACAGAGCACAGCCGGGGCCAGGGACCAGCCTGCCCTGTGTTGCCTT
30 GTCCCGAGGGCCACTGTCAGCAGGTCTCTGGCATGGGGGAGGCTTAGGGC
CTGAGCCCCAACAAGCAGCAGCGGAAGAGGAGAGGGGAACTGTGGACAGGC
CTGGCATTTCAGTGGCCAGGTGTTGCAGTGTCCCTGAGGAATAGCTTGGCT
TGAGGCCGTGGGGAGGGCTGCCGGCCAGCGCACCCCCCATGCCAGATGG
TCACCATGGCGTGCATCTTCCAGCTCTTCGACTACATCTCTGAGTGCATC
35 TCCGACTTCCTGGACAAGCATCAGATGAAACACAAGAAGCTGCCCCCTGGG
CTTCACCTTCTCCTTTCCTGTGAGGCACGAAGACATCGATAAGGTGGGCC

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

GGGTGGAGGGGCGAGAAGGCAGATGAGGGGAGGCCACAGGCACCCCAGAGGA
ACTCTGCCTTCAAAATGTAGCCCCCATACCATGTGTCTCAGAAGGGAGATCT
GGATTCAAATTGTGGCCATGTCACTTGCCACCTCTAATGCTGTGGAAAAG
AAGCATCACATTAGCTAATTCTGGCTGTGCGCCTTGTGAGGCACCAGCTA
5 TGATCACCCCCTCCAGTGGAAGAGCAGCTGGCAGTAGGGTGGGGCTCA
AACTCAGGCAGCCGGGCTCTGGGTCACCTGCAGGCCACGGTCATGTCACA
CTGCCTCTAGCTGAGTCAGAAATGTGAAGGAAGTGAGATTCTACCCTTCC
TGCAAGCTAGCAAAGTGGCCTGCCAGTTACATCTGTGCATGCACACACAC
ACACAGTTATATATGCACACACATAAAACACGAGACCTTTGGGTCAGGGA
10 GAAAGCCAGATCCTCACTCACGGCAGAAGCAGCAGCCAAAGCAACATCTC
ATGTGGTTTTCCAAGCCCCAGTCCCTACAGAGACAGAGAGGGGCCAGGTGG
CACCTGTGCATGCAGCGGGGTACCTTGCAGGAGGGAAATCCTGATTTTAC
ACAAAGCTGCTCCCCCAGCCCTGCCTTGACTCTGGGATGACGTCTCAG
AGCTGTGCAGTACAACATTCTTAAATTGGCTGGGACTCAGCCCTGCAGAA
15 ATATGATATCTTCAAGGAGAATCGTTCCCAAACCTCTCAAAGCTATGGG
GCTGCTCTGAGCCTGTTTCCTCAGCTGTAAAGTAGGGTGCATACTTTTAT
GGCCCTGTGCAGGAGGTAGTGACAGGCCCTAGCACCCCTGCCTCCAGTATA
TGTTAGCAGCCACGAGGCCTATCTCTCCCCACAGGGCATCCTTCTCAACT
GGACCAAGGGCTTCAAGGCCTCAGGAGCAGAAGGGAACAATGTCGTGGGG
20 CTTCTGCGAGACGCTATCAAACGGAGAGGGGTGAGGGGGGCACCTGTACCT
GCCGGGGGGGCTGCCCTGGGGCACCCACCCCAGCACTGCCTGCCTTTCTC
CTTGGCTTCCAGCACTGCAGCTTCTGTGCTTCTTGGCAGGACTTTGAAAT
GGATGTGGTGGCAATGGTGAATGACACGGTGGCCACGATGATCTCCTGCT
ACTACGAAGACCATCAGTGCGAGGTTCGGCATGATCGTGGGTAAGGGCTCC
25 TTGCACCCCTGCCCCCTTCCAGACTGCTGAGGCTCCCTGTGTACAACAGGC
TTCAAGGGCCCTGTGGGGGTGAGGACCAAACCTACTTAACAACCGGTGATGT
CAGAGCAGAGCCTGGTGCTACAGCCTGGGTGGTCTTGGGGTATCAAGATG
GAAGCACCGTGTACAGTAGGAAGCATTTCAACGCCATGATGCCACATTCC
TGCATCAGATGGTATGCCAGCTGCATATCCACCTCACCCATCAGGATTAT
30 AATTAAAACTTATCTGGTAAATTGACCAACTGGACAGATTGGTCCAAG
TGGAAGAGGATAAGCAAAAGTGGTACCATCTCCACCCGAATGGTCTTTCC
ACGGGCCCTGCCCCCTGCCCCCTGCCCCCACCCAAAGTGAAGGCAGGTACCAG
GAAAGGGAGCAGCAGTCCGCCCCCTCCAGCAGAGGGGTCTTCCACACCAA
CTCGGACCTTTCTCAGAAGTTCCGGAGGTCATTATAACCAGCCTTCACTG
35 AGGAGCAATCCAATCAGATCAGTTATCTGCTGTGCGCACAGCCGTGTGGT
TCTATACTTCTCTTACTTCCATTTTACCTTTTCAGAAGGAACGTTGTCTT

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

TAAATCCAGCATCTAAACGTGAGCCCCAGCCATCCCTGGCTGTGATCCCC
CCAGCCCTTTCCACCTATCCTCTGGAAGTGCCTGGGGCTCCCCAAGACA
CTTCCACATGAATTCCCAACCAAGCCAAGCTGCAGCTGCTGGGGCCAGGCA
TAACCCCTCCTGGGGCAGAGGTGGCAAGGAGTGACCCACCACTCAGATCT
5 GCCCCACATCCACTCTTGACTCTGCTCAGTGTTTAAAAACATGTTTATAA
CAATTACCAAGATCTGAAAATTAGGAGAATTCACATCAAAGTCTGGATTT
CTGTTTGTTCATAAAAACTAGAAGGCAGCCAGGCAAGGTGGCTCACGCC
AGTAATCCCAACACTTTTGGGAGGCTAAGGCAGGCGGGTCACTTGAGGTCA
GGATTTGAAGACTAGCTGGCCAACAAGGTGTAACCTCGTCTCTACTAAAA
10 ATACAAAAATTAGCTGGGTGTGATGGCGCATGCCTGTAATCCCAGGTACT
CAGGAGACTGAGGCAGGAGAATTGCTTAAACCCTGGAGGCAGAGGTTGCA
GTGAGCCAAGATCACGCCACTGCACTCCAGCCTGGGTGATGGAGTGAGTG
AGACTCTGTCTCCAAATAAATAAATAAATAAATAAAAACTGGAAGTCTAA
GCATCACTGAGCCCTGATTCCTATGTGGCAGCTCGACTGACCAGCATTG
15 AGTTGCTGTCCCTGACAGCTTTGGGGGTGTGCAGCCACACAGTCATGCT
AGCTTGAGGCTCTGCTGTCAGCAGTTTGAAACTCTTAATAACTTTGTGAAC
AAAAGACTCCATGTTGTCCTCTGCACAGGGGCCAGCAAATTACAAAATT
CCATATCCGGAATTGTCTACAGGAGCCTCTGGGCTGCTCCCAAGGGCCCA
CACCATGCCTTACTCACTTTGGGTGTCATCCAAACATGTCTCATGACAA
20 AGAAGCTCAAACATGTGCATGGACAGTGCCAGAAAAACAAGGGTCGTACAT
AGACAAAATAAAATGATAACGTCCCAACAACCATTTCTTTGATACACACTG
TTTCTCTCAGTCCTCCCAACCACCTAGGTAACAGGCAGGGAAGGTGTTAC
TGTTGCCTGTTAGGAAAGAGGACAGCCCTGAAAGCTGTCCCTGGCCACTG
AAGCAACCCAGGTCTTCCAGCCCCAGGGAGAGCCGCCTTTCCATTGTTCC
25 AGACAAAGCAGAGACAGGCATGGGGGAGCGGGAGAGGGACTCCTGTGGGG
AGGAACCAGGCCCTACTCCGGGGCAGTGCAGCTCTCGCTGACAGTCCCCC
CGACCTCCACCCCAGGCACGGGCTGCAATGCCTGCTACATGGAGGAGATG
CAGAATGTGGAGCTGGTGGAGGGGGACGAGGGCCGCATGTGCGTCAATAC
CGAGTGGGGCGCCTTCGGGGACTCCGGCGAGCTGGACGAGTTCCTGCTGG
30 AGTATGACCGCCTGGTGGACGAGAGCTCTGCAAACCCCGGTGAGCAGCTG
TAAGGATGCCCCCTCCCCACAACCCAGGCCCTGGGCGGCTCTGGTGCA
GCGGCAGATGGGAGCCGGGCCATTGCAGATAATGGGCTTGTTTTAAACA
ACTCTGGGGAAAAGCAAACCTGACAATCCGTTGTAAGCTCCATCCCTTCT
GCTCAGTCATGACCTGCCCCCTGTGAGAGATGAAGGGTTAGTCCCAGTTGT
35 GATGTGATAAGCCCAGACCTCTTTCCTTCCGACAGGTGATCGTGCATGCA
GAGGAGGCTCTGAGACGCCCCCAGCAAGGTTCCTGGGTTTAACCCAACAT

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

TCCCCAAAGTATGTATTTGGCCACATTCACAGAAAGAATATTAGTCTTTT
GTGGAATGCTGCGGGTTGACAGTCACAGCTTGGAACCAACCCACAGAGA
GCTCATCATTAAATCATGGCTATCACTTGTTTACCACCTACTGTGCCAGGC
CTATGCTAATTACTTTATTAGCGTCCTCTCTGCCGCTCGCAGGCCTCTAT
5 TATTATAGGTCAGTAGTATTCGATTTATTTAAATTAAATACGGAAGGTCA
TAGATTAAGCAAGAAAGTGCCAGCAACATGGTGCGTGCCTCTGACTGGGC
ACTAACCCTCCAAGTCTTAGTTTTCCCAACCATAACTGGCCAATGAACAG
CAGCTCTGGATGCAGCTAAAGGAAGACTGAAGCTGTAGGTCCCGTGCTCG
GCGCAGGGCCCCCTGCAAGGAAGGTTTCGGAGGGACTGGATGGGGTCTTT
10 GAACTATCTGTCTTTCCCTTTACTGCAGTGGGCCCAGGGGCAGGCCAAAG
TTGCTCCCGTGATTGACTTGAACGTGCACGTTCCCTAATCCCTGACATTTT
TAAAGCTCTGGCTCATTAAACGAGGGAAAGACGTGAACCAGCTGGGGGAGT
GGGGATCGCAGTGCCCCACGTGGCCGCTCGTGACCTCAGTGGGGAGCAG
TGGGGCCGGCTCCCGGCTTCCACCTGCATGAGGGGCCCTCCCTCGTGCT
15 GCTGATGTAATGGACCTGCCCTATGTCCAGGTATGAGAAGCTCATAGGTG
GCAAGTACATGGGCGAGCTGGTGCGGCTTGTGCTGCTCAGGCTCGTGGAC
GAAAACCTGCTCTTCCACGGGGAGGCCTCCGAGCAGCTGCCGACACGCGG
AGCCTTCGAGACGCGCTTCGTGTCGCAGGTGGAGAGGTGTGCGGAGGAGG
AGGGTGGGTGCAAAGGGCAGGGGCTGGGGACGCCCCGGGCACTGCAGACTT
20 GGTCTCAGGGCGACGCTGAGTCCCAGGCCCGGGGCGCAGGGATGGGAAAC
TAGGGCCTGGGGCGGGATTCCGGGCGTGGGCGGGGCCCGGGCGGGGCAC
AGGGGGCGGGGAGTGGGCGGGGCCCCGAGGCCGGGCGCTGGAGGCGAGGG
CGGGGCAGGGACGGGTCCAAGGGCAGGAGGCTGGGACAGGACGGGGATGC
AAAGGGAGGGGCGGGGCCCGAGACGGGGAGGAGGGGGAGGGCCCAAGGGG
25 AGGAGGCGGGGTCCGGACGGGGATGCCAAGAGCAGGGATGGGAGCGAGCC
TGCGTCCGGGCACTGGTCCCCATCCGTGAGTCCCCTCGGTGCTCCCTGCC
CGCCGTGGCCATCCTCTCACATCACTCACAACCCCAAGGCGCGGCATGGT
TGACACCCCCACGTTAGGACGGAGACCCTGGGCTTAGTTAGAGGGGGCAG
TACTAACCAGTCCCTGGCGGAAACGCTTTGGCTGGGTGAGGTGAGCGGGA
30 TCGCCCCCATTTCTCCAGAGAGGGGTCCCGGCTCAGCGAGGGAAAGAGGC
CGCCGCTGGGGGGACGGCTGGCCGGGGGCCCTCCCTGGAGAACGAGAGGC
CGCCGCTGGAGGGGGATGGACTGTCGGAGCGACACTCAGCGACCGCCCTA
CCTCCTCCCGCCCCGCAGCGACACGGGCGACCGCAAGCAGATCTACAACA
TCCTGAGCACGCTGGGGCTGCGACCCTCGACCACCGACTGCGACATCGTG
35 CGCCGCGCTGCGAGAGCGTGTCTACGCGCGCTGCGCACATGTGCTCGGC
GGGGCTGGCGGGCGTCATCAACCGCATGCGCGAGAGCCGCAGCGAGGACG

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

TAATGCGCATCACTGTGGGCGTGGATGGCTCCGTGTACAAGCTGCACCCC
AGGTGAGCCCGCCCCGCTCTCTCCCTGGTAAAGTGGGGCCCAAAAAGCGC
GCGCTCCAAGGTTCCCTTGCGGTTCCCAAGCTCCAAGATTTTCGTAGTCCTC
TTCTCGTCCCCCTTGGCCTAGATTTGGGGGAAGGGTCGACTGCGTGCAGG
5 GCGCCCCGTAATGAATGTGGAGGATGAGGTGGGAGGAGGGACGGCAGCCC
TGCTTCTCTTCTGCCCAGCTTCAAGGAGCGGTTCCATGCCAGCGTGGCGA
GGCTGACGCCCAGCTGCGAGATCACCTTCATCGAGTCGGAGGAGGGCAGT
GGCCGGGGCGCGGCCCTGGTCTCGGCGGTGGCCTGTAAGAAGGCCTGTAT
GCTGGGCCAGTGAGAGCAGTGGCCGCAAGCGCAGGGAGGATGCCACAGCC
10 CCACAGCACCCAGGCTCCATGGGGAAGTGCTCCCCACACGTGCTCGCAGC
CTGGCGGGGCAGGAGGCCTGGCCTTGTGAGGACCCAGGCCGCCTGCCATA
CCGCTGGGGAACAGAGCGGGCCTCTTCCCTCAGTTTTTCGGTGGGACAGC
CCCAGGGGCCCTAACGGGGGTGCGGCAGGAGCAGGAACAGAGACTCTGGAA
GCCCCCACCTTTCTCGCTGGAATCAATTTCCCAGAAGGGAGTTGCTCAC
15 TCAGGACTTTGATGCATTTCCACACTGTCAGAGCTGTTGGCCTCGCCTGG
GCCCAGGCTCTGGGAAGGGGTGCCCTCTGGATCCTGCTGTGGCCTCACTT
CCCTGGGAACCTCATCCTGTGTGGGGAGGCAGCTCCAACAGCTTGACCAGA
CCTAGACCTGGGCCAAAAGGGCAGCCAGGGGCTGCTCATCACCCAGTCCT
GGCCATTTTCTTGCTGAGGCTCAAGAGGCCCCAGGGAGCAATGGGAGGGG
20 GCTCCATGGAGGAGGTGTCCCAAGCTTTGAATACCCCCAGAGACCTTTTC
TCTCCCATACCATCACTGAGTGGCTTGTGATTCTGGGATGGACCCTCGCA
GCAGGTGCAAGAGACAGAGCCCCCAAGCCTCTGCCCCAAGGGGGCCACAA
AGGGGAGAAGGGCCAGCCCTACATCTTCAGCTCCCATAGCGCTGGCTCAG
GAAGAAACCCCAAGCAGCATTTCAGCACACCCCAAGGGACAACCCCATCAT
25 ATGACATGCCACCCTCTCCATGCCCAACCTAAGATTGTGTGGGTTTTTTA
ATTAAAAATGTTAAAAGTTTTTAAACATGGCCTGTCCACTGTTCTTTGACT
TCTGTGCATTAGGACTGTGGGGACAATCTATAAAGAGTCTGCGTCACATG
CATGAAGACACTTCAGTATCTCGGCAATGCCCTCCAGACAGCTCCTCCAG
CCATCTGTGCCAAGGGGAGTGTGAGGAGTGACAGACCAGGCTGTAGGAAC
30 AGGAATGGGGTGTGATGGGGGATGGCAGAGCAGTGGACAGTACACTGCCT
GGCCCGGGCCCCCTGCTTGCTTGCCCATGGAATGTGTGCAGAGGGAGTGCC
AGGCCAGGTGCTGCTCTGGAGAAGTGGGGGAATGAGGCTGGTCCTGCTGC
AGGTCAGTCTCAGCACCGTCCTGTCCAGTCAGAGTCACTTAGGTTTGCCA
GTGAGTAGGGGGCCAGATACATGTTGGATTTCTAAGGTCCCTCCAGATGC
35 TCCGTGTCAGTGGAACGCCTATTTAGAGTTAGCCAAGCGTAGGCATAATGC
CATCTTTCTGCAGCATAAAAATACAGTGACATAGAAACATATTTGTGTGAT

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

TTTCATGCATTTCCTTTTTTGTATGAGAGATATTACCCAGCTAATTAGGAAC
AACTGTTTTGTTTCCTTCAGATCATAACCCAAAGTTGTGATTTTGAAAAG
TCATGTCCCCCTTCAGATTTCTTGTTTTCTGCTACTTCTCATGTGGAATT
GCTTTGGCTCTTCTTAGTTCTCTTGAGTCTAAATTATTCCTTATAAGTTG
5 GTGCAAGCATCTGATTATTTTGTATCATTACTGTTATGCTCAAGCATTC
ACAGAGTGGAACACATTTTAATATCAATTGCTTTCTATTTCTCCTTTATA
TTACAGTTCAGGACATTGTATTAATTATTAATAATTCTATTTCGTAGGTAGG
TTATATGACTGAATTGAAATAGATAAAAATGAATTTCTTTTCTAGATAACA
AAGGAGGTGTCATAAAACACTTGTTATGGGCCAGTGTGATGGCTCATGCC
10 TATAATCTCAGTGCTTTGAGAGGCTGAGGTGGAGGATTGCTTGAGGCCAG
GAATTTGAGACCAGCCTGGGGCAACATAGCAAGACCCCATCTCTTAAAAA
AAAAAGGGTGGGGCGGGGGGGCACTGCTGGGGCGGGTGGCTCATGCCTGT
AATCCCAGCACTTTGGGAAGCCAAAGCAGGTGGATCAAAAGGTCAGGAGT
TCGAGATCAGCCTGGCCAACATGGTGAAACCCCAACTCTACTAAAAATAC
15 AAAAATTAGCCGGGCATGATGGCGGGTGCTTATAATCCCAGCTACTCAGG
AGGCTGAGGCAGAAGAATTGCTTGAACCCAGGAGGCGGAGGTTGCAGTGA
GCAGAGATTGCACCACTGCCTCCAGCCTGGGCAACAGAGCGAAACTCTG
TCTCAAAAATGAATTAATTAATTAATAAAAAAGAAAAAAAAAAACACTGGGCA
GGGTGGTGTGCACCTGTAGTCCCAACTACTCCAGAGGCTGAGGCAGGAAG
20 GAGCACTTGAGCCCAGGAGGTTGTCTGCAGTGAGCTCTACTCATGCCACT
GCACTCCAGCCTGGGTGACAGAGCTCAGTGGCTTACACCTGTAATCCTAG
CACTTTGGGAGGCTGAAGCAGGCAGATCACCTAAGATCAGGAGTTTCGAGA
CCGGCTGGCCAACATGATAAAAACCCCGTCTTTACTAAAAATAAAATAAAA
TAAAAAATATATATAAAAATTAGCTGGGTGTGGTGGCACATGCCTATAAT
25 CCCAGCTGCTTGGGAGGCTGAGGAACAAGAATGGCTTGAACCCGGGAGGC
AGAGGTGGCAGTGAGCTGAGATCGCGCCACTGCACTCCAGCCTGTGCGAG
AGTGAGACTCTGTCTCAAAAAAAAAAAAAAGGGAATTTAAGAAATTTAAAAG
AAAACCTCTTGTTATATAAAAAGGGCTATTGGGTCTGACAGATAAGAGCTCC
TGCCTCTACCAGCCAGCTACTGACAGACATAGGTCTGGCTCCAGTGGAG
30 GGGCAGCAGCCAGTGAGCCCAGCCTGGGGTGGCCCACTCCTGCTGCCTCC
AGGATGTCCCTGTTTTCCCGAGCCCTCTGCTGTGCCCTCGGGCCCCAGAA
GCTGGCGAGACTGCTTCTCTGGAACAGCATCACGCAGGCCTGCCCATCGG
CCCCTGTGCACCAAGGCCTTCTGGGGATACAGATGTCAACCAGGTGGGGT
GCTCAGGAGGGGCACAGAAGCCAGGAATGACAAACACATCAGCCACCAGG
35 CAAATGGGAAATGTGCCCCAGAAGCTCCCTGCTGAGGATGTTAGGGAGAG
CATTCTGAAGTAGTGTGGTTGAGATGAGGCTTGAGGAAGGCAAGGCTCCA

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

AACAGCAGGGCAGACTGGGAGCAAGGTAGACTGCATGGGAGGGCAGCTGA
TGGAGCTCCTTAAACCCCTCTGGAATTGCCCCAAAGCCAAGCAAAGTGTTCT
TCTTGGGGTTCACAGCTAGCTCAGGGATGCCCTTCTGCCCCCTTGGTCAGAGG
GGCAAAAGGTCAGAGCCTAGGGTCACCAAAACCTCTGGGAAGCCCCGGGG
5 GTCTCAGGCCACAGACCATCCTCAGAACTACACACTGCCCTCCCATGCCT
GGCGGGGGCCCTGGACTGGCCCTCACCAGCTGTCTTCTTGCACTGGCCAG
GGTTCTGGCTGGACTGGCAAGGAGGGGTGGTCAGATACAGGAGTAACTGG
ATCCCTTCATCAGGACCTAGGGTGGTGAGAGCTTTGAGCCTGCTCTGCTC
CAGGCAGACATTGTGTCTGGCCCTGCCAGGATGGATAGACAGCAGGATGT
10 TACACGTTGAGGACATGAAGGTCATCAGGAATGTGGCTGGAATCTGTTAG
GCCTCCCCCAGCCCAGGCGGGGGCTGCCAAGTTTGGGCCTATCCTCTGTT
CCTCTCCTTATTTGGACCTTCAGGTGATAAGGCTGAGACATAAAGGAGGC
TGGGCCCTGCCACCACGACAGCAGCCACACCTCTGCAGAGAGAATGGTGA
GTGCCTGCTGGGGAAGAAAGGCTAGCGGTCTCCCAGGTGCTGGCCTTTGG
15 GCTGGGGGAGCAGAGTTTTCTGTGCTTGTGTTGGGTTGAGGGTGGTCCCC
AGGGAGAGGAAGAGGATCCTGGCCCTGGCTCTCCTGGGAATGCTCTGGGA
CTGTGCATGATGGGTGGGGTGGGGAGACTCTGAGGAGTTGGGGAGAGGAC
CCCTCCCTACTCACAGTGTTGCAGGCCAGCAGGAAGGCGGGGACCCGGGG
CAAGGTGGCAGCCACCAAGCAGGCCCAACGTGGTTCTTCCAACGTCTTTT
20 CCATGTTTGAACAAGCCCAGATACAGGAGTTCAAAGAAGTGAGTGCCAC
TCCCAGTAGCCTCAGATCCCATCCTGGCCCCCCCCACCCCACCCACATAC
ATACCCCCCTTCTACCCTGACCTTGCCTCTCACACCACCCAGGTCTCTCC
CCCACCTCCCACCTTCCCTAGAGCTGGGGGCTGCTCCCACCTGAAGGCCC
CCATCCCACAGGCCTTCAGCTGTATCGACCAGAATCGTGATGGCATCATC
25 TGCAAGGCAGACCTGAGGGAGACCTACTCCCAGCTGGGTGCGTGACCCA
CCTCCCACCCTGCGCACTGGGGTCCCTACTCTGAGCTGCTGGGCGGGTGG
GAGTGGCTGGGGGGACAGGACTCTGCTCCCCTGCTTCCCCTCCTCCCCGT
CTCCTCACACTGCCCTTCCCCCCTTGTACAGCCTTGCTTCCACTTCACCT
TCCCGACCCACAGCTGCCTCTGCCCCCTCCAGCCCCTGTGGCCAGGATGGA
30 GGGAGGGGCGGCCTGGGCCTTCTGGGGGACACCCAGGGTCCCTGTGTGCAC
CTCATGCCCCACCCCCACCAGGGAAGGTGAGTGTCAGAGGAGGAGCTG
GACGCCATGCTGCAAGAGGGCAAGGGCCCCATCAACTTCACCGTCTTCCT
CACGCTCTTTGGGGAGAAGCTCAATGGTGAGCCTGGGACAGAGCTGGGCA
CCCTTGGCCAGGCAGGGAGCCTGCACCCTGCCTGAACCCACCTGAACCC
35 TGCCTGAACCCACCTGAACCTTACATGAACCCACCTGAACCCCTAACTG
AACCCACCTGGACCCACCTGGACTCTTCCTGGCCATGACCCATTCCAAG

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

CACATCCTCTGCCCCAGAATCCCATGTGCACTGGTCACCCCAGTGCTGAC
TTGGAGCCAGGAAATGTGCCTTCAGCCCCCACCSCCAAATTCCAGTCTCC
CAGCCAAGCTGCCCCGCTCAGGAGGATGACCATTCAGCCCCACTGATC
CCCGAGAAACATTTTATGTTAGGGAATACCCCCACCTCTTCTGGGATGTG
5 GGAGGCTCCTCATGCAGCCCAGTTCCTCCTGCGGGGGACCTGGGATGCTG
GAGACATGGATGCTCACCTGGCTGCCTCGGCCTTCAGGGACAGACCCCC
AGGAAGCCATCCTGAGTGCCTTCCGCATGTTTGACCCCAGCGGCAAAGGG
GTGGTGAACAAGGATGAGTAAGTATGGGCCCAGCCAGATGAGGAGCACCG
TGGTGGAAAGCAGAGAGCGGGGTGAGGCCCCCTAGTGAGGGGGGCTGCCTGT
10 GCTTCGGGGCCTTACACTGCTCTTTGGGGTGCAGCCAACCCTTCCCTGCG
CCATGGGAGCCTCCGTACCCACCTTCCCTGTGCAGTCACTCCCCCGCAGT
CTCCTGCTCAGACCCTCCTCACCCCCCAGGTTCAAGCAGCTTCTCCTGAC
CCAGGCAGACAAGTTCTCTCCAGCTGAGGTGAGGCTGCCCAGCCCCCTCA
ATACTCATCCCCAGCACCTTCTCTGGGCCTTCACCCATGACCCAGAGCCC
15 AGTACCAGTGAGGCAGTTGCTGGAAGGGTGAGCCGAGGGGCCCTTCTGGAG
GAGGTGCCATCTCTGTTGAGACCTAGAGGGTAAAGATGTGGAGTCAGAAA
AGAGGGCAGGGTGCGCCAGGCAGGGAGACTGTGCACAGACCTGGGGGGAA
GTGGATAGGGAGAGGTTTCGTACACTCGGGGTGGGCCTGTGCCTGTGGCT
GGAGGGGCGTCCTTTGCCTCTTGGCCCACATTTGCACTGACTCCTCACTC
20 TCCCCAGAGTCAGCCAAGAGAAAAACATTAACCCAGAGTCTGGGGTCTAG
GGTTGAAAAGCTAAGGCAAAAAGCACAGATGCAGGGGGCAGACAGAAAGG
CCACAGGACTCAGGTGAGGTCTCTGCCGGGCTGGGCCAGGAGCCAGGGGA
CTGCCACTCACAGTGTCCCTGCAGGTGGAGCAGATGTTGCCCTGACA
CCCATGGACCTGGCGGGGAACATCGACTACAAGTCACTGTGCTACATCAT
25 CACCCATGGAGACGAGAAAGAGGAATGAGGGGCAGGGCCAGGCCACGGG
GGGGCACCTCAATAAACTCTGTGTGCAAAATTGGAATTGCTGTGGTGTCTT
GTCTGTGACAGATGGGTGGGGACCAGCCAAGGGGGATCCCAGGGTCTCA
GTGCGCACATCACCATGATCATGGCCACCATCTACCTCCTGGGAGCTGGC
CCCTCGCCAGCTCACCTTGATTCACTCCCATGATGCCAAGTGAAGTGTGA
30 ACTATGATCATGCCTAGTTTACAGATGAGGACACTGAGGCCCAGAAAGTG
TGAGCATCTTACCAAGGCCAGCCCTCTAGAAGAGGAGATGGTGGGATTTA
CACCACCTCCACCAAGCCCAGGAATGAGCCACAAAGTGGGCACTGCCCAG
CTACTTGGGGCTGTGCAGAGAAGAGGCTGCTTGCTGGGCACTCAGCAAAC
TCTGCCCAACAGCCCAGCGGGTGGGCAGCAGCCCTGGGACCCCCACACCC
35 AACCACACAGCCTCCCTGGCCCCACTGCTCGCACCCCATCTCAATACACT
GGCTTGGGTGCCTCCCTGCATGGGCCCTTTGTGAAAGGCAGAGAGGTACC

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

CATTTGAAACACAACCAGCTTCTCATTGCAAATACAGGCAAGGCACTAAG
ACATGAGGAACATGGACACCAAAGCAGGGGCCAGGTAACATGCAAATTC
TAGAGGAAATGCCCAGAACCTGGCATCATGCCTCCTGAGCCCCCTCATGCG
CCGTGAGGGGTAAAGAGGGTCAGACAGCTGGAGTGTAGGGAGACGACTTCT
5 CAGGAGAGAATAGTTAGTGCTCCCGTCACCCTTCATCTGAGAACCCAAGA
GCTAGAGGAGAAAAGTGATCCTCATGAGTACCAGAGGAGCAGCAGGGGACA
TCCAAAGCACCAGAGAGAGAGAAACAGAGACAGAGAGACAGGCAGTGACAGC
TCAAACCTCAGCCAGATCCAGAGCATACAAAGTCTCCTGCCTACAGGACA
GCCCAGTAAGAGCTCTCAGCTTGCCTCCTTCCCTCCCCACAAGCCCTGCT
10 GCAATCCCTGTACCTGGGGGTGAGTGGGAAGGAGGTGAGCGAGAAAAGGAG
GGGCACCCCTTCCTGAAGGCCCCAAGAGGAAAGGCGTTTTTCACCCAGACA
GGTGTTTCACTTTTGTATTTTATCTGGCGCCTGGCAATTTAATTACTAAATT
GAAACTTGAGACTTTCTGGAATTATGGCATTCTTCTGTTGCTTAGAGAGAT
TACAAAAGTCACGAACTGCCTGAGTTTCCATCCTGAAAGCAGGCCACCAG
15 CCCACTCCACTGACCATGCTGGAACAGTGGATGAACAAAATCAAGTACCA
TTAGGATTCTACCATGAGTCTGCTTGTTCACAAGCTGATTTTCATAAA
GTAAGGGATCATGTTATAATCCAAGCTCTACAGGGGTAAATTGTGAAAGA
CTAAATGAACCAAAAAGATCATAGGTGTCCAGTTATCTGATTTGATGGG
GTGTCTGAACCTTTTGTATCTTTGAGCTGTTTCAAACTCTCTAAATTA
20 TTATTATTATTTTGTAGACAGAGTCTCTCTCTGTACCCAGGCTGGAGTG
CAGTGGCATGATCTCAGCTCACTGCAACCTCCACCTCCCAGGTTCAAGTG
ATTCTCATGCCTCACCCCTCCCAAGTAGCTAGTATTACAGATGGGCACACC
TTGCCTGGCTAATTTTGTATTTTAAATAGAGACGTGGTTTCACCATGTT
AGCCAGGCTGGTCTCGAACTCCTGACCTCCGTTGATCCACCTGCCTCTGC
25 CTCCCAAAGTGCTGGGATTACAGGGGTGAGCCACCGTGCCCTGCCACAAC
TCTAAATTATAACTAATAGCAAGGCAATGGTTCTTCTCTATTAACGTGCA
AATAAATGTTGTCCAGTGGAAAGCACAACCTGATTTTCCCTTCTCTGTGGA
AGAAGCCAAATTTTGCATCTATTAAGCAAATTCATCTGGGCATTCTTAACC
GTCTACACATGCACCGGCTCTTTGAATTCTTCTCTGAACCAGGCCAGGA
30 ATAAGCCACAAGATGAGCACTGCCCAGCTCCTTGGGCTGTCACATCTTAT
TGATTCCCACATGAATTCACAAGTAAATAAAATATTTGGCGGTTGTTTAC
TTAGTATGCAAGTCAATATTTTGCTTTAAAAATATTATCCTTTTCACTC
CTGATATAGTTGTCTGATAAGGTTAGTCCTTCCCACACCAAACTGCCTG
TATTAGTGTGTTTGGAAATAAACTGAGGGTAGAATGTATATGGTGTGTGT
35 ATGTGGTGTGTGTGTTTGTGTGTGTGTGTGTGTGAGAGAGAGAGAGAGAC
AAAAGAGAGAGACAGAAGGATAGAGAGAAACAGATGGGCACAGACCCAGG

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

ACATGAGTTCAGCCTACACTGACCAATATGACAGCCACTGGCCACTTGAA
ATGTGGTGTGAGTTGGGATATGCCAAAAGTGTAATAATGCACACAATATTT
TGAAGATTTTCATACAAAAAAGAATGCAAACATCTCATTATAAATTTTAT
ATAGATCACATGTTGAAATGATAATGTTTTGGATATTAGATTATTACTAA
5 AATTAATTTTACCTATTTCTTTTCACTTTTTTAAATGTGGCTACTAGAATA
TTTAGAATTCCATAAGTGGCTTGCATTTCTGGCTTTCACTCCTGTTGGAA
AGCACTGAGTTAGACTGTGTAGTACGTCTATTTAAGACTGCAGTTTCCAG
GCCGAACACCGTGGCTCACGCTATAATCCCAGCACTTTGGGAGGCCGAG
GCGGGCAGATCACCTGAGGTCAGGAGTTTGAGATAAGCCTGGCTAACGTG
10 GTGAAACCCCTGTCTCTACTAAAAATACAGAAATTAGCCAGGTGTGGTAGT
GCATGCCTGTAGTCCCAGCTACTAGGGAGGCTGAGGCAGGAGAATCTCTT
GAACCCAGAAGGGGAGGTTGCAGTGAGCCAAGATCAAGCCACTGCACTCC
AGCCTAGATGACAGAGCAAGACTCCATCTCAAAAAAAAAAAAAAGTAGAATA
AAAAATAAATAAATAAATAAAGACTGCAGTTTCTGGGAGACTCTGAGGCAG
15 GCATTAGCCTTCTCTGCAGAGAGTACTTGCAGCAGGGAGCAGCAGTTTTG
ATGTCCTCAAAGGAGCCAATTTCAATTTGGGTAGGGTTGCCTCTGAGTAT
TCTAGCAGTACAGACAGAAAGGAGAGAAGGCTGTTTCCAGAAAGCAGAGA
TCATACGAATTACTTGTGAGACCAAACCTTGTTCCCTCAGGTGAAGCTCAGG
CATCCCTTATGTGGAGTGTCTAACAGTCTACACCTGAGGATGTTGGACAT
20 AAGGGGGTGTGAGGTGGGCATGGCTGGGGAGAGCTCTGGGAGGGGGAAAA
CCAGCTCCATGTTGTCCACCCACTGAAAGGAAAGCTCCCTCTGGGGGAGG
TAGATGCCCCCTGGCCAGGCCTGCAGGGCCCTGCTCACTGTGAGCCCTGT
GTGGTCCCTGGCCTGGGTCCCACCAGCCATTGCCAGGCAACAGCTCCCAGT
TGGAAAAACAGAGCAAGGCTCCCTCTTAGAAAAAAAAAAAAAGAAAGAAAGA
25 AAAGAAAAAGAAATACAACAGGTAACATAAGCATGACGGCTCACGCCTGAAA
TCCCAGCTACTTGGGAGGCCAAGGCAGAGGATTGCTTGAGACTGGGAGGT
TGAGGCAGCAGTGAGCCAGGATTCTGCAATTGCACTCCAGCCTGGGTGAC
AAAGTGAGACCCTAGTAAAAAAAAAAAAAAAAATAGAGACAGAGAAAGAAAGA
CATGCAACAGGGCCAGGCGCAGTGACTCATACCTGTGATCCCAACACTTT
30 GGGAGGCAGAGAAGGGAGGATTGCTTAAGACCAGGAGTGCAAGACCAACC
TGGGCAACATGGCAAAAACCCATCTCTTCAAAAAATAAAAAAATTAGCCT
GTTGTGGTGGTGGCGACCTATAGTCCCAGATATTCAGGGAGCTTGAACCA
GGTCCAGGCTGCAGTAAGCCATGATCGTGCCACTGCACTCCAGCCTGGGT
GACAGAGCGAGACCTTGTGAGAAAGAAAAGAAAGAAAGGAAGGAAGGAAG
35 GAGGGAAGGAGGGAAGGAGGGAGGAAGGGAGGAAGGAAGAATATAGGACC
CAAAGGCCTAAATGCCCCCTACTGTGCCCCAGTTCTGCGTGACTCAGGACC

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

AGCCTCCTCCACACTCCCACCACCACAACCCTGCACCCTACTTGTTCTTG
GGGGCCCCAAGGGGAGCCTCACCAGAAGCCTCCTCATAAACCCACTGCCC
CTTACCTTTCTGTCTTTCTAGAAAGCCTCAGAAGCCTTGCCACTCTAAGG
ACACCTCCATCTGAGCCAAGGCGCTCGCTCCAGATGTCCCAGAGCTCCTG
5 GTCTGGGTGTCCCTGCCACACAACCCCCCATGGAGCCCTGCTCTGGCTC
AAGCCCCCTGACTGTGCATGAGCAGGCCTGTTGCCCTCACTGGGACTGTC
CAGAGCCTTCCCATCTCTCTGGAGGGACTTCCATCAGTTTCTGCCCTTC
TCCTCTGCCAAGAACTCACGTTCACTCTGATAGCAGAAGAATCATCTGGC
ACCCTCCTGAATGGAACCCAGAGTACCTCCTTTGTGGACCGGTCTCTGGA
10 TTTTCCCCACTCTCTCCCTTCAGCCATGCTGATGGCAGAGAAGGTAAGAA
CTTCAGCCCCACTTCTCTGGCGAGGGGAACCTGTCATCTGGGTCTGCAGA
GAAGGTTCCACCTTATGCTCATAGTACATTATCTTTACTATGTACTAGGA
TATCACATTTAAAAGGACAAAAAAGGCCAGGCAGTGGCTCATGCTTGTA
TCTTAGCACTTTGGGAGGCTGAGGCAGGTGGATTACCTGAGGCCAGGAGT
15 TCAAGACCAGCCTGACCAACATGGCGAAACCCCATCTCTATTAATAATAC
AAAAATTAGCTGGGTGTCTGTCATGTGCCTACAATCCCAACTACTTGGG
AGGCTGAAGCAAGAGAATCACTTGAACCCAGGAGGCAGAGGATGCAGTGA
GCTGAGATCGTGCCACTGCACACCAGCCTGGGCGACAAACCGAGACTCCA
TCTCAAAAAATAATAATAATAAATAACAACAAAAATAAAGAACAAAAAA
20 AAGAAATGTAAAATACTTGAAGGGGCTTGTATAACATTAATAGGATTGAC
AGTATCTGCTTTCCAGGCTGAAGTGATTTCATTATTCTAGACGTCTT
TAGTCCTTTGCAATTTGTGGTAATTAGGCTTTTCTTTTAAACATTAAAAA
TATACAAAAATAAAAGGCCAAAAAAGCATCATCCCATTAGTCTGACCTTC
CCCTCCTCCATCCCTGCCCCAACACCCTGAAGACCCTGGATGCAAACAAA
25 GGGCCGAGGGAGCCTCTTCCCTCGCAGTGCAGGCCTCACCTGGGGCTCAG
AGTCAGAATCTGCATTTTATTCCCTAGGACAACCTCTAGTCAGGGCAGAG
GCCGGCTGTGCTGCCCAAGTGCCCTAACCTAGCTTTGAGGCACCAGAAG
GGCAAATGCAAATTAATAATGAGAATAAGTTTATTCTCCTTGGTGAAAAA
AAAAAAGAGACTTTCCCCCTCTCCTTTTTCTTTAGAAAATCTATCATTG
30 CAAGTTCCTTCCCTGGACTTTTTTTATGTAGATCTGTTCAAAAGCTAAATA
AGCCTCTTTCAAGTTTCACATCCCAGGAATGTCTCCTTAAGGACCTAGGA
GCCACCATTGTAAGTGTAATCACCAAGGGAGATACATCCTTATCTCCAG
TTTCCGTGGGCAAAGGGGAGCCTAAGTTAGCCCGGTGCCTAGCTCAAGT
TGCAAACACACTTCCAGTCTTAAAGGAATGAATTTATTTTTTCTTTA
35 GGCAAACCCAGGTAGCCACCACAGTTACCTGGGGATTACAGAGAAGTGT
GTGTGACCACTGGTGCTGTCAAGTCCTTACCTGAGCACCTGTGACGTT

TCCCTTIGAGAACGTGTACGGGATGGGTTGCACCTGGTTATATACAAGCGT
GAGACTTCTTTCTGCCTTTGTAAATTTATTAGCAGATTATCTGTGATGAGC
ATCGCAATCTGTTTAATGCCTATTCAATAATTAAATTTTCTTTCTCTTC
TTTTGTGGAAAGGTTTTCTGCATTGGCAGGAGATTTTTGTTTTTCGATTAT
GTCCCCAACATGCCTGATGTTCACCCCTCAAGAGCCTCAGCCTTGCCCCA
GGGAGGGCATGGGGGTGAGTGGCCTCTCCCACAGAGAGTGCTGGCCAAGT
TGGCCCAGGTGCGCAGCAAGGGCTGCTGCCCAAAGGCTCCCTCCTGGTTG

The human adipocyte enhancer binding protein 1 has the amino acid sequence depicted in

MAAVRGAPLLSCLLALLALCPGGRPQTVLTDDEIEEFLEGFLSELEPEPREDDVEAPPPPEPTPRVR
KAQAGGKPGKRPGTAAEVPPEKTKDKGKKGKKDKGPKVPKESLEGSPPPPKKGKEKPPKATKKP
KEKPPKATKKPKKEPPKATKKPKKEKPPKATKKPPSGKRPPILAPSETLEWPLPPPPSPGPEELPQEGG
APLSNNWQNPGEETHVEAQEHQPEPEEETEQPTLDYNDQIEREDYEDFEYIRRQKQPRPPPSRRRRP
ERVWPEPPEEKAPAPAPEERIEPPVKPLLPPLPPDYGDGYVIPNYDDMDYYFGPPPPQKPDAAERQTD
EEKEELKKPKKEDSSPKEETDKWAVEKGKDKHKEPRKGEELFEEWTPTEKVKCPPIGMESHRIEDN
QIRASSMLRHGLGAQRGRRLNMQTGATEDDDYYDGAWCAEDDARTQWIEVDTRRTTTRFTGVITQGR
DSSIHDDEFVTTTFVGFSSNDSTWVMYTNNGYEEMTFHGNVDKDTPLVSELPEPVVARFIRIYPLTWN
GSLCMRLEVLGCSVAPVYSYYAQNEVVATDDLDFRHHSYKDMRQLMKVVNEECPTITRTYSLGK
SSRGLKIYAMEISDNPGHEHELGEPEFRYTAGIHGNEVLGRELLLLLMQYLCREYRDGNPRVRSVLVQ
DTRIHLVPSLNPDGYEVAQAQMGSEFGNWALGLWTEEGFDIFEDFPDLNSVLWGAEERKWVPRVVP
NNNLPPIPERYLSPDATVSTEVRAIIAWMEKNPFVLGANLNGGERLVSYPYDMARTPTQEQLLAAA
MAAARGEDEDEVSEAQETPDHAIFRWLAISFASAHLTLTEPYRGGCQAQDYTGGMGIVNGAKWN
PRTGTINDESYLHTNCLLSFYLGCDKFPHESELPREWENNKEALLTFMEQVHRGIKGVVTDEQGI
PIANATISVSGINHGVTASGGDYWRILNPGEYRVTAHAEGYTPSAKTCNVDDYDIGATQCNFILAR
SNWKRIREIMAMNGNRPIPHIDPSRPMTPQORRLQORRLQHRLRLRAQMRLRLRNATTTLGPHTV
PPTLPPAPATTLSTTIEPWGLIPPTTAGWEESETETYTEVVTEFGTEVEPEFEGTKVEPEFETQLEPEF
ETOLEPEPEEEEEEEEEKEEEIATGOAFPETTIVETTYTVNEGDF

and is encoded by the genomic DNA sequence shown in SEQ ID NO:78.:

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

CAGCAGGGGCAAGGTCTTGTGACAATGTCTGGAGGTGCCCTATTGTCACACTGGGGGTCTCC
 TACTGGCCTGCAATGGGAGGAGGGGCTGCAGCCCCACATCCTGTGCAGAGTGCTAGTGCTGA
 GCGGAACCCCTCCTCAGAGCTGCCCCCTTCTCCTCCAGGTTGTTACCCCTTCTACAAAACCTGACC
 CGTTCATCTTCCCAGAGTGCCCCGATGTCTACTTTTGTGGCAACACCCCCAGCTTTGGCTC
 5 CAAAATCATCCGAGGTAATTTTGTCTTCTGGGGGCCAGGCTGATTTGCTGATTTGCTCTCAC
 CTGGGGACAAGGTTACAGAGAAGAAAACCTGCATTGTGGAGTCCCCCTGGCCCTTGTGGGA
 TGGACAGCTGAGGTCTTCTGCACAGCTGCCATTTCACTGTGGGAGCCAAGCTGCCTCGCCAGC
 TGGGCAGGGACTGGAACGGCTCCAGCCTGTGTGCCCTCTCAAGGCTAATCTCTGGTCTCCT
 ATTGTCACTGCCCCACTGTGTGCCAATGGGGACTCCTGTTTATTTCTGGCAGCTTCTCTTTGAG
 10 GCAGGACTTACTTGGAACCTACAGTGGGTCCTATGTGACTTCTTTGCAGGTCCTGAGGACCAG
 ACAGTGCTGTGGTGACTGTCCCTGACTTCAGTGCCACGCAGACCCGCTGCCTTGTGAACCTGC
 GCAGCCTGGCCTGCCAGCCCCATCAGCTTCTCGGGCTTCGGGGCAGAGGACGATGACCTG
 GGAGGCCTGGGGCTGGGGCCCCTGACTCAAAAAAGTGGTTTTGACCAGAGAGGGCCAGATGGA
 GGCTGTTCAATCCCTGCAGTGTGGCATTGTAAATAAAGCCTGAGCACTTGCTGATGCGAGCC
 15 TTGAGCCCTGGGCACTCTGGCTATGGGACTCCTGCAGGGGTGCCACAGTGACCATAGCCCAT
 GCACCCACCAGCCGGTCTCCCTCCTCCCCATCCCTGACACCTCAGAATGTGAGCAGTCCGTGCC
 ATGAGCTTGTTTTATTGGAGTGACCTTGGCTCCCTCCCTCTGCCCCCTACTCCAACACTGCAGCA
 ACCCCATCTCTTACGAGACTGGCAGGTGGAGCAGGAGCCTCTACACAGCCTCTGGCTCTTAGG
 TCCCAGTCATGTTTGCACCCCCCTCAAAGGGGCAGGACCAGCCCTTCCTTTTCAGTGTCCATACCA
 20 GGGGCCCTTCCATGTGCTGATGGGTGATGTGACTGTGGTCAAGCAGGCTTGGGAAGTGC
 TGCTGCTGTAGCTTGAGTTGGGCTGGGGTCTTGGTAGGACGCTGATCTCAGAAAGTCCCCAAAG
 TTCACTGTGTAGGTCTCTACTGTTGTGAAGGGGAATGCCTGGCCAGTGGCTATCTCCTCCTCTT
 TCTCCTCCTCCTCCTCTTCTCAAACCTCGGGTTCAGCTGGGTCTCGAACTCAGGCTCCAACCTG
 GGTCTCAAACCTCGGGCTCCACCTTGGTCCCAAACCTCGGGCTCCACCTCGGTCCCAAACCT
 25 CTGTCAACCACCTCTGTGTAGGTCTCAGTCTCCGACTCCTCCCAGCCAGCGGTGGTTGGCGGTAT
 GAGGCCCCCAGGGCTCTATGGTAGTGCTCAGGGTGGTGGCAGGGGGCAGGGGGCAGCGTGGGAG
 GCACAGTGTGGGGGCCTAGGGTGGTGGTGGCGTTGAGGCGCCGCAGCCGCATCTGTGCCCGA
 AGCCGCAGGCGGTGTTGTAGGCGTCGCTGCTGCAGGCGTCGCTGTTGGGGGGTTCATAGGGCG
 CGATGGGTCTATGTGTGGGATAGGCCGGTTCCTCGTTTCATGGCCATGATCTCCCGGATGCGCTT
 30 CCAGTTGGAGCGAGCCAGGATGAAGTTGCACTGAGTGGCCCCGATGTCATAGTCAACATTGC
 AGGTCTTGGCGCTCGGGGTGTAGCCCTCCGCGTGGGCTGTACGCGGTACTCACCCGGGTTC
 AGATTGCGCAGTAATCACCACTGGCTGCGGAGGGAGAACGATCCGGCTGCCCCAGAGCGC
 CCGTCCAGGCCCCCACCCTCCCACTCAGTCTGCCCCCAGCCCCGCGCTCCCGCTCTGAGTTCC
 CGCCCCCAGCACCGCCCTCCCTCTCTGAATTTGCCCCCAGGCTCCCCAGACTCTACCTGCTCGC
 35 TGAGTTCCTCAAGCCCCCACCCTCTCTGGCGGGTCCCTCCCTCAGAAAGATGGGGTAAAGGTGT
 GCACACTAGGTACCTGTCTTCACGCCGTGATTAATGCCACTCACAGAGATGGTGGCGTTGGCA

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

ATGGGGATGCCTTGCTCGTCCGTCAACCACCCCTTAATGCCGCGGTGCACCTAGGGAAGCAGG
 TGAGGGCTGCTGGTCCTCAGGAAGGTCCAATGTGGTCCGCTGCTCCCTCCCGCCCATCCAGGA
 GCCTGTGCAGCCTCCTCTCCCCAGGCATTGCCCTAGCCACCCACCTGCTCCATGAAGGTGAGC
 AGCGCTCCTTGTTGTTCTCCCACTCGCGGGGCAGCTCACTCTCATGAGGGAACCTTGTCACAGC
 5 CCAGGTAGAAGGAGAGCTCCAGGCAGTTGGTATGCAGGTAACCTGAAGTCATTGATAGCTGGC
 CGGGGACAGATACAGACCCAAAGTCAGCCCTCTCCGGACCAGGCCCGCCACAGCCCTCC
 CAGGCTGACTCACTCCCGGTCCGGGGGTTCACCTTGGCCCCGTTGACGATGCCCATGCCGCGG
 TGTAGTCCTGGGCTTGGCAGCCTCCGCGGTAGGGCTCGGTCAAGGTGAGGTGTGCGGAGGCG
 AAGGAGATGGCAAGCCACCGGAAGATGGCGTGGTCTGGAGTCTCTGGGCTCGGAGACCTC
 10 GTCCTCATCCTCCCCCGGGCTGCTGCCATGGCTGCGGCCAGCAGCTGCTCCTGGGTAGGCGTG
 CGGGCCATATCGTAGGGGTAGGATACTAGCCGCTCGCCGCGGTTTACAGATTTGCTCCCAGCAG
 AAGGGGTTCCTTCTCCATCCAGGCAATGATGGCCCGGACCTCCGTGGATACCTGGAGTGGCCAG
 CACGTGTGAGGCCAGGGCTGCAGCTCCGGCCACTATCCCCAACCTAGCCCGATCACCTCCATG
 AAGCTTCACACCAGTACTCGCACGATCCCCTGTCCCCCAACCCCCAGAGCCTCAGCGTCTGGAG
 15 TTCAGGCACCGTCAGCCCCACCCCAAGCCCAGAACACCAGGACCCAGGGTCCAGCTGCTCCC
 TCCTGCCCTTTTACGCCAGGCTGTAGCCTCACCGTGGCATCTGGCGAAAGGTAGCGTTTACGGGA
 TGGGCAAGTTATTGTTGGGGACCCGGTAGGGGACCCATTTCTCTCCTCAGCTCCCCAGAGCA
 CAGAGTTGAGATCCGGGAAATCTTCAAAGATGTCAAAGCCCTCCTCAGTCCACAGTCCAGCG
 CCCAGTTCCCAAACCTCTGAGCCCTGTGGGGAGCCAGCAGGGTAGGCATCGGCTACCCACACCC
 20 CCACAACCCCCAGCTGCCTGGACCCCTGGCCAGCCTCACCTTCAACCCACCATCTGCGCTGCCA
 CCTCGTAGCCATCAGGGTTCAGTGAGGGCACCAGGTGGATGCGTGTGTCCTGCACCAGGCTGC
 GCACACGTGGGTTCCCATCGCGGTACTCTCGGCACAGGTACTGCATGAGCAGCAGCAACAGCT
 CTCGGCCCAGCACCTCGTTGCCATGGATCCAGCAGTGTAGCGGAACCTCGGGCTCCCCCTGCAA
 GGGCGGGAGCCTCAGTGAGCACTCAGTCTCCCGAGGCCCAGGGCAGCTGAGGAAGGACCCAG
 25 ACCCACCTCATACCCGAGGGTCTGGGGGACAGCTGGGGCTCCTAGGGCCCTGTAAGACAAGCC
 AGAATCCCCAGAGAGGCTCCGGAACAGGCGGGAGGCAGTGAGCTCTGCACATCAGCAGCAGA
 GGCCAGCTGCTGGCCCCACAGACCCCTCCCCCAGTTTCATGCTCCCCAGGGTTGTCTGAGATCTC
 CATGGCATAGATCTTGAGGCCTCGTGAGCTCTTGCCCAGGCTGTAAGTGCGGGTGATGGTGGG
 GCACTCCTCGTTACCCACCTTCATGAGCTGGCGCAGAGGGGGAGGACGTGGAATCAATCATGC
 30 AATCCGTCCCCCGCTGACCATGCCCTTCCACTTCCAGGGCTGCTCTATGGCGAGGGACGGGG
 ATGACCCCTTCACGCAGCCCCCAGGTAAGTGGCTCCTTCCTAAGGTGAGGGACAGCCAGCATC
 CCTGGAACCAGTAGGGACTGGGCCCAGTGACAGAAGCACCAGGCACACACTCCCGTCAGCCAG
 AGACAGGTCCCACCCCCAGCCCCAGGATATATGCTCCCAACCTGGCGCATGTCTTGTAGCTGT
 GGTGCCGGAATCCAGGTCATCGGTGGCCACCACCTCATCTGTGCGTAGTAGCTGTAGACAG
 35 CTGCAAGGGAGGCGGGGTGTCTTTAGCTGGGTGCCGGCTGGCCC

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

ACCCTAGCACCCACCTCCACTCAGAGCCCCTGCCAGCCCCTCCACACTCACGGGCCACAGAGCA
 CCCCAGCACCTCCAGGCGCATGCACAGGCTGCCATTCCAGGTGAGTGGGTAGATGCGGATGAA
 ACGAGCCACCACCGGCTCTGGGAGCTCACTCAGCACGGGTGTGTCTTGTCCACGTTCCCATG
 AAAGGTCTGGGGAGAGGGCAGGCCTCAGAGCAGTACTGCCAGCCCCTCTGAGAGCCCACCC
 5 CTCGCCCAGACAATGGGAGCAGAGCCAAGAGCCTGGGCATGGTGCCCACCATTTCCTCATAGC
 CGTTGGTGTACATCACCCATGTCTGGCTGTCAATTGCTGAAGCCCACGAAGAAGGTGGTCACAA
 AATCGTCACTGTGGAGTGGACAGTGGTCAGAGCAAGGGTCTTCCCCCTCCCAGGCCCTCAGGT
 GGCCTGAGCCTCCCTCTTCCGAGCCCCAAGAATTTAAGAGCTAGCAGGGGTGGTGCTGCACG
 GCCCAGGTGTTGAGCCTGGGTCTATGCCCCGTACATAGCCATGGGCAGGTGATCTGTCCCTA
 10 AACTCATGTGCTATCAGGACACAGGGGCTGACTGACCAGGCTGAGGAGTGGGGATGGGCAGG
 GTGAGTCCCTCACTGATCTTTTTGGCCTTCTTTGGCTGGGCCAAAGAAGGGGCCCACTGGAATC
 TCCTTAATGGGACACAGAGCCATGCCTATGTAGCCACTCCCCTCTGCCAACTATCCATGAGC
 CTGGCCACGCACTGGATGCTGGAGTCTCTGCCCTGGGTGATGACGCCTGTGAACCGGGTAGTC
 CTCCTGGTGTCCACCTCTATCCACTGGGTCTGGCATCGTCTCGGCACACCACGCACCATCAT
 15 AGTAGTCGTCTCAGTGGCACCGGTCTGTCCAGGGGGCAGGGGAGGCTGAGCATGGGCGGAG
 GAGTCCCTTATCCCAGTTGGGAGATGGGCCCATCCCAATGCCACCTGCATGTTGAGCCGG
 CCGCGCTGTGCCCCCAGGCCGTGGCGCAGCATGGAGGAGGCTCGGATCTGGTTGTCTCAATA
 CGGTGTGACTCCATCCCAATGGGGGGACACTCTGAGGACGCGTACCCCAAGAATGGTGGCTCAC
 TAGCTCCATCCTTCCCTCCACCAAACCCAGAACCAAGGAGCCCAGAGCCCCTCCCGGCACATC
 20 GGGGGCACAGTCAGAGGGCAGCTCTGGTCAGCTGGTGGCTCCCTGGTGCCCTGCACCAGC
 CCACCTGGAATCGACTCAAAGCCAGGCCAGGAGCTGTTTCCAATCCCAGCCTGTGCTTCCCCTC
 CCTGGGCCTCAGCTGCCCCATCTGGAGAACGGGCTGACCATGCCCAGCTCTCAGGGGACACAC
 GTGAAATCACAGGTAGAGCTCCCCCAGGGCGCAGCCACAGATGTCATCCAGATGGGGACCGT
 CTGCACAATGGCCCTGCAGGGATACCTGTGAAGGTACCTGAGGTCTCACTCCCCACCAAGGC
 25 CCCAGGTCTCTCCCCCTACCACGCCCAGCCACTAGGGGGCCCTGGGGAGCTGCCACCTCCTGAAG
 CAGGCCAGCCTGGGGTCCAGGGCTGGGGCAGCCAAGCGAGGCTATCCTGGGCTCCCGGGGCCC
 CTCCTTCTGGGTCCCAAGAATCTGAGTAGGAAAGGGTTCCGGGGACCTGGGTCTGTGTTGTG
 ACATTGGGCCAGTCACTTGTCCAGCACCCCCATCCTGTGGCCCCCACCCTCACCCCCCTGTGCC
 CCCCCTTACTGACTTTCTCCGTAGGCGTCCACTCCTCCTCCAACCTCCTCGCCCTTTCGGGGCTC
 30 TAGGGACAATGAAGGGAGGACATGGCACCAAGGGCCCCGGGAGGCAATCAGGAGTCCAGATG
 CTGCCCCACAGGGACCCAGGCCCAAGCCCCAGCCACACACCTTTGTGGTCCCTTGCCCTTCTCC
 ACTGCCCCTTGTGGTCTCCTCCTTGGGGCTGCTGTCTCTCTTTTGGGTCTCTGGAAGGT
 GCAAGGTAGGAGGGGGCAGTCAGCCTGGCTCTGGGCTTTGAGGACCATGTGGGGTGGATCAG
 GCAGGGCCCCAGGTGGCCTTCAGGGCAGGCCTGGTGTGGGAAGTCCTTGGTCCCACTCACTCAG
 35 CTCCTCCTTCTCTTCGTCCGTCTGGCGCTCAGCATCGGGCTTCTGGGGCGGAGGAGGCCAAAG
 TAATAGTCCACTATGGGGAGGGAGAGCCAGCTGAGGCTGCCCTGACCCTGCTGCGGGGCTCA

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

GCTCCTGGGTCCACAGGAGCTCAGCAGGACAGGACCGCGCCAGAGGGGAGGAGGACGGGAG
ATGGGGGACAGCTGAGTTGGGAGAGGGTCTTGCAGGAGTCAGGAGCAGCCCGAGCTCAGGG
GCAGCTGAGCAAGACCCTGCTGAAGTCACCAGCCCGGCCCTTCCAGGAGCATCTGGCCTGGGGA
AAGGACTCGAGGGCCAGGGCATGGGAAAGGCCTGGAGGGACAACCTGGCACCTGTGCCTGGGG
5 TTGCGGGCTGGGGGGTGAGATGGGGAGACATTGGAGGCACTGATGGGGACCTGGGGGCAGG
GAAATGGCGATGCACGGGCTGCCACCCAGGAGGAAAGGGAACTGAGGGGCTCCAGGGACGCA
GGGGCATGAGCAACAGGGAGGCCAAAAGCCCTCGGGCTCCCTGAAGAGAGTGGGGCAGTGGCC
ACGAGCCAGCGGGAAGCCAGTTAGAGCACAGGACTGGGAGGGCTGGAACCCACATGGGTGAC
AGGGCAGAGTGTGTGCCTAGGGACACCCCTGTGGGGGTACAGCCAAGCAGGAACCAGGGAA
10 GCGGCCAAGGAAAGACCAGCCTGAGGGCAGAGGAGACAGGGCAGTGGCTGGGGTGGGCACG
CAGGGACAGCAGGGACAGCGAGGTAACCACGGGCACAGGTGGGGTTGCAAGGTGGGTGAGT
TGCCCCAGCTGGCTCCTGACCACACCCAGCCCCGACCCCACTGCCTATGTCCCTCAGACTCT
GGGGTGCTGGGTACTCACTGTCATCGTAGTTGGGGATCACGTAACCATCACCATAGTCAGGGG
GCAGCGGGGGCAGCAGAGGCTTCACAGGAGGCTCTGGGGAGGGGGGAGGTTAGGAGGGGG
15 CCAGAGCGCCGTGGCCATGGCACCTCCTCTCCTGCCCCCATCCTACCAATCCTCTCCTCCGGG
GCTGGGGGCCGGGGCCTTCTCCTCAGGGGGCTCTGGCCAGACCCGCTCGGGCCTCCTCCTTCTGC
TTGGGGGTGGCCTGGGTGTCTTCTGGCGCCGAATGTACTCAACTGAGGGGGAGGCTGGCTCA
GAGTGGGGCCCAAGGCTGGGATGGGCCCATTGGGCACATCCCCAGGCCAGGGGTCCGACCCA
GGTGGGGCTGGCAGGACCCTACTCAAAGTCCTCATAGTCCCTCCCTCTCGATCTGGTCAATTGTA
20 GTCCAGTGTGGTTGCTCGGTCTCCTCCTCCGGCTCTGAGGGGAAAGCGCTGGTAGCTGCCTG
ACAACCCACCCAGGCCTACTCTGGGGAAGCCCTCAGTCCAACCAGCCAGGGCAGCTGGCCCC
AAGGCCAGGCGGATGACGGCCACTCACAGGCTGGTGCTCCTGTGCCTCCACATGGGTCTCCT
CTCCTGGATTCTGCCAGTTATTTGAGAGGGGGCGCCCCTGCAACACAGGAGTTCCAGAAGCAGG
TGGGCGGGAGGCCTGCTCTGACCACCTTGGGAGCCTCAGGCCACCAGCCACCCATAGAGCCCA
25 CACAGAGCCTGTGGACACCCTCCTGAGGCCGAGCTCACTCCAAGGAGGCCTGAGCTCCTCTGG
CCTTCAGCATCCTGCTGGCATCTCATGGGGCCAGAGAGCTGGGCCCACCTTCTGGGGAACCTA
CTGTGCTGCTGGAGGCCCTACCACAAAGCTGTCCCCAGCGGGAGAAGGCAGGAGGGAACTCC
ATGGGCTCAGAGCCCAGGGACATCTGGGCAGGGGCCTGAGGGACAGAGGTCCCACCCAAAAG
GCTGCCAAGCCCTCTCCCTACCCAAAAGAGGCTACAGCACTGAGGGAGCCCACCAATCAAATT
30 GTGAAATTTATAGCAAAAAGTGAGGTTCCCATCCAGTGGGGAGCTGAAGGTCTATAGGAAGCA
GGGCCCCAGAAACCTGCCTCCCACTCCCTGCCTCCACCCGAGCAGGCAGTCAGAGCCCCATCAC
CCCAGAGGAGCCCCGGCACAAACCTCCCTCCTGGGGTAGCTCCTCGGGGCCAGGGCTGGGGGGT
GGGGGCAGTGGCCACTCCAGGGTTTCTGAGGGAGCCAGAATGGGGGGCCTCTTCCCTGACGG
GGGCTTCTTGGTGGCCTTGGGTGGCTTCTCTTTGGGCTTCTTGGTGGCCTTGGGTGGCTCCTCC
35 TTGGGCTTCTTGGTGGCCTTAGGTGGCTTCTCCTTGGGCTTCTTGGTGGCCTTGGGTGGCTTCT
CCTTCCCTTCTTGGGCGGCCTGGGGGACCCCTCCAAGGACTCCTTGGGCACCTTGGGGCCTTT

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

GTCTTTCTTGCCTTTCTTCCCTTTGTCTTTGGTCTTTTCCGGAGGCAGTGTCCAAGATGCAGACT
 CGTGTCAAATGAACAGAGCCAGCTCTGTGCCCCATGAGGCCCTCTCTAGATGCCCAGAACC
 TGGGCACAGGGACTCTTGTCTAGTTCCCACTGCGGATCAGCAAAGTGTGAGAGGTAAAGTCATTTG
 CCAAGTGGCAAAGTGGGATCCGGACCCAGATTTTCTGTCTGCAAGTCTGGGGCTGTGACCAC
 5 CAATCTCAACCTCTCTAAAGACTGAGCGTAGGGTTCCTTACTATCCACTCCTCCACTATTCTGTTCTGGG
 CCCCACCTGCCAAAACCTCAATAGGGGTTCTTACTATCCACTCCTCCACTATTCTGTTCTGGG
 CACAGAAGGGGCGAGAGAGGTGACTGAGCCATCCAGGCCTGGAGGAGCATCTGGTCATCCCTG
 CCAACTGCCATACAAAGGAAGGGACATGGGGCCCAAGACCTTCCCCTGGTCTCCTACGGGGGCAA
 GAAAAGCTTCAAAGAAAAGGGACACTTGGTTGAGTATTGAAGCCCAAAGAAGAGGAAGTGG
 10 TCTCCTTTTCGAGAAGTAAGGGGTTTGAATTGATTGGAAGGATAGGGAGTCTTGGGGGGTTC
 AGGGATCACACAGAGGACAGAAAAGACAGGTAGGGAGCTTGTGGCTGCACACTCATTTTCTGAGA
 GTCTGGGAGAGGGAGCAGGGACTGGTTGTGAGGATTCCCCATGGGAATCCTCCCAGGACCCCT
 AAGCAGGAGCTGCAAGTGTCTGTTGAGAACCTGATGAGAGGTGGGGAGCATGAGGGAAAGTTT
 GGCAGAAAACACAGGAAAGCTACCAATGCAGACAGCCAGGGGACGCAGGGCTGCTAGAGCG
 15 GTGCCCCAGAGCCAGGAGAGCAAGCCTGGAAGGAGAGCCAGAGGCAGGAGGGGCGACAGGCA
 GCCCAGGGTGTGGGAAGCAGCCAGGAAAGATCTAGAGCTGGGGTGGCAGGGGAGGGGCTGC
 TGACATCAGGAATGTTGGATGGTGCCTTGAATCTCCTGGGAGACAGGGATCACAAGACCCCT
 CTGCCACCTTCCAGAGGGGCCACGATGAAAACAGCTAAGATTTACTGACAAGTATTATGCAAG
 AGGCCGTGGGTAAATGCTTCAGTGATGCATCACCTCATCTAATTTCTGTACTAATGTAGGA
 20 CCACCCATTGCTCACCACCACCTGAAGCCCTGTGCTCACCACCACCTGAAACTCTCTCACCTAG
 GTGAGACCTCCTGGAGTAGGAGGGCAAAGGCAGGAGGGAGGGACGACGTGAAGCTGTGCCA
 CCAACAGGGAGAGTGGTCCCATTAGTATGGCAGGGGGTGACACAGCACAGTCCCCTGTGGCT
 CAAGCCTAGTACCTGTCCGCTACTGGAGGAATGGGGATAAGCGACCCGTACAACCACAGCAC
 CAACCCCTAGAGCCACCGGCCCCCAAAAGCGGCCCTGCCGCCCGGGTGCTGGATGTGCCTCCAC
 25 GCCAGCGCTGACCTCGGCCTAGCACAGGGTCCCTCCAGGCATCTGGGCTCGCGTGCGCATTAG
 TAAGCCAGCCATTCTCCTCCCTAGCAGACTGGGGAGTGGCCAGACCCCTACCGAATCCCCCTGTTT
 CCACCTGAGATGCCAGCCCCCACACCCCCGCCCTGCCCTGGGCTCTTACCTTCTGCGGCCGTCC
 CTGGCCGCTTCCCTGGCTTGCCCCCGCCTGGGCTTTTCGGACCCGCGGGGTGGGCTCGGGAGG
 CGGCGGGGCTCCACGTCGTCTCCCGGGGCTCAGGTTCTAGCTCTGACAGGAAGCCCTCGAG
 30 GAACTCCTCGATCTCGTCGTGCTCAGCACCGTCTGCGGGCGCCCTCCAGGGCACAGGGCCAG
 CAACGCCAGGAGGCAGCTGAGCAGGGGCGCCCCGCGCACGGCCGCCATGGCCGCGGCACGCG
 CGGGGGGCTCCGGGGAGGGCGCGGGGGGCTCAGGGGCTCTGGGTCTCTGGGAAAGGGCGGAG
 AGGGGATCGAGACGGGTGAGGGAATCCAGGAAGGGGCGGGAGAGAGGATGGGGTGAGCGA
 GGGGAATCCGGGAAAGGGAGGGAGAGTGGATTAGGGTGGGCGAGGGGACCCGGGAAGGGGT
 35 GCTGGGGGGCTCCGAAGCCAGAGGGGCTCAGGGGTGGTCGGGGCGCTCCGAGGTCTGGCGGC
 TAATAGGCGCTCCGGCCCCCGGTGGCGCACTCCCGCGCGGATAGCCGTCTCCAAAGCGCTGGC

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

GGGGCCCCGGGGCGGGGGCGCCGGGGCTTCCGGAGCCGGCTCCCCACCCCCGGGGAGGAGGAG
GAGGAAGAGAAGGAGGAGCCGAGAGTGGACGGAGGGGCTGCGGGGGGGCGGGGGGGCGGGG
GGCGGGGGGGCTAGGGGCGGGGCAGGCGGGCGGGCGCTGGCGGGGAGCGTCCCAAGCCCCGA
GACTTGCGCCTAGGACAGAGGGGGCAGGGGGCGGGGGCGACTGGGAAGACAGAGGGCCTGAGG
5 GAAGGAAAGGTGGTGGGGAGGGCCTGGGGTGCGGGTCTGAGGGGGCCGACATCCCTCCTCCT
TCTGCCCTAGGCACCCCCCTTAAGGCGGGACCCCGAGTCCACCGGGGCTCTGAGCCCTCCGCGG
GTGACCAGGAACCCCTGGACGGAAAGCCGTGGTGTGACGGCCTCTGAGACCTCTCTCAATTGGA
GGGCCACAGAAAGGCCACCCCATCCTTCCCAGGCTCTGGAGCCTCTGCCCATGGGCCCCTGCTGC
ATCCAGCGTCAATTCAATTCAGTCATCCTACCAACCTCTTCAGGTGGGTGTGGGGCCGGGGCCCC
10 GTGCTGGGGCCCCAGGGAGGGACAGCACAGTGGGAACCTCACTTTCCAGCCAGGAGGCAGGTGC
AAAACCTGCCCTCAGAGTGGCCAGCTGCCCCGCTGGGGGTAGGAGTCCCATGTAAGGGCATGCC
ATCCCTCCCCCTCCGGGTCCCAACGTGGACAAATAGCCATTTATCACCTTCTTCTTACCAGAACT
CATTTTTTAAAAAGTGTCTACCATACCTCCAGCTGCCACATGGACCCAGAGGGCCCAGAGGAC
CCAGAAGGCAGGTGGATTGAGTGTCAACTGATCCCAGGATCCATCAGGGATGTGCACCTTGG
15 TGCCTGGTGTTTGCCATAAGGCTTCTCCAGGGCAAATGTTGGCTGCCCTACAACGGCCATCAA
CAGGCAGAGTGGTCCCATTAGTATGGCAGGGCGTGACACAGCACAGTCCCCCGTGACTCAAGC
CTAGTCCCTGTCTCATACTGGAGGAATGGGGAGCTAAGGACAGAGCTCCGAGGACATTCCCCC
TTAAAGGAATGAGGACACAAGAGAAAGCTCACAGGTAGTCCATGGGCCAAGTGCAGAGGCA
GACAGCCCTAAGCCACGATTGTCTGCGGGGTTTGGCCCCAGTGAAGTAGTCAAGGTAGGGAAG
20 CCTAGGAGCCCCTGGGATGATTGACAGGGCAGAGTTTGGACCTGGGGTCAAAAGGAAAGAGG
AAAAGTGGGTCAAGGAAGCACCTGGGTCCCCAGAGCAGCCCCGAGTGAGTTGGAGCAGGCAGC
AGCCGGGGAGGCCACAGTGGAGGCTGCTGGGCCTGGGATACATGCCACCCCCTGGGAGCAGG
ACCACAAGGAGGCCTTGCCTCCTCTCACACCTGGTCTGCCAAGACCCCTGCCTTTGCTTTCTCA
CTGCATCTCCTTGAAAAAGCAGTGGGACTGTGTGACGGTTCTGGCTCTACCTCCCAGGCACCAC
25 ATCTCGGCAGGTAGCCTCAGTGCCGTCCACCTGTGTC
CCTGTTCTCCTTGTCGTTACATACAGGATCATGCATGTGCTGTGCCTAGCACACATTCTTGGCAC
TCACACTGCTGCCTTTTAGCTCTCATCATTTGCCCTCAGAGATCAACCTGAGCTGTGCCCACTG
GGGCGCTCAGAGCAGACCCTGAGCCCCAACACCCAGGCTCCCTGTGCACCTGAGCCTGCCTCT
GCCTGCCACGTGCCCCCAGGCCAGTCCCTGGTGGCAGCAAGGATCCGCAAGCTCTCCCCCTTTCT
30 CATCCTCTGCAAAGCTCTGAATCATCTTTCTCAAAACTTGTCTGGGAATTTGCTCCGTTGCC
CAGTTGAGCATGTCAAGCCCCGGCGGCCCAAGGCTGGGGTGAAGCAGCGTGGCAGTCACTTCC
CTGGGAACAACCTCACACATGGATTGGATTGGGTCCAACATCCTCTGCCAGGGAAAATAGAA
GCCATAAGAAAAACAAAAAAGGAACAGAAGGAGGCTTTTCTTCAGTCACAGCGAGTCACCAAC
AAAAACATGTGCAAAAGCTCTCATGGAGAGCTGGGCCACAAGGAGGGCCATGATGTTGGGGG
35 CCCTCTGACACCAAGGGTGTGGGCAGGTGGATGGGAGGCAGCTGCCCTCCATGCCAGGCTGAT
GTGCCTCCCTTTGGGTGGTGGGGCTGGGACTCCCACTCCACTTGAAGACCTGCACCAAAAAGT

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

CCTTTAGCCCTGTGCCCAGGCTCTGCCACGGGGCCGGTGAGGGGACTTCTCCCCTCTGCTGCCA
GAGTGAAGCCAGTCAGGGGGATGGGAGGCTTGTAGCCAAGAGCACCTAGTGGCTTTCAGGGT
CCCTTACCCCTGCCACTTAGCAGGGTCTGCACCTGCATCCAAGTGTTCTCCTGGGCTACAGTGG
GGGGCTGGTAGACACTCTGGTGATCCACTTTCAGCTTCCCACATGGATGTGGCAGGGACTGCT
5 TTGGCATITCCCTACCCCAAGGGACAGCCACTGCCGCAGGACTGGGCTGGGGAGGGTGGGGC
CTGCGCTGGGGAGGGTGCCCCCTGTCCCTTGCTGCTGCTGGAATGGGAAGGAGAGTTGTTGAG
AGAGCCAGAACTGTCCAAGGGTGGAAGCTGGCGAAACTGACCTGCAGGGAACAGGGAGACA
GGGAGCATGGCCCAGTGAGTAGGTCCATGTAGCTCTGAGGGCCATCAACCCTGCCATGAGGGC
TGAGACCCCAAGAGAGAAGTTGAGGTTGGGTGAGGGGCCTGTTAGTGCCAGCTGAGGAGGGG
10 GACAGGGCAGCCTCCTCCCCTGAGGACCCAAAGCTATAGCTCCTGAGCCTCCAGAGCTGCCTGG
TGCCTCAACCTGGTCAGAGGTGGAAGCTCACCTGCCAGCAGGCCCAGTGTGCCTGAGTTCTGA
CTGTGGGGATCTGCAGGGCACAGAAGGATAAGAGGTCATCAGGGCCTGGGGACAGGCAGGA
GTGGCAGGGTCTGGGAGGGTGGGAGCAGACCCTCCCAACCTGCCCCATGGCCTCCGTGGCCCC
CAGGACCCCATGGCAGCAGCTCAGACACGGGTTGTGCCTCAGAAGGAAGTGAAGCTGTGTG
15 TACCGAGATGGCCCAGCAAACCTTTGTATGTAACTTCCGCCACAGCCCAGCTGTCCAGCAC
CAGCATGTGTATCTGGGGGAGGGGGATAAATAGAAGGTCTGGGAGGCCTGGGATCTGGCCAG
CAGGCTACTGGGATCACAGATGCCAGCCCCCTCCATATCTCCGCTTGAGTCCCTGGATCTGCCTCC
TGGGACCAAAGGGGAAAGGACCAGGCTAGGCTCCTTCCCTTTTTGTTCTTCCCTCTTGGGGGAG
GCTCCTAGAACTCCCCCTTCTCTGCCGCCCAAGTGCCTGGATATTACCAGTGGGGTTAGCCTG
20 TTTGGGGCCACAAGATGGGATGGCTCCCAGAGCCATGGGACCTGAGGTCTCCCAGACAGTGTG
TAGCCACCCTCACAACCTGGCAGAACAAATTTCTTGGTTTTCAACAACCTTGAAAAACATATGTG
ATTTCCACAGTCCGGTGCTTCTCAGGCCTGGCTGCTGAGTGAGCAGAGTTCATGCTGAATTC
CTTCCACTCACACAGGGCAGACAGCAAGCCCAGCTGTGGGGACTCGGTGGGGTGGGGGTC
ACCACAGCAAGGCGCGGGGAGTGGGGAGGGGGGCAGGCTTCCAGCACTGATGAGTAATTCTG
25 CTGCCCCGAAGATCTGGGAAGAGGGCATGTGACAACCTTAGTGCAACAATCTGCCCAGTGTTAG
GTCAGAAGGAAGGAGAGGTCTGTTCAAAATGGAGTCTGGTGGAATAATAATGTTTGGCCCCA
CCTCATACCTCCCTCAAAATTAACCTCCAGATTAATGAGGTAGATGTTAGAAGAGGAACCAGG
GAAGGACTACAAGAAAATATGGAGTCTTTATTTACATTGTGAGGTTTTCTTTAGGTTTTGTTT
GTTTTTGTTTTTGATATGGAGTCTCACTCTGTCACCCAGGCTGGAGTGCAGTGGTGCGATCCC
30 GGCTAACTGCAACCTCCGCCTCCCAGGTTCAAGAGATTCTCCTGCCTCAGCCTCCCAAGTATCT
GGGGATTACAGGCACATGCCACCATGCCCGGCTTTTTTTTTTTTTTTTTTTTTTTGTAATTTTA
GTAGAGATGGGGTTTCACCATGTTGACCAGGCAGATCTCAAACCTCCTGACCTCAAGTGATCCA
CCCGCCTCAGCCTCCCAAGTGCTGGGCGCCCGGCATGTGTGCCAGCCTATATTGACATTCTT
GATGGAGAAGTCTCTTAAGGAAGGACAGAGAAGTTTGGTTGCATAAAAGTTTTTACCTTCTG
35 TACATCAAAATATACTGAAAATGAAAATAAAGAGCAAACAAAATACTGAGAAAGAATGCAG
TGCTTAGAGAGCGAACATTCCCTGGCCTCCTGTAGTTTTAGGAAGCAGCTGTGGCCTCAGAC

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

CCATCTGCTGTGAACCTCTACTCCATATTTATTGCACCTTTCTGTCTGTGAGCGTCGGTTTCTCTC
CTCTATAACAATAGGATAATAATGACACTACCATGCCTTGCAAAAATGCTACAAGGGTTCACT
GAGATAAATCTGGAGAGTCATGCCTGAAAAATAGTAAGTCGTTGATAAAGGGAAGCTGCTAT
TAATAAATAAAAGCTTTTTTCTTTTTTTTTTTTTTTGAGATGGAATCTCACTCTGGCGCCTAGGCTG
5 GAGTGCAGTGATGCAATCTTGGCTCACTGCAACCTCCGCCTCCTGTGTTCAAGCAATCCTCCTA
CTTCAGCATCCTCAGTAGCTGGGACTACAGGTGCGCACCACCATGCCCCGGCTAGTTTTTTACAT
TTTTAAAGCTATTAATAGGCCAGCCACAGTGGCTCATGCCTATAATCCCAGCACITTTGGGAAG
CTGAGGCAGGTGGATC

- 10 The adipocyte enhancer binding protein 1 is 16,000 base pairs in length and contains 21 exons (see Table 23 below for location of exons). As will be discussed in further detail below, the human AEBP1 gene is situated in genomic clone AC006454 at nucleotides 137,041-end.

POLD2 has an amino acid sequence depicted in SEQ ID NO:4:

15 MFSEQAAQRAHTLLSPPSANNATFARVPVATYTNSSQPERLGERSEFSRQYAHYATRLLQMRPFLEN
RAQQHWGSGVGVKKLCELQPEEKCCVVGTLFKAMPLQPSILREVSEEHNLLPQPPRSKYIHPDDE
LVLEDELQRIKLKGTIDVSKLVTGTVLAVFGSVRDDGKFLVEDYCFADLAPQKPAPPLDTRFVL
LVSGLLGLGGGGGESLLGTQLLVDVVTGQLGDEGEQCSAAHVSRVILAGNLLSHSTQSRDSINKA
KYLTKKTQAASVEAVKMLDEILLQLSASVPVDVMPGEFDPNTYTLPPQPLHPCMFPLATAYSTLQ
20 LVTNPYQATIDGVREFLTSGQNVSDIFRYSSMEDHLEILEWTLRVRHISPTAPDTLGCYPFYKTDPEI
FPECPHVYFCGNTPSFGSKIIRGPEDQTVLLVTVPDFSATQTACLVNLRSLACQPISFSGFGAEDDDL
GGLGLGP

and a genomic DNA sequence depicted in SEQ ID NO:8.7.

CCCTCCTCCATCCCTGCCCAACACCCTGAAGACCCTGGATGCAAACAAAGGCCCGAGGGAGC
25 CTCTTCCCTCGCAGTGCAAGGCCTCACCTGGGGCTCAGAGTCAGAATCTGCATTTTATTCCCTAG
GACAACCTCTAGTCAGGGCAGAGGCCGGCTGTGCTGCCCAAGTGCCCTAACCCCTAGCTTTGAG
GCACCAGAAGGGCAAATGCAAATTAATAAATGAGAATAAGTTTATTCTCCTTGGTGAAAAAAA
AAAAAAAAGACTTTCCCCTCTCCTTTTTCTTTAGAAAATCTATCATTGCAAGTTCCTTCCTGGA
CTTTTTTTATGTAGATCTGTTCAAAAGCTAAATAAGCCTCTTTCAAGTTTCACATCCCAGGAAT
30 GTCTCCTTAAGGACCTAGGAGCCACCATTGTAAGTGTAATCACCAAGGGAGATACATCCTTAT
CTCCCAGTTTCCGTGGGCAAAGGGGAGCCTAACCTTAGCCCGGTGCCTAGCTCAAGT
TGCAAACACACTTCCAGTCTTAAAGGAATGAATTTATTTTTTTTCTTTAGGCAAACCCAGGT
AGCCACCACAGTTACCTGGGGATTACAGAGAACTGTGTGTGACCACTGGTGCTGTCAAGTCC
TCTTACCTGAGCACCTGTGACGTTTCCCTTGAGAACGTGTACGGGATGGGTTCACCTGGTTA
35 TATACAAGCGTGAGACTTCTTTCTGCCTTTGTAATTTATTAGCAGATTATCTGTGATGAGC

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

ATCGCAATCTGTTTAATGCCTATTCAATAATTAATTTTTCTTTCTCTTCTTTTGTGGAAAGGT
TTTCTGCATTGGCAGGAGATTTTTGTGTTTCGATTATGTCCCCAACATGCCTGATGTTCCACCCC
TCAAGAGCCTCAGCCTTGCCCAGGGAGGGCATGGGGGTGAGTGGCCTCTCCCACAGAGAGTG
CTGGCCAAGTGGGCCAGGTGCGCAGCAAGGGCTGCTGCCCAAAGGCTCCCTCCTGGTTG
5 GCATGGGTGCGGACCTGTGTGTGTGTGTTTTCGCTCTTTTTCGTAGAGTTCAAGGGGGTCCT
GCTATGTTGTCCAGACTGGTCTTGAACAGCTCAAGGGATCCTCTCGTCTCAGCCTCCCAAAG
TGCTGGGATTACTGTGCCCAGCTTTGTGTGTGATTTTCTGATCTTATCCTGCAACCTCTTGAGC
CCCCAACCTGGGCCCCAGTTCTCTGCTGTGCCCCAGCCTGCCAGCCCTCTCTCTCTGCAT
ATTCTTTCTTTAGCTGAGTTAACACCACTGATAAGGTAAAGACAGGCTCTTAAATTTCTGCC
10 CTGGCATGAGAAATATGTGACCCACATGCTTCTCCAGCTTAGCTGTCCAGTGTAAGTGTGAGG
GACTGATGGGCGCGTGCTGGCCACAGCCACCTCAGTCCTGACCCTCCCTGACAGGCTGAGA
GAGGCCCCAGCCTGAACCTGGACTCCCCCATGTTCTGATATTCTGACACAAGAGTGCAGAG
GCCTGGTTAAGCTGGAGAAACATAAGGAATAGGTAGGTCTGCACACACTCACCTCTTCCTTTG
CAGTGAACCTTCTAGAATCTTCTAGATGGAAAAGCTGGGGGTGTGGAGGTGTAGGGATAGGA
15 CAGCTGGGGGAGGCCTTGGCCAAGGTCAAGGAGTAGGCCAGTCTCCCTCTCTGTGTGCCTGT
CTGGGACTCGGTTTTCTGTCTGTGAAGCAGGGCTGGACGGGATATTGACAGCACCTGATGGTC
ATTGAGCTCCTCTGCCCCAGGCACTCAGCTGCTGGGCACAGTGCACACGTGGCAGTCCGGTGC
CCTCTCAGGCTCCGTGATGACTGAGTCTGTAGTTACACCCCTGGCCTCAGAATAAAGACTACA
CTTTCTGCCTCCCTCACTGGCAGGTATGACTAGGTGTGGTGGCAGTTTTCTCCTTAAGAGACA
20 GATGTTTGTGCTCCCTCCAACCCGCTGGCTAACACCTAGCTGGCACACAGCCTCCTGGGGCTA
TGAAGATGAGGGCCACAGCCACAGGGTGGGGGAGCCGTGAGCTGGGTCTGGCTGCGTCTCTG
ACATATGGGGGCATCACACATCACCTCTACCTCCCATCGAATGCTACACGAAGAGAAACAACT
CCACCTGATGGAAGCTGCTGTTGTTGAAGTCTTTCATGCTCACAACAGAACCTAACCCCAAC
CAATACAGTATGAGTATTGGCCCCACGTGGTTAAGCAAGCTGTCCAAGGTTACACACAGCTGG
25 GAGGTGGTGGAGCTGGGTTTGAGCCTGTTATTGACCTTTGTGCAGACAGACCTCAGAGCAGA
GCACAAGGCAGCAAGGCTGTGGGTCTGGGGCTCCCTCTCCAGGAGAATCAACTGGCTGCACAC
AGCCTGGAGAGCCCATGGGCAACCTGAGTCCTTGACCTGGAAGTTTCTGTGTCCACACATA
TCCAGGAGCTTAAAATGAAGATGTCTGAATTACCCAACCTCTTGATAGCACCAACCCAACTT
CCCAGCCTCCTCTTCTGAGGTCAGCCCAGAGCAAGCCCCCTTGCAAAGCTGATTTAACTCAGAA
30 CCACTGGGCATACCCACAGGGCAGTGACCCTGCAGCCCTCGATCAAATGTGCAGATGGACTTG
GGGGTGGGCTGGTACCCAGATGGCCTCATTTCTCCAGGGTTGCAGAGCCCCCTGAAAGCCACA
GCCCTGTGTGCACACCACTGGGGAGTCATCACAGGATACTTCAAGAATTCAGTGCCAGGCAAG
GTGGCTCATGGCTGTAATCCAGCACTTCGGGAGGGCTGAAGCGGGCAGATCACCTGAGGTCA
GGAGCTAGAGACCACCCTGGTCAACATAGGGAAACCCCATCTCTACTAAAAATACAAAAATT
35 ATCTGGGCGTGGTGGCGGGTGCCTGTAATCCAGCTACTCAGGAGGGCTGAGACCGGAAAATC
GCTTGAGCCTGGGAGGCAGAGGTTGCAGTGAGCTGAGATTGCACTGCTGCACTCCAGCTTGG

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

GGGACAGAGTAAGACTCCATCTCAGAAAAAAGAGTTCTGTGTATCATTTAATGTGGAGATCC
TCCCATCACGAGGATGAGGCTGTTTTCTCTACTCCCCAGATCTGGGCTGGCCTGTGGTTTTGTTGA
CCTCAGCCTTGTAAGTTCTCACTTTCTGGAACCTGAATGCCACCACGCGACATCCATAAGACAA
AGCCCAGGATAAAAAGATCACTTGGAGAGACAGGCCTGGCCTGGCACCAACCCCGGCTGAGGCT
5 GGACCCCTGGGAAGGAGACTCTGATGGACCTCCAGACCCAGT
CAAATGACCACTTCCAAGGTCAGGCAAGAAGGGACAAAGAGCCACTGGCTCAGCCCACAGCA
TCTGAGAAATAAGAAACCGCTGCATTTTTTGAGCCAGTAAGATTTGACAGGTTTGTGTTTGCAG
CAATAGATGAGTGGTACCTCATCTTAGCCCATGTTCTGATGAAGACAAACAGTAGCATTGACA
AAGTTTTAAGAAAAGTTAACCACAAAACCTGGGATTCTTTCTTCATTTTGACCCCTTGTACAA
10 GAAACAGAGGCCCAACCCACCAGACTCACTGTTCACTGGTCCCTGAGTGCCTGTGAGTCTCAG
TGGGAGTTACCTTGAGACCAGCCCTTCTGAGTGGAGGGTGCTGGGTGCTGAGGTCAAGTCGA
GCTCAGTCCAGGCTAAAAGGAGAGCAGCTCTGGCCAGGCTGTCAGGGCTGTGGCCTCCCCAAG
AACCTCCTACCCCTGGCCCCCTCCAGGCTTTGCTGCTATGGTTGTGTGAGGGGAGTTGCTGTCCA
GCATTCTGGCCCCCTTGGCCCCAGCCCTCCCTGACCTCCACGGGCTTCAGGCCTCAGTCCAGA
15 GTCACCTCCTCTAGGAAGCCATCCCCCAGTGCAAGTCTGGGCAACATTCCTCCTTGCTGGCCCC
ACCTGCTCACTCTCATGCTATGGCTTTCTGTAAGCAAACACAAAAGATAGGAACAACCTCTGTCC
CTGGCACAGAGCAGATGCTCTGGCAATATCTCATGAGTGAATGAAGGCACATGACAAACCTC
CAGACCTGTGGAGACTGAAGGCTGAGAGCCCTTATAGATGCTGTGGGGGCCGAGGAGTTTGCC
AACTAGAGCAGGTCATGCCCAGAGGTTTTCTCTCTGGGTAGCAAGGTGTGTCTCCACCAAAGG
20 CCATTGGCATGGGGCCCCGCCCTGCTGACCCGAGGCAGTGACAGCAGAGGCCAGATGCAGTG
AGAAGGAGCCTCTCCTTGCCCTGCTGTCTGCTGCCATGCCTGTGGGGGGCGTGGACACAAGTGT
GTGGCATAGAAGGTGGTGTGGCAGGTGAGAGGTTGGGGGTGTGTATGTAGCAGGTGTCTGTG
TGTGTATGTGCATGTGGGGGTGTGTGTGCATGCATGTGTGTGTGTGCATATGCACGTGTGTGC
ATATGCATGTGTGTGCATGGAGAGAGAAGACCTCCTCTTTCTGGCCCCCTCTCCTAGCTGCCCCC
25 CTCCCTCCTGCTGCCAACACACTGTCAACCCTTCACTGTCTTTTCTTGGGACTCGTTGATCTG
TCTCTACCATCCCAGGTGTCTGGAGCAGCCTCTAACCTTCCATCTGCCAAGGTACTTCAGCCCC
ACCCCTCCCAGCTGTGGAATGTCCCCTAGGATGTGCCACTGACACAAAGAGCCACACAGCTCC
AAAATAGAATATTATCTAACCCACTGCTCCCTTTGCTGTGTCAGCAACACCTCCACCATGCTTCTC
CCAGGACCCCCCTTGAACCTCTCTGCTTCTCCTGAGGCCAAAGGAAAGACAGGAAAGGGGCC
30 ACCTTCCTGTCTTGGGTCCCACAGAGATGTATCCTTGTAATGAAACCTACTTTATGCTTGAGT
TGTATCCAGTTAGTTTTCTGTGGCTTGCAATCAAGACCCACACCCACCTCAACCCAGGCTCTAGA
GAGTAGACCCTTGTTTTTGCCTGGCTTGGGTGACCTGGCACCTGCCAGGGTCCCAGCCTCTGA
GTCAGCCCACTTGGCCTCATCGGTGCCACCTCCAGGCGGCTGT
ACATAGACTCTGGCTTCTGCCCTGGCCTGGCCTCTGGGAACTGCAGCTGTCTGCTTCCATCCTA
35 TGTGGATGGTGCTGAAAGTGAATAGGGATCAGTTACCAGCCAGTATCTGTCCCCTTCTCAA

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

TAGCACTGATTCCTATGGGGAACTGCTTTTCTTGGACTATGTATGGGTTTGGTGGGAGGGTAG
TTCCTGTAACCAACCTACAGGGTGTAGGAACCTAGACTCTCAGCAACATAACAGGCAGC
AGGCTCCCAAGCTAAGTCTGGCCAGCTGGGCCACCTCTCCCAGATTCTGTTTCATGAGAGCAT
CATCCAAGAGCAGTGGGAACACTGGGGACGGTCCAGCCTAGGACTGGTATGCAGATCAGAGA
5 ATCCCAGATAGAAGGTGATTGCTGTTCTTCCAGTTTCTTGGCCCTCCAGAGCAACCATACTTCC
CATCTGCCCCAAAACCTGATCCTCCAAACTCCCACCATTCTGTGTCATCCCCAATATCTAA
TAGATCAACTGCCTTTCATTTACATTTGTCACAACCAAATGATACACCTGCCCITCACCCACTA
CTGAACTGCAGCTGGGTTAGTCCAAATTCAGGGCCCACGTGTCATTTCAAGCCTGTCTTGAAT
AATGTACACCTTCCTGCAATGTGAGGATGGCCACCACCTTGGTCTTATACCCACGGGTGTCTT
10 GAGCTACATTCTCATAATCAAAAATAAACTCAACACATCACTCCAGCCTGAGCAACAGA
GCAAGACACTAGCTCTAAAAATAAAAAATAAAAAACAAATGAAAAACCCAGCAAACTT
GGGGAAAGAGGAAGCACCTGATTTCCAGAGTTTCCACATCATGAGATGCAAATGTCCAGTTT
TCAACAACAACAACAACAACAAAAAAAAAATCACAAGGCATACAAAGAAATAGGAGACTAA
GACCCACTCAAAGGAAAAAGAATAAATAAGCAGAAGCCATACCAGAGGAAAAACCAGATGGCT
15 GACTTACTAGACAAATACTTTAAAACAACTGTCTTAAAGATGCTTGAAGAGCTAAAGGAAAA
TGTGAACAAAGTCAAGAAAGTGATGGAACAAATGGAAATTCCAATAAAGTGATAGAAAAC
TTTTGGAGTTTTTTTTCTTGGTAGCAAAAAATTATGAAGCTGAAGAATACAATAAATTCCCTA
GAGGGCTTCAAAGGCAGATGTAAGCAAACCTTGGCCAGGTGCAGTGGCTCATGCTCATAATCC
AGCACTTTGGAAGGCTGAGGCAGGAGGATTGCTTGAGCCCAGGAGTTTGAAACCAGCCTGGG
20 CAACATAGAAAAACCTATCTTTAAAAAACTTATATAAAATTTAAAAATTATAAAATTTAT
TTAAAAAATCAGCAATTTGAAGACTGGACAGGGAAATTATCAAATTTGAGGAACAGAAAGG
AAAAAGATGGAAGAAAAATAAACAGAGCCTAAGAGACCTGCGGGACACCATCAAGCAGACT
AATACCCATTGTGGAAATTCCAGAAAGAAAAAGAGAGTGAAGGACCAGAGAGATTATTAGGA
GAAATAATGGCTGAAAATGTCTCAAATTTGATGAATGACATGAATATGAACATTCAAAAATC
25 TCGACAAACTCCAAGTAGGAAAAACTCAAAGATACTCATACTGAGATTCAATCATAATCAAAC
TGCTGAAAGCCAAAGACAAGGAGACAATATCAAAAGCTGCAAGAGAGAAGTGACTCATCAC
ATACAAGGGATCTTCAAAAAGATTATCAGATATCTTGGCTGGGCACGGTGGCTCACACCTGTA
ATCTTAGCACTTTGGGAGGCGGAGGCAGGTGGATCACTTGAGGTCAGGAGTTTGAGACCAGC
CTGGCCAACATGGCAAAAACCCATCTCCATTAAAAATACAAAGATTGGTGAGGCATGGTGCT
30 GCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAAGCAGGAGAATCACTTGAACCTGGGAGG
CGGAGGGTGCACCAAGCCAAGATCGTGCCACCCTGCCTCCAGCCTGGGTGACAGAGTGTG
ACCTTGTTTCAAAAAAAAAAAGAAAAAGAAAAAGAAAAAAGATCATCAGCTATCTCATCA
GAAACCTCAGAGGCCAAAAGGCAGTAGATTGATATATTCAAAGTGCTAAAAAGAAAAAATA
AATCTGTCAGCTGAGAATCCTGTATCTGTATCTCACTTAACCATTATTTTAAAAATAAGGGAAA
35 ATGAAGACATTCCCAGATAAACACAAGCTGAGGGAGTTCATTATCACTAGATCTGCCCTGCAA
AGAAAGCCAAAGAAAGCCTTTCAGGATGAAATGAAAGGATACTAGACAGTGACTCAAAGCT

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

GAATAAAGAGGCCAGGCATAGTGGCTCACACCTGTAATCTCAGCACTTTGGGAGGCTGAGAT
GGGCGGATCACCTGAGGAGTTGGAGACCAGCCTGGCTAATATGGTGGAACCCCATCTCTACG
AAAAATACAAAAATTAGCCAGGTGTGGTGGCACATGCCTGTAATCCCAGCTACTTGGGAGGC
TGAGGCAAGAGAATCACCTGAACCCAGGAGGCGGAGGTTGCAGTGAGCCGAGATTGTGCCAC
5 CGCACTCCAGCCTGGGTGACAGAGTGATACCCTGTCTCAAAAAAAAAAAGCCGAATAAACGAA
TAAAGATCTCATCTATGGCCGTACCACCCTGAATGTGTCCAATCTCAGAAGCTAAGCAGAGTT
GGGCCTGGTTAGTACTTGGAGGGGAGAAATAACGGTCTATGCTAAAGGAAAATTCAGGTGCA
ATTAAAGTAAAATTAATTATATAAAAGAGAATACATTAAGCTAGTATTATTGTAACCTTG
GTTTGTAATTCCACCAAGTGGAATTTGTTCCCTGAAATGCTAGAATGGTTCAACATAAAAAATCA
10 ATAAATGTAATAGACCACATTAACAGAAAAAAAAACCCACACGGTCATCTCAATTGATGTCAA
AAAAGTATTTGACAAAAATTCAACACTCTTTTGAAAGAAGAAAAAGCTCAACAACTAAGAAT
AGGAGGAACTACCTCAAATAATAAAATCCATAGGCCAAATCCCCAACTCACAGCTAGCAA
CATATTTAATGCTAAAGACTGAAAGCTTCCCTTTAAGATCCGGAATAAGACAAAGATGCCCA
CTTTCACCACTTCTACTCAACATAGTATGGGAAGTTCTAGCCAGAGTAATCAGGTAAGAAAAA
15 AGAAATAAAAAGCATCTGAATTGGAAAGGAAAAAGTAAAATTATTTGTTTGCCCAATACATG
TACAATGTTTCAGGTGAAGGCTCAGAACAGTACAACCTTACCAGCAAGAGTCCTGCTGTCTCT
GTGTGAATCCCAGCTATTACTCACTAGCTACATGATCTCTCTTGCCCTCCCTGCCTCAATTTCTT
CATGTGTAAAGTGGGAGAAAAATAATAGTTTCATGCTTCAAAGGTTTTTTGTTTGTTTGCTTGC
TTTGAGACAGCGTCTGGCTCTGTGCTCAGGCTGAAGTGCAGTGGTGCAATCTTAGGTCACTG
20 CAACCTCAGCCTCCTGGGCTTAAGCGATCCTCCACCTCGGCCTCCCAAAGTGTTGGGATACAG
GCGTGAACCACTGTGTCTGACCCAAAGGATTATTTGAGGAGCAGATGAATTAATGTGTCATA
ACCTCAAAGCAGTTGCAAAGGCGTTTAATAATTAATAATATCACATTTAAATTAATAATATAA
GGCTGGGCGTGGTGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCTGAGGTGGGAGGATC
ACTTGAGCCCAGGAGTTCCACACTAGCCTGGGCACCATTTGGGAGACCCTGTCTCTACACACAC
25 ACGCACACACACACACACACACAACTTAAGTAGCCAGGCGTGGTGCTGCGCGCCTGTTG
TCCCAGCTACTCGGGAGGCTGAGGCGGGAGAATCACTGGAGCCTGGGAGTTGAGGCTGCAG
TGAGCCGAGATCGCACCACTGCACTCCAGCCTGGGCCACAGAGCAAGACGCTGCCTCAAACAA
ACAAACAAAAACAAAAATTAATAATTAAGTAATAATTAACGAGTGTTAATATCCACTCGTT
GTGGAGACAAGACCTGGACTTAGGAAACAGGCCAGGGAAAGTAGCAGAACAGTAGCGCTAG
30 AGGACGCCTGGGAGAATCAGCGCGCGGCGGGGAAGAGCCCGGGAAGCTTAGTGGGGAAGCGT
CTCTTGATGGGGTGAGGAATTCTATAAATTAGTGGAGATGGAAAAAAAAAAAAAAAAAGTAT
TCCCAAAGTGGGAGACAGCACTCAGAAAGACGTGGTGGTAAGAACGAGTATGAGTAACGGG
GACAACGAGGACACTGGAGATTGGGGAGTGTGGGCTGGAAGCTGGTGTGCAGCTGTGGGCA
AGCTAGGGAGGACCCCGAAACCGCCAATGCGTTTCCCGGACGCAGACGCTGGCAGGACGGGA
35 GGAACCCCGAGACCCCGCGCCATCCCTTCAGGAAGAGTTACTTCTCCCCGGCCAAGTTAGTGG
GCCTTGGGCCTTCTTTCTGTTGGGATCCTCCTCGCGTGTGCGCATCGCTACAAGTGGGCAGCTC

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

TGCGGGGAAAGCTGGGACGCTGGGGGCTTCACCAAGGAGGCTGGCGGGCCGACCACTGGGAGG
TCTGGCGGGGTGACGACCACTGGGAGGTTTGGGCAGGGCCTGACGGGGTGACGCGGTCAGCC
CACTGGAGGGCCGACACCCCCCGTCAGCCCAACCCCTGCACGCGCGGGCCGCAACCAAAGACCC
GCGGCGCCGGCCTGCGAGCCCCCGCCCCGCGTTGCCAGGAAACCGAGGGTGTGGCTCCGCGT
5 TCTCTGGGCGTCCCAGGGACTGGGCGCACAGTGGTGGCGGGGATGAGGCGCCTGGTGACGGA
CGGGGCGAGGAGGGCAGCGATTGGTGAGATTAGGCGATGGGCGGGGAAGCCGCGCGGGGAT
TAGCGAGTTGCGGCGATGGGCGGGGCAGGCGCGCGGGGATTGGCGGGATGCGGCGCGCCGCG
CGTTGAGTGGGGTCCAGGGAAACGGGGTCAGCTGGGGGTGGCAGTTCAGGCCGCGAGGCCG
GGCTCCTGGGTGCGTGGGCTGGTGTCTTGGCGGACGTCCCCGAGCTGCCGCGTGGATCCGAGC
10 CCGGGCACCCGCCGTGACTGGGACAGCCCCAGGGCGCTCTCGGGCCCCATCCCGAGTAGCGCG
GCCTGGCTGCTGCCGCCATCAAGCACGTTTCGAGCCAAAAGCTCCTAACGAGTCACTCGTTAGA
CACGTGTGCGGAGCCTGTGTCCCAGGCCAGTGTGTCCCGTGGAGATAGATTGCAAGCCGCTA
GGGAATTTTTTAACCTTCTAGTAGGTGTACGAAAAAAGTAAAACGAAACAAATCAATTGGAG
TAAATCCATAAATATATTCAAACCTATTATTTCAATTGTATGTGAAAAAATTATTGGGATATTC
15 TTTGTACTATTCTTAGAAATCCATTGTGTGTCCAACCCAAACATCACAGTTGGACTCACACAT
CTCCTGTACTTCGTAGCCCTAGGTGGCTAGTGGCATAAGACACAAAAATCTCAGCTCTCCTGG
AGCTTATGGTCTAGTTGGAGCAGGCAGACAATACATTTAAAATATACAGTTTGTAGAAAGGT
AAATGTTGTAAACAACAATAACAGTTGAAGTACTGGGGAGAGTTGCAGTTGTAAATCAGATG
GGCAGGGGCACAAGGTAACATTTGAGTAAAGATGTAAGAACTTGAAGGAGATGGGCAAGTGA
20 GCTCTATAAGTATACGGGAGAGGGGCAAGCAAGAGTTCAGAGGCCCCCTTGCTGTGGGGAGGG
ATCCAAGGTGGAGGAGTGGGAACCAGGAGGGGAGAGGACCAGTGGAGCAGATCTCATAGGC
AGTTGTAAGGACTTGGGGCCTTATTCAATGAAATGAGGACACTTTGGAGAGTTTTGAACAGA
GCAGTGACTGATTTATGTTTTGGTTTTGGTTTAGTTCTATTATTATTTAATAATAGGCTTATTA
TTTCACAGAAGTTTTATTTAATAAGGCAGACCTCTTGTCTGGAAATGAGACAGGTGCCGGAG
25 AGCTGGATGGAGGCAGATCGGGAATTCATTTGGGGCAAACCTGAACTTGATTGAGACCCTGG
TAGTTGTCCAGATGGAACAGGACACCTGAGTCTAGGGTTTCGGGAAGAACTCCAGATGGGACA
AACACTCCTAGCTTTCCTTTTCTTTTTGGATGACCGCTACAGGGTGAGACATCGGTATCCAG
GCACGATAAAATTTCCAAGTGGACACAATGTCTGGTGTCAACTACAGCTGTTCTCCTTCTTTCC
CAGTATCCTTTGGGTGCAGTGAGACACCAGGAGAGCTGCTGCTTTGGGGGATGGACAGGGGC
30 AGCAGGAATGCCTTTGTGTTTTTCGCAGTGAACCTCCTTGGCCTGGGCGAAGCTGTGTGGACCA
AGCAAGTCAGGAGTGTGGCCATGTTTTCTGAGCAGGCTGCCCAGAGGGGCCACACTCTACTGT
CCCCACCATCAGCCAACAATGCCACCTTTGCCCGGGTGCCAGTGGCAACCTACACCAACTCCTC
ACAACCCCTTCGGGCTAGGAGAGCGCAGCTTTAGCCGGCAGTATGCCACATTTATGCCACCCG
CCTCATCCAAATGAGACCCCTTCCTGGAGAACCAGGGCCCAGCAGCACTGGGGTAAGTGAGAGTT
35 TGGGAAGGTGCTTCCCCCACAGCATCCCTGAACTTAGAAGTGTTCTGCAAGAGAATGGGAAC
AGTTTATCTAATTGATCCCACTTCCTGTTACCTTGGGAAAATTAACCTCTTTTTCCCTCAGTTT

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

CTTCCTTAAGATAGTAACAAGGATTAAATTAAGTAATTTGTGGGTTTGGAGTTAGTTTTAGTTT
 AGAGGCTGGTTGGAGATGAGGACTTAGTTCTGGCGGTGATGGCGATTACTTCACTGGCAGAG
 GAAAATGGTTTTCTATCTTCAGTGCAGATTATTCAGGTATTTGCCTGTGCTGTAGCCAGAGA
 GCCCCTCAGTGTGGCAAGCCTGGCGCCAGGCACCAGGAGCCAAGACTGGTGAGGATGCACTCT
 5 CTGGTCTCGAGGGGACCCCCCTCTGTTCACTCATGTCTGTTTGCCTCTCCTCCTGGCCCCCATATT
 TGCTGGCCATGAATTTTCTGTCCCTTGGGCCCTCTGTCTTTTCTTAATAAAGTGGCCTGCCCAA
 CACAACCCCTTGTTCTTTGGCCCCCATTTCTTCCCTGGTGATCTCTCCTGCAGTTGGATTACTCTTG
 GTGGTGAAGCAGGGACCCCCATCTCCCCCTTTGAGTTTATTTGAGTTTATAGGTGCTGCTGCATT
 CCCCCATTCTACCACCTTACATAAGAGTGGCTTTCCAGGTAATTTTCAAATCCATCTCCTATT
 10 TATTTTTAAACTGAGGATTTAGTAGGTGAGACCAGGTCTTACTCATTTTTACTGTCCTTGGCA
 CCAGGCCAAAATGGATCTCAGCCCTAGTTGCACATTGGAATCCCCTGGGGAGCTTTGAGAAGCC
 CATCTCATCCCATGCCAAGCCAAGATCAATTCTCGTTATAGGCAGGCGGAGAACCCCTGGGCCT
 AGAAATCTAGCTAGAACCTCAAATTCATTAGGGATATGTATTAGTCCATTTTACATTGCTAT
 AAAAACTACCTGAGATAGGGTAATTTATAAAGAAAAGAGGTTTAATTGACTCACAGTTCTCT
 15 CATGGCTGGGGAGGCCTCAGGAACTTAAACAATCATGGCAGAAGGTGAAGGGAAAGCAAGG
 CTCTTTTACATGATAGCAGGAGAGAGAGAGCAAGGGGAACTGCCAACCATTTTTAAACCATC
 AGATCGCATGATGGCTTGATCTCACTCACCATCACAAGAACAGCATGGGGGAAATCCACCCCC
 ACAATCCAGTCACCTCCACACAGGTCCCTCCGTCAACACCGTGTGGATTATAATTCCAGATGA
 GATGTGGGTGGGGACACAGAGCCAAATCATATCAGGATGTTTTCTGTTTTGTTTACCTGAGAC
 20 AAAGTGCTGTTCACCTCTCCTCTCCACATAATCAGGGGGCTCCCTCCTGCGGCTCCGGTAGCTT
 TTCTCACTTTCTTTTACAGCCCTCGGGACACCTTCCTTGGCTCCTTTTACAGAGCTCAGTTACTACT
 TGGGCCCCAATGTCAATGCCACCTTCTAGATTCCTTTCCGGCAGCACCTCCTCTGGTCCGACATTT
 CTCTTCCAGTTATTGGAGCTGTCAAAAAAGCTCCCCAGTGATGGACGATAGCGATTTCACTGT
 GCTCACAGACTGGTCAGGAAACCAAACAGCTGCCACAGTGAATGTGTTGATAGCAGCGGGGC
 25 AGCAGTAGCACTCGCTCACAGGCCTGGTGGTTGGTGTGCTGGCCCCCACCCTGAATACCTACATG
 TGGCTTCTCCATGTGGCCTGTGCATCCTCACTGAAGCTCAGCCTGTCTCTCCAAATTGGTCTTT
 CCACTCACCTGTTCCCCAAACCTGCCACAGACCTTCCTGCTGTAGGCTTTTCCCTTCACTTGGCAC
 ACTCTTTCCCTTGTCTTCCCATGGCCCCATCTAAGCCCCACTGTCAGCTGAAGTGTTATATTCTT
 TGAGGGGGCCACCTGAAGCCACCTTGCAATGAGGGCCCTCCGTTTTCTACCTCAGCTCACCATTG
 30 TTCACAGCACTTGTCACTGTGGCGAGTTACTTGTCTATGGCCTGTTGTGCTTCTCCTGCCTAGA
 CCCAGTGGGCTGAGTGGGGGCAAGTGTGGCTTTTATGTCCAGTTTGTATCTTGGTGCCAGCA
 CATTGCCTGGGTGGAAGCATGTCTTACTATCGGTTACAGGGATGTCATTCTGCCCAGTGCTCA
 GGGGCATACACTTGGATCCCAGTTGTGTGCCCTTGGACACATTGCTTAACCTCTCTGTGCATCA
 GTTGGGTGATAATATCTACTCCTGGCACATTTTCAGCGTTGGCTGAGTTACATTACAGTGCTT
 35 AGGCCACCTGGGGGAGAGTAAGAGTGGGATACGTGAGGATGTGGAGTCTGTTGCATTTCTGT
 CTGCTGCTGGCATCCTTCTTGTCTTGTGTTTTGAGTTGCTCGCCTCTGTCTGCTCCCTAGGGCGTA

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

GATTTGAGGAATATTCTCTGGTTCTTCCCAGGCAGCAGGGGGCTCAGGCTGTGCTGGAGTCAGCT
AGGCTAAGGGGGCTGGTCTGGCATCCGCGTTGTCCTGTCACCTCCTTGGTGTCTTCTCCAGGCCT
GGATCTGTGCTGTGTGGGCACCTGTATTCCCTCCCTCCTGCCCTCACTGATTCTCCATACCTTTCT
TCTCGAGAGTGCCAAGCCCCCTCCCATGTGTCTTGTTCATACCTAGGATCCCGGGAAGGGGGCT
5 GGGGAAGACGGTGCCCAAGGTGCCCTGGGTAAACAAAGCCACCTGACTCCACGGGAATGGAAT
GGGTGGAGGGGATCTGAGGTCTGCATTTTGAGTATCTCTGGTCTCAGAGGATGAAGCATTG
GTGGGGGTGGGGGGTGGGGGGTAGGGTGGAAGAATCTAAAGTCTTAAAAGAAAATGGCAGT
TATTTGTGGGACAGGGCTGTGTTGAGACTTGGCATGCTTCTTTTTAAGAGTCAGTGTGTGAAT
TTAGGTATAAGTGAAGCAGTACTTTGTATTAGTTTCCTGTAGGCGCTGTAACAAAGCACCCACA
10 AACTGGTTGACTTAAAACAACAGACATGGCCGGGCACGGTGGCTCAGACTGTAATCCCAGC
ACTTTGGGAGGCCGAGGCGGGCAGATCACAAGGTCAAGAGATTGAGACCATCCTGGCTAACA
CGGTGAAACCCTGTCTCTACTAAAAATACAAAAAAAAAAAAAAAAATTAGCTGGGCGTGGTGGCAC
ACGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCG
GAGCTTGCAGTGAGCTGAGATCGCGCCACTGCACTCCAGCCTGGATGACAGCGAGACTCCGCC
15 TCAAAACAAAAACAAAAACAGAAACAACAATAACAGAAAAACACAGACATTTACTCTCTGGC
AGTTCTGGAGGCCAGAAGTTGAAATCCAGATGTCAGCAGGATTGGCTCCTTCTGAAGGCCCG
AGGGGAGGGTCCCTCCTGGCCTCCTCCCTGGTGTTCCTGGGCTTGTGGCCGCATCACTCCGCTC
TGCCCGTCTTCACACTCCCTCTTGTCTGTGTGTCTGTCTCTCTGTTCTCATGAGGACACTTGGCA
TCCAGGGCCCAACCACACCCAGAGTCCCTGGTCTCCTGTGGCTGACTCACTTTTTACTGTCAAC
20 GTGAAGTCCAGGGGGTCCCTTGTA CTTGATGTTCTCTCCTGGCAAGGCCAGGGCCCTGTGATTG
GCCTCTCATGGAGTGCTGGGCAGGGCCTCCATGGCCTCTGTGCGGGCGGGGGGGCTACTTCATC
TCTGAGTCTGTACCCCTCGTGTCCCAGGCAGTGGAGTGGGAGTGAAGAAGCTGTGTGAACTGC
AGCCTGAGGAGAAGTGCTGTGTGGTGGGCACTCTGTTCAAGGCCATGCCGCTGCAGCCCTCCA
TCCCTGCGGGAGGTCAGCGAGGAGGTGAGGCAGGGTGCTACACAGTGGGGCCGCCAGGCAGAC
25 CTGGCCTCCCCTAGAACACCTCCCTGGAGGTGGGGTGTGGGGGAAGCAGGTTTCAGAGACAA
TGGACTCCAGAGGGGTGGGGGCTGCGGTGCCAGCTCACTAACACCAGAGCTTTGGTGGGCTCT
GGCCCCAAGATTATACCTCCTGTCTCTGCATTCCAGCACAACTGCTCCCCCAGCCTCCTCGGA
GTAAATACATACACCCAGATGACGAGCTGGTCTTGGAAGATGAACTGCAGCGTATCAAACTA
AAAGGCACCATTGACGTGTCAAAGCTGGTTACGGGTAGGGAGCCCAATGAGAGGATGTGGGT
30 GATGCAGGTGAAGAGCCCAGCGGTGGTGTGTTAGGGATGGTGTGAGTGGGGAGCCTGGGGG
GAGTGGGGGGGTGTGGCCTGGGCACACGTGTGTTCTTGAGGAGGTAGGTGAGGCTCCAGGCG
GTCGGAGGCCATCAGATTGGGTGAGACCTGGCTGGGAGATGGGTCTCCCCACCTCCATCCAAG
GGCAGTGACTCCAGGAAGCAGGCATGCATCCTGGAGTCTAGGTGAGAATTCACCAATGTGG
TTGTGGAGAACTGGCTTGTTTTGCCCGTTGGGGTGA CTGGAAGGAGTGGTAGCACCTGGGGC
35 TCCCTGCTCAGGCCTGATGCCACTGCTCCCCAGGGACTGTCTGGCTGTGTTTGGCTCCGTGAG
AGACGACGGGAAGTTTCTGGTGGAGGACTATTGCTTTGCTGACCTTGCTCCCCAGAAGCCCGC

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

ACCCCCACTTGACACAGATAGGTGAGCAGCAGTTCTCGGGAGCTGGAACCAGCTCATGGTCAG
TGGAATCTTTGAGTTGCACCTAGGAGGGGCTGCCTCCCTTCTCGGCACCCTGGAGGACCCAC
CTTCTCCCGCAGGTTTGTGCTACTGGTGTCCGGCCTGGGCCTGGGTGGCGGTGGAGGCGAGAG
CCTGCTGGGCACCCAGCTGCTGGTGGATGTGGTGACGGGGCAGCTTGGGGACGAAGGGGAGC
5 AGTGCAGCGCCGCCACGTCTCCCGGGTTATCCTCGCTGGCAACCTCCTCAGCCACAGCACCCA
GAGCAGGGATTCTATCAATAAGGTATGGAGCCCACCTGGCTGCATTACGCCCCAGCCCAGGAG
CCTGCAAGCCTGTAAGACCCTCCTTCCCCAGGGCGAGTAGGGTACCCTGTGAGGTCTCGCAGG
TCGGTGGGAAGCGCCCTGCAGTGA CTCTGGGGCCTCCTGCAATGGGGCTCCTCATGCCCAGGC
CCTCGCTGAGGATGGTGGGAGGCTTGAAGGGAGTGAGGGTCTATGGGACAACA ACTGCATCT
10 TCCAGCTGGTGGGGCTCTACTCTCCTCTGAGCCTGGGACTCGCCTGGGCCTGATGGCCTTCTGG
GCTTCTATTCCAGGCCAAATACCTCACCAAGAAAACCCAGGCAGCCAGCGTGGAGGCTGTAA
GATGCTGGATGAGATCCTCCTGCAGCTGAGCGTGAGCGAGCTGGGGGCTGGAGGGGTGATGG
GGATTGCAGTCTTCAAAGCTGCCACTGGGCAACAGAAGGCAGGCAGGAGGGCAGGGGGAGT
GGCCGGAGTTGGTGTAGGGGGCTCCTTCGGGGCCCTGTGAGCTCTCCCTGCCCTGTGCCTTCCA
15 GGCCTCAGTGCCCGTGGACGTGATGCCAGGCGAGTTTGATCCCACCAATTACACGCTCCCCCA
GCAGCCCCTCCACCCCTGCATGTTCCCGCTGGCCACTGCCTACTCCACGCTCCAGCTGGTCACC
AACCCTTACCAGGCCACCATTGATGGAGTCAGGTAGCTGGCACAGCCACACTTCAGTCTGACC
CAGCCTTTTGCCTCAGGAGGCACAAAGAAGGGAGGGGAGGGAGGGGCCAGGAAGGTGGCAG
GGCTGCAGAGGCCACCTAGCATCTGTTCTCTCTCTGGGGCATCCCCACAAGAGCGCCAGA
20 TGAGCTCTGGGCTGACCACTATGGGTGGCACCCAAAGCCAAGAGTCAGCTGAGCTTTGCCTTG
CAGATTTTGGGGACATCAGGACAGAACGTGAGTGACATTTTCCGATACAGCAGCATGGAGG
ATCACTTGGAGATCCTGGAGTGGACCCTGCGGGTCCGTCACATCAGCCCCACAGCCCCGGACA
CTCTAGGTAACAGGCTCAGCCATACAGGGTGGGAGCAGAGGGCCAGGAGGCCTGGCAGGACC
CTGAAGTGCACAGGGTCCCCCTGTGGGTTTGC ACTTGCCAGCATTGCTGAGAACTGTCTGAGG
25 AGAAGTTCAGAGGCTTGGCACCTGCTCTGGAAGCTACTCTGGAATCTTAATTCTAAGGCCAAT
GGCTGCCCAACCCCAACGGGCAGCAACAGCAGGGCCAAGGTCTTGTGACAATGTCTGGAGGTG
CCCCTATTGTCACACTGGGGGTCTCCTACTGGCCTGCAATGGGAGGAGGGGCTGCAGCCCCAC
ATCCTGTGCAGAGTGCTAGTGCTGAGGCGGAACCCCTCCTCAGAGCTGCCCCTTCTCCTTAGGT
TGTACCCCTTCTACAAA ACTGACCCGTTTCATCTTCCCAGAGTGCCCGCATGTCTACTTTTGTG
30 GCAACACCCCCAGCTTTGGCTCCAAAATCATCCGAGGTAATTTTGTCTTCTGGGGGCCCAGG
CTGATTTGCTGATTTGCTCTCACCTGGGGACAAGGTTTACAGAGAAGAAAACCTGCATTGTGG
AGTCCCCCTGGCCCTTGTGGGATGGACAGCTGAGGTCTTCTGCACAGCTGCCATTTCACTGTG
GGAGCCAAGCTGCCTCGCCAGCTGGGCAGGGACTGGAACGGCTCCCAGCCTGTGTGCCTCTCA
AGGCTAATCTCTGGTCTCCTATTGTC ACTGCCCCACTGTGTGCCAATGGGGACTCCTGTTTATT
35 TCTGGCAGCTTCTCTTTGAGGCAGGACTTACTTGGAACCTACAGTGGGTCTATGTGACTTCTT
TGCAGGTCTGAGGACCAGACAGTGCTGTTGGTGACTGTCCCTGACTTCAGTGCCACGCAGAC

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

CGCCTGCCTTGTGAACCTGCGCAGCCTGGCCTGCCAGCCCATCAGCTTCTCGGGGCTTCGGGGGCA
GAGGACGATGACCTGGGAGGCCTGGGGCTGGGGCCCTGACTCAAAAAAGTGGTTTTTGACCAG
AGAGGCCCAGATGGAGGCTGTTCATTCCCTGCAGTGTCCGGCATTGTAAATAAAGCCTGGCACT
TGCTGATGCGAGCCTTGAGCCCTGGGCACCTCTGGCTATGGGACTCCTGCAGGGGTGCCACAG
5 TGACCATAGCCCATGCACCCACCAGCCGGTCTCCCT

The POLD2 gene is 19,000 base pairs in length and contains ten exons (see Table 14 below for location of exons). As will be discussed in further detail below, the POLD2 gene is situated in genomic clone AC006454 at nucleotides 119,001-138,000.

10 The polynucleotides of the invention have at least a 95% identity and may have a 96%, 97%, 98% or 99% identity to the polynucleotides depicted in SEQ ID NOS:5, 6, 7 or 8 as well as the polynucleotides in reverse sense orientation, or the polynucleotide sequences encoding the SNARE YKT6, ~~AEBP1~~, human glucokinase, AEBP1, or POLD2 polypeptides depicted in SEQ ID NOS:1, 2, 3, or 4 respectively.

15 A polynucleotide having 95% "identity" to a reference nucleotide sequence of the present invention, is identical to the reference sequence except that the polynucleotide sequence may include on average up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference
20 sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence, the ORF (open reading frame), or any fragment specified as described herein.

25

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence are calculated for the purposes of manually adjusting the percent identity score.

For example, a 95 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 5% of the sequence (number of bases at the 5' and 3' ends not matched/total numbers of bases in the query sequence) so 5% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 95 bases were perfectly matched the final percent identity would be 95%. In another example, a 95 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

not matched/aligned with the query sequence are manually corrected for. No other manual corrections are made for purposes of the present invention.

A polypeptide that has an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence is identical to the query sequence except that the subject polypeptide sequence may include on average, up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the referenced sequence or in one or more contiguous groups within the reference sequence.

A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Com. App. Biosci. (1990) 6:237-245). In a sequence alignment, the query and subject sequence are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C- terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C- terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

The invention also encompasses polynucleotides that hybridize to the polynucleotides depicted in SEQ ID NOS: 5, 6, 7 or 8. A polynucleotide "hybridizes" to another polynucleotide, when a single-stranded form of the polynucleotide can anneal to the other polynucleotide under the appropriate conditions of temperature and solution ionic strength (see Sambrook et al., *supra*). The conditions of temperature and ionic strength determine the "stringency" of the hybridization. For preliminary screening for homologous nucleic acids, low stringency hybridization conditions, corresponding to a temperature of 42°C, can be used, e.g., 5X SSC, 0.1% SDS, 0.25% milk, and no formamide; or 40% formamide, 5X SSC, 0.5% SDS). Moderate stringency hybridization conditions correspond to a higher temperature of 55°C, e.g., 40% formamide, with 5X or 6X SCC. High stringency hybridization conditions correspond to the highest temperature of 65°C, e.g., 50 % formamide, 5X or 6X SCC. Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of T_m for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher T_m) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA.

Polynucleotide and polypeptide variants

The invention is directed to both polynucleotide and polypeptide variants. A "variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar and in many regions, identical to the polynucleotide or polypeptide of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred.

The invention also encompasses allelic variants of said polynucleotides. An allelic variant denotes any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences. An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.

The amino acid sequences of the variant polypeptides may differ from the amino acid sequences depicted in SEQ ID NOS:1, 2, 3 or 4 by an insertion or deletion of one or more amino acid residues and/or the substitution of one or more amino acid residues by different amino acid residues. Preferably, amino acid changes are of a minor nature, that is conservative amino acid substitutions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to about 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.

Examples of conservative substitutions are within the group of basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine, isoleucine and valine), aromatic amino acids (phenylalanine, tryptophan and tyrosine), and small amino acids (glycine, alanine, serine, threonine and methionine). Amino acid substitutions which do not generally alter the specific activity are known in the art and are described, for example, by H. Neurath and R.L. Hill, 1979, *In, The Proteins*, Academic Press, New York. The most commonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, as well as these in reverse.

Noncoding Regions

The invention is further directed to polynucleotide fragments containing or hybridizing to noncoding regions of the SNARE YKT6, AEBP1, human glucokinase and POLD2 genes. These include but are not limited to an intron, a 5' non-coding region, a 3' non-coding region and splice junctions (see Tables 1-4), as well as transcription factor binding sites (see Table 5). The polynucleotide fragments may be a short polynucleotide fragment which is between about 8 nucleotides to about 40 nucleotides in length. Such shorter fragments may be useful for diagnostic purposes. Such short polynucleotide fragments are also preferred with respect to polynucleotides containing or hybridizing to polynucleotides containing splice junctions. Alternatively larger fragments, e.g., of about 50, 150, 500, 600 or about 2000 nucleotides in length may be used.

Table 1: Exon/Intron Regions of Polymerase, DNA directed, 50kD regulatory subunit (POLD2) Genomic DNA

EXONS LOCATION (nucleotide no.)

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

	(Amino acid no.)	
1.	11546 ----- 11764	
	1	73
2.	15534 ----- 15656	
	74	114
3.	15857 ----- 15979	
	115	155
4.	16351 ----- 16464	
	156	193
5.	16582 ----- 16782	
	194	260
6.	17089 ----- 17169	
	261	287
7.	17327 ----- 17484	
	288	339
8.	17704 ----- 17829	
	340	381
9.	18199 ----- 18303	
	382	416
10.	18653 ----- 18811	
	417	469

'tga' at 18812 – 14

Poly A at 18885 – 90

Table 2: AEBP1 (adipocyte enhancer binding protein 1), vascular smooth muscle-type. Reverse strand coding.

EXONS	LOCATION (<u>nucleotide no.</u>)
	(Amino acid no.)

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

21.	1301 ----- 1966 1158 937
20.	2209 ----- 2304 936 905
19.	2426 ----- 2569 904 857
18.	2651 ----- 3001 856 740
17.	3238 ----- 3417 739 680
16.	3509 ----- 3706 679 614
15.	3930 ----- 4052 613 573
14.	4320 ----- 4406 572 544
13.	4503 ----- 4646 543 496
12.	4750 ----- 4833 495 468
11.	5212 ----- 5352 467 421
10.	5435 ----- 5545 420 384

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

9.	6219 ----- 6272	
	383	366
8.	6376 ----- 6453	
	365	340
7.	6584 ----- 6661	
	339	314
6.	7476 ----- 7553	
	313	288
5.	7629 ----- 7753	
	287	247
4.	7860 ----- 7931	
	246	223
3.	8050 ----- 8121	
	222	199
2.	8673 ----- 9014	
	198	85
1.	10642 ----- 10893	
	84	1

Stop codon 1298 – 1300

Poly A-site 1013 – 18

Table 3: Glucokinase

EXONS	LOCATION (<u>nucleotide no.</u>)	
		(Amino acid no.)
1.	20485 ----- 20523	
	1	13

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

2.	25133 ----- 25297	
	14	68
3.	26173 ----- 26328	
	69	120
4.	27524 ----- 27643	
	121	160
5.	28535 ----- 28630	
	161	192
6.	28740 ----- 28838	
	193	225
7.	30765 ----- 30950	
	226	287
8.	31982 ----- 32134	
	288	338
9.	32867 ----- 33097	
	339	415
10.	33314 ----- 33460	
	416	464
Stop codon 33461-3		

Table 4: SNARE YKT6. Reverse strand coding.

EXONS	LOCATION (<u>nucleotide no.</u>)	(Amino acid no.)
7.	4320 ----- 4352	
	198	188

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

6. 5475 ----- 5576
187 154

5. 8401 ----- 8466
153 132

4. 9107 ----- 9211
131 97

3. 10114 ----- 10215
96 63

2. 11950 ----- 12033
62 35

1. 15362 ----- 15463
34 1

Stop codon at 4817 – 19

Poly A-site: 4245 – 4250

TABLE 5: TRANSCRIPTION FACTOR BINDING SITES

BINDING SITES	SNARE_YKT6_GLUCOKINASE	POLD2	AEBP1
AP1FJ-Q2	11		11
AP1-C	15	7	6
AP1-Q2	9		5

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

AP1-Q4	7			4
AP4-Q5	36		5	43
AP4-Q6	17			23
ARNT-01	7			5
CEBP-01	7			
CETS1P54-01	6			
CREL-01	7			
DELTAEF1-01	64	12	5	50
FREAC7-01		4		
GATA1-02	19			
GATA1-03	12			6
GATA1-04	25	6		
GATA1-06	8	5		
GATA2-02	10			
GATA3-02	5			
GATA-C	11	6		
GC-01				4
GFII-01	6			
HFH2-01	5			
HFH3-01	10			
HFH8-01	4			
IK2-01	49			29
LMO2COM-01	41	6		27
LMO2COM-02	31	5		7
LYF1-01	10	13	6	
MAX-01	4			
MYOD-01	7			
MYOD-Q6	32	19	7	12

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

MZF1-01	99	40	15	94
NF1-Q6	5			7
NFAT-Q6	43	8	7	8
NFKAPPAB50-01		4		
NKX25-01	13	14	5	
NMYC-01	12			8
S8-01		30	4	
SOX5-01	21	20	4	4
SP1-Q6				8
SAEBP1-01	4			
SRV-02	5			
STAT-01	6			
TATA-01	8			
TCF11-01	47	28	5	19
USF-01	12	8	6	8
USF-C	16	12	12	8
USF-Q6	6			

In a specific embodiment, such noncoding sequences are expression control sequences. These include but are not limited to DNA regulatory sequences, such as promoters, enhancers, repressors, terminators, and the like, that provide for the regulation of expression of a coding sequence in a host cell. In eukaryotic cells, polyadenylation signals are also control sequences.

In a more specific embodiment of the invention, the expression control sequences may be operatively linked to a polynucleotide encoding a heterologous polypeptide. Such expression control sequences may be about 50-200 nucleotides in length and specifically about 50, 100, 200, 500, 600, 1000 or 2000 nucleotides in length. A transcriptional control sequence is "operatively linked" to a polynucleotide encoding a heterologous polypeptide sequence when the expression control sequence controls and regulates the transcription and translation of that polynucleotide sequence. The term "operatively linked" includes having an appropriate start signal (e.g., ATG) in front of the polynucleotide sequence to be expressed and maintaining the correct reading frame to permit expression of the DNA sequence under the control of the expression control sequence and production

of the desired product encoded by the polynucleotide sequence. If a gene that one desires to insert into a recombinant DNA molecule does not contain an appropriate start signal, such a start signal can be inserted upstream (5') of and in reading frame with the gene.

Expression of Polypeptides

Isolated Polynucleotide Sequences

The human chromosome 7 genomic clone of accession number AC006454 has been discovered to contain the SNARE YKT6 gene, the human-liver glucokinase gene, the AEBP1 gene, and the POLD2 gene by Genscan analysis (Burge et al., 1997, J. Mol. Biol. 268:78-94), BLAST2 and TBLASTN analysis (Altschul et al., 1997, Nucl. Acids Res. 25:3389-3402), in which the sequence of AC006454 was compared to the SNARE YKT6 cDNA sequence, accession number NM_006555 (McNew et al., 1997, J. Biol. Chem. 272:17776-177783), the human-liver-glucokinase cDNA sequence (Tanizawa et al., 1992, Mol. Endocrinol. 6:1070-1081), accession number NM_000162 (major form) and M69051 (minor form), , AEBP1 cDNA sequence, accession number NM_001129 (accession number D86479 for the osteoblast type) (Layne et al., 1998, J. Biol. Chem. 273:15654-15660) and the POLD2 cDNA sequence, accession number NM_006230 (Zhang et al., 1995, Genomics 29:179-186).

The cloning of the nucleic acid sequences of the present invention from such genomic DNA can be effected, *e.g.*, by using the well known polymerase chain reaction (PCR) or antibody screening of expression libraries to detect cloned DNA fragments with shared structural features. See, *e.g.*, Innis *et al.*, 1990, *PCR: A Guide to Methods and Application*, Academic Press, New York. Other nucleic acid amplification procedures such as ligase chain reaction (LCR), ligated activated transcription (LAT) and nucleic acid sequence-based amplification (NASBA) or long chain PCR may be used. In a specific embodiment, 5' or 3' non-coding portions of each gene may be identified by methods including but are not limited to, filter probing, clone enrichment using specific probes and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., 1993, Nucl. Acids Res. 21:1683-1684).

Once the DNA fragments are generated, identification of the specific DNA fragment containing the desired SNARE YKT6 gene, the human-liver glucokinase gene, the AEBP1 gene, or POLD2 gene may be accomplished in a number of ways. For example, if an amount of a portion of a SNARE YKT6 gene, the human-liver glucokinase-gene, the POLD2 gene or AEBP1 gene, or POLD2 gene or its specific RNA, or a fragment thereof, is available and can be purified and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton and Davis, 1977, Science 196:180; Grunstein and Hogness, 1975, Proc. Natl. Acad. Sci. U.S.A. 72:3961). The present invention provides such nucleic acid probes, which can be conveniently prepared from the specific sequences disclosed herein, *e.g.*, a hybridizable probe having a nucleotide sequence corresponding to at least a 10, and preferably a 15, nucleotide fragment of the sequences depicted in SEQ ID NOS:5, 6, 7 or 8. Preferably, a fragment is selected that is highly unique to the

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

encoded polypeptides. Those DNA fragments with substantial homology to the probe will hybridize. As noted above, the greater the degree of homology, the more stringent hybridization conditions can be used. In one embodiment, low stringency hybridization conditions are used to identify a homologous SNARE YKT6, the human ~~liver~~-glucokinase, the AEBP1, or POLD2 polynucleotide. However, in a preferred aspect, and as demonstrated experimentally herein, a nucleic acid encoding a polypeptide of the invention will hybridize to a nucleic acid derived from the polynucleotide sequence depicted in SEQ ID NOS:5, 6, 7 or 8 or a hybridizable fragment thereof, under moderately stringent conditions; more preferably, it will hybridize under high stringency conditions.

Alternatively, the presence of the gene may be detected by assays based on the physical, chemical, or immunological properties of its expressed product. For example, cDNA clones, or DNA clones which hybrid-select the proper mRNAs, can be selected which produce a protein that, e.g., has similar or identical electrophoretic migration, isoelectric focusing behavior, proteolytic digestion maps, or antigenic properties as known for the SNARE YKT6, the human ~~liver~~-glucokinase, the AEBP1, or POLD2 polynucleotide.

A gene encoding SNARE YKT6, the human ~~liver~~-glucokinase, the AEBP1, or POLD2 polypeptide can also be identified by mRNA selection, i.e., by nucleic acid hybridization followed by *in vitro* translation. In this procedure, fragments are used to isolate complementary mRNAs by hybridization. Immunoprecipitation analysis or functional assays of the *in vitro* translation products of the products of the isolated mRNAs identifies the mRNA and, therefore, the complementary DNA fragments, that contain the desired sequences.

Nucleic Acid Constructs

The present invention also relates to nucleic acid constructs comprising a polynucleotide sequence containing the exon/intron segments of the SNARE YKT6 gene (nucleotides 4320-15463 of SEQ ID NO:5), human ~~liver~~-glucokinase gene (nucleotides 20485-33460 of SEQ ID NO:6), AEBP1 gene (nucleotides 1301-13893 of SEQ ID NO:8) or POLD2 gene (nucleotides 11546-18811 of SEQ ID NO:7) operably linked to one or more control sequences which direct the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences. Expression will be understood to include any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

The invention is further directed to a nucleic acid construct comprising expression control sequences derived from SEQ ID NOS: 5, 6, 7 or 8 and a heterologous polynucleotide sequence.

"Nucleic acid construct" is defined herein as a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or which has been modified to contain segments of nucleic acid which are combined and juxtaposed in a manner which would not otherwise

exist in nature. The term nucleic acid construct is synonymous with the term expression cassette when the nucleic acid construct contains all the control sequences required for expression of a coding sequence of the present invention. The term "coding sequence" is defined herein as a portion of a nucleic acid sequence which directly specifies the amino acid sequence of its protein product. The boundaries of the coding sequence are generally determined by a ribosome binding site (prokaryotes) or by the ATG start codon (eukaryotes) located just upstream of the open reading frame at the 5' end of the mRNA and a transcription terminator sequence located just downstream of the open reading frame at the 3' end of the mRNA. A coding sequence can include, but is not limited to, DNA, cDNA, and recombinant nucleic acid sequences.

The isolated polynucleotide of the present invention may be manipulated in a variety of ways to provide for expression of the polypeptide. Manipulation of the nucleic acid sequence prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying nucleic acid sequences utilizing recombinant DNA methods are well known in the art.

The control sequence may be an appropriate promoter sequence, a nucleic acid sequence which is recognized by a host cell for expression of the nucleic acid sequence. The promoter sequence contains transcriptional control sequences which regulate the expression of the polynucleotide. The promoter may be any nucleic acid sequence which shows transcriptional activity in the host cell of choice including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.

Examples of suitable promoters for directing the transcription of the nucleic acid constructs of the present invention, especially in a bacterial host cell, are the promoters obtained from the *E. coli lac* operon, the prokaryotic beta-lactamase gene (Villa-Komaroff *et al.*, 1978, *Proc. Natl. Acad. Sci. USA* 75: 3727-3731), as well as the *tac* promoter (DeBoer *et al.*, 1983, *Proc. Natl. Acad. of Sciences USA* 80: 21-25). Further promoters are described in "Useful proteins from recombinant bacteria" in *Scientific American*, 1980, 242: 74-94; and in Sambrook *et al.*, 1989, *supra*.

Examples of suitable promoters for directing the transcription of the nucleic acid constructs of the present invention in a filamentous fungal host cell are promoters obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *Aspergillus niger* neutral alpha-amylase, *Aspergillus niger* acid stable alpha-amylase, *Aspergillus niger* or *Aspergillus awamori* glucoamylase (*glaA*), *Rhizomucor miehei* lipase, *Aspergillus oryzae* alkaline protease, *Aspergillus oryzae* triose phosphate isomerase, *Aspergillus nidulans* acetamidase, *Fusarium oxysporum* trypsin-like protease (WO 96/00787), NA2-tpi (a hybrid of the promoters from the genes encoding *Aspergillus niger* neutral alpha-amylase and *Aspergillus oryzae* triose phosphate isomerase), and mutant, truncated, and hybrid promoters thereof.

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

In a yeast host, useful promoters are obtained from the *Saccharomyces cerevisiae* enolase (ENO-1) gene, the *Saccharomyces cerevisiae* galactokinase gene (GAL1), the *Saccharomyces cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase genes (ADH2/GAP), and the *Saccharomyces cerevisiae* 3-phosphoglycerate kinase gene. Other useful promoters for yeast host cells are described by Romanos *et al.*, 1992, *Yeast* 8: 423-488.

Eukaryotic promoters may be obtained from the genomes of viruses such as polyoma virus, fowlpox virus, adenovirus, bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and SV40. Alternatively, heterologous mammalian promoters, such as the actin promoter or immunoglobulin promoter may be used.

The constructs of the invention may also include enhancers. Enhancers are cis-acting elements of DNA, usually from about 10 to about 300 bp that act on a promoter to increase its transcription. Enhancers from globin, elastase, albumin, alpha-fetoprotein, and insulin enhancers may be used. However, an enhancer from a virus may be used; examples include SV40 on the late side of the replication origin, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin and adenovirus enhancers.

The control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleic acid sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present invention.

The control sequence may also be a suitable leader sequence, a nontranslated region of an mRNA which is important for translation by the host cell. The leader sequence is operably linked to the 5' terminus of the nucleic acid sequence encoding the polypeptide. Any leader sequence that is functional in the host cell of choice may be used in the present invention.

The control sequence may also be a polyadenylation sequence, a sequence which is operably linked to the 3' terminus of the nucleic acid sequence and which, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence which is functional in the host cell of choice may be used in the present invention.

The control sequence may also be a signal peptide coding region, which codes for an amino acid sequence linked to the amino terminus of the polypeptide which can direct the encoded polypeptide into the cell's secretory pathway. The 5' end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region which encodes the secreted polypeptide. Alternatively, the 5' end of the coding sequence may contain a signal peptide coding region which is foreign to the coding sequence. The foreign signal peptide coding region may be required where the coding sequence does not normally contain a signal peptide coding region. Alternatively, the foreign signal

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

peptide coding region may simply replace the natural signal peptide coding region in order to obtain enhanced secretion of the polypeptide. However, any signal peptide coding region which directs the expressed polypeptide into the secretory pathway of a host cell of choice may be used in the present invention.

The control sequence may also be a propeptide coding region, which codes for an amino acid sequence positioned at the amino terminus of a polypeptide. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to a mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the *Bacillus subtilis* alkaline protease gene (*aprE*), the *Bacillus subtilis* neutral protease gene (*nprT*), the *Saccharomyces cerevisiae* alpha-factor gene, the *Rhizomucor miehei* aspartic proteinase gene, or the *Myceliophthora thermophila* laccase gene (WO 95/33836).

Where both signal peptide and propeptide regions are present at the amino terminus of a polypeptide, the propeptide region is positioned next to the amino terminus of a polypeptide and the signal peptide region is positioned next to the amino terminus of the propeptide region.

It may also be desirable to add regulatory sequences which allow the regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems would include the *lac*, *tac*, and *trp* operator systems. In yeast, the ADH2 system or GAL1 system may be used. In filamentous fungi, the TAKA alpha-amylase promoter, *Aspergillus niger* glucoamylase promoter, and the *Aspergillus oryzae* glucoamylase promoter may be used as regulatory sequences. Other examples of regulatory sequences are those which allow for gene amplification. In eukaryotic systems, these include the dihydrofolate reductase gene which is amplified in the presence of methotrexate, and the metallothionein genes which are amplified with heavy metals. In these cases, the nucleic acid sequence encoding the polypeptide would be operably linked with the regulatory sequence.

Expression Vectors

The present invention also relates to recombinant expression vectors comprising a nucleic acid sequence of the present invention, a promoter, and transcriptional and translational stop signals. The various nucleic acid and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the nucleic acid sequence encoding the polypeptide at such sites. Alternatively, the polynucleotide of the present invention may be expressed by inserting the nucleic acid sequence or a nucleic acid construct comprising the sequence into an appropriate vector for

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression.

The recombinant expression vector may be any vector (*e.g.*, a plasmid or virus) which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the nucleic acid sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids.

The vector may be an autonomously replicating vector, *i.e.*, a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, *e.g.*, a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. Furthermore, a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon may be used.

The vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. Examples of bacterial selectable markers are the *dal* genes from *Bacillus subtilis* or *Bacillus licheniformis*, or markers which confer antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracycline resistance. Suitable markers for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3. An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the nucleic acids of the present invention, such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al., Proc. Natl. Acad. Sci. USA, 77:4216 (1980).

The vectors of the present invention preferably contain an element(s) that permits stable integration of the vector into the host cell genome or autonomous replication of the vector in the cell independent of the genome of the cell.

For integration into the host cell genome, the vector may rely on the polynucleotide sequence encoding the polypeptide or any other element of the vector for stable integration of the vector into the genome by homologous or nonhomologous recombination. Alternatively, the vector may contain additional nucleic acid sequences for directing integration by homologous recombination into the genome of the host cell. The additional polynucleotide sequences enable the vector to be integrated into the host cell genome at a precise location(s) in the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should preferably contain a sufficient

number of nucleic acids, such as 100 to 1,500 base pairs, preferably 400 to 1,500 base pairs, and most preferably 800 to 1,500 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding nucleic acid sequences. On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination.

For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, and pACYC184 permitting replication in *E. coli*, and pUB110, pE194, pTA1060, and pAM ϕ 1 permitting replication in *Bacillus*. Examples of origins of replication for use in a yeast host cell are the 2 micron origin of replication, ARS1, ARS4, the combination of ARS1 and CEN3, and the combination of ARS4 and CEN6. The origin of replication may be one having a mutation which makes its functioning temperature-sensitive in the host cell (see, *e.g.*, Ehrlich, 1978, *Proceedings of the National Academy of Sciences USA* 75: 1433).

More than one copy of a polynucleotide sequence of the present invention may be inserted into the host cell to increase production of the gene product. An increase in the copy number of the polynucleotide sequence can be obtained by integrating at least one additional copy of the sequence into the host cell genome or by including an amplifiable selectable marker gene with the nucleic acid sequence where cells containing amplified copies of the selectable marker gene, and thereby additional copies of the nucleic acid sequence, can be selected for by cultivating the cells in the presence of the appropriate selectable agent.

The procedures used to ligate the elements described above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, *e.g.*, Sambrook *et al.*, 1989, *supra*).

Host Cells

The present invention also relates to recombinant host cells, comprising a nucleic acid sequence of the invention, which are advantageously used in the recombinant production of the polypeptides. A vector comprising a nucleic acid sequence of the present invention is introduced into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector as described earlier. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication. The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source.

The host cell may be a unicellular microorganism, *e.g.*, a prokaryote, or a non-unicellular microorganism, *e.g.*, a eukaryote. Useful unicellular cells are bacterial cells such as gram positive bacteria including, but not limited to, a *Bacillus* cell, or a *Streptomyces* cell, *e.g.*, *Streptomyces lividans* or *Streptomyces murinus*, or gram negative bacteria such as *E. coli* and *Pseudomonas* sp.

The introduction of a vector into a bacterial host cell may, for instance, be effected by protoplast transformation (see, *e.g.*, Chang and Cohen, 1979, *Molecular General Genetics* 168: 111-115), using competent cells (see, *e.g.*, Young and Spizizin, 1961, *Journal of Bacteriology* 81: 823-829, or Dubnau and Davidoff-Abelson, 1971, *Journal of Molecular Biology* 56: 209-221), electroporation (see, *e.g.*, Shigekawa and Dower, 1988, *Biotechniques* 6: 742-751), or conjugation (see, *e.g.*, Koehler and Thorne, 1987, *Journal of Bacteriology* 169: 5771-5278).

The host cell may be a eukaryote, such as a mammalian cell (*e.g.*, human cell), an insect cell, a plant cell or a fungal cell. Mammalian host cells that could be used include but are not limited to human Hela, embryonic kidney cells (293), lung cells, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese Hamster ovary (CHO) cells. These cells may be transfected with a vector containing a transcriptional regulatory sequence, a protein coding sequence and transcriptional termination sequences. Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The host cell may be a fungal cell. "Fungi" as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth *et al.*, *In, Ainsworth and Bisby's Dictionary of The Fungi*, 8th edition, 1995, CAB International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth *et al.*, 1995, *supra*, page 171) and all mitosporic fungi (Hawksworth *et al.*, 1995, *supra*). The fungal host cell may also be a yeast cell. "Yeast" as used herein includes ascosporogenous yeast (Endomycetales), basidiosporogenous yeast, and yeast belonging to the Fungi Imperfecti (Blastomycetes). Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as described in *Biology and Activities of Yeast* (Skinner, F.A., Passmore, S.M., and Davenport, R.R., eds, *Soc. App. Bacteriol. Symposium Series* No. 9, 1980). The fungal host cell may also be a filamentous fungal cell. "Filamentous fungi" include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth *et al.*, 1995, *supra*). The filamentous fungi are characterized by a mycelial wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as *Saccharomyces cerevisiae* is by budding of a unicellular thallus and carbon catabolism may be fermentative.

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known *per se*. Suitable procedures for transformation of *Aspergillus* host cells are described in EP 238 023 and Yelton *et al.*, 1984, *Proceedings of the National Academy of Sciences USA* 81: 1470-1474. Suitable methods for transforming *Fusarium* species are described by Malardier *et al.*, 1989, *Gene* 78: 147-156 and WO 96/00787. Yeast may be transformed using the procedures described by Becker and Guarente, *In* Abelson, J.N. and Simon, M.I., editors, *Guide to Yeast Genetics and Molecular Biology*, Methods in Enzymology, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito *et al.*, 1983, *Journal of Bacteriology* 153: 163; and Hinnen *et al.*, 1978, *Proc. e Natl Acad. f Sci.s USA* 75: 1920.

Methods of Production

The present invention also relates to methods for producing a polypeptide of the present invention comprising (a) cultivating a host cell under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide.

In the production methods of the present invention, the cells are cultivated in a nutrient medium suitable for production of the polypeptide using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (*e.g.*, in catalogues of the American Type Culture Collection). If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it can be recovered from cell lysates.

The polypeptides may be detected using methods known in the art that are specific for the polypeptides. These detection methods may include use of specific antibodies, formation of an enzyme product, or disappearance of an enzyme substrate. In a specific embodiment, an enzyme assay may be used to determine the activity of the polypeptide. For example, AEBP1 activity can be determined by measuring carboxypeptidase activity as described by Muise and Ro, 1999, *Biochem. J.* 343:341-345. Here, the conversion of hippuryl-L-arginine, hippuryl-L-lysine or hippuryl-L-phenylalanine to hippuric acid may be monitored spectrophotometrically. POLD2 activity may be detected by assaying for DNA polymerase γ activity (see, for example, Ng *et al.*, 1991, *J. Biol. Chem.* 266:11699-11704).

The resulting polypeptide may be recovered by methods known in the art. For example, the polypeptide may be recovered from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.

The polypeptides of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (*e.g.*, ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (*e.g.*, preparative isoelectric focusing, differential solubility (*e.g.*, ammonium sulfate precipitation), SDS-PAGE, or extraction (see, *e.g.*, *Protein Purification*, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).

Antibodies

According to the invention, the SNARE YKT6, human glucokinase, AEBP1 or POLD2 polypeptides produced according to the method of the present invention may be used as an immunogen to generate any of these polypeptides. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library.

Various procedures known in the art may be used for the production of antibodies. For the production of antibody, various host animals can be immunized by injection with the polypeptide thereof, including but not limited to rabbits, mice, rats, sheep, goats, etc. In one embodiment, the polypeptide or fragment thereof can optionally be conjugated to an immunogenic carrier, *e.g.*, bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*.

For preparation of monoclonal antibodies directed toward the SNARE YKT6, human glucokinase, AEBP1 or POLD2 polypeptide, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique originally developed by Kohler and Milstein (1975, *Nature* 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, *Immunology Today* 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals utilizing recent technology (PCT/US90/02545). According to the invention, human antibodies may be used and can be obtained by using human hybridomas (Cote et al., 1983, *Proc. Natl. Acad. Sci. U.S.A.* 80:2026-2030) or by transforming human B cells with EBV virus in vitro (Cole et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, pp. 77-96). In fact, according to the invention, techniques developed for the production of "chimeric antibodies"

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

(Morrison et al., 1984, J. Bacteriol. 159:870; Neuberger et al., 1984, Nature 312:604-608; Takeda et al., 1985, Nature 314:452-454) by splicing the genes from a mouse antibody molecule specific for the SNARE YKT6, human glucokinase, AEBP1 or POLD2 polypeptide together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention.

According to the invention, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778) can be adapted to produce polypeptide-specific single chain antibodies. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse et al., 1989, Science 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for the SNARE YKT6, AEBP1, human glucokinase or POLD2 polypeptides.

Antibody fragments which contain the idiotype of the antibody molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.

In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, e.g., radioimmunoassay, ELISA (enzyme-linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. For example, to select antibodies which recognize a specific epitope of a particular polypeptide, one may assay generated hybridomas for a product which binds to a particular polypeptide fragment containing such epitope. For selection of an antibody specific to a particular polypeptide from a particular species of animal, one can select on the basis of positive binding with the polypeptide expressed by or isolated from cells of that species of animal.

Immortal, antibody-producing cell lines can also be created by techniques other than fusion, such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., M. Schreier et al., "Hybridoma Techniques" (1980); Hammerling et al., "Monoclonal Antibodies And T-cell Hybridomas" (1981); Kennett et al., "Monoclonal Antibodies" (1980); see also

U.S. Pat. Nos. 4,341,761; 4,399,121; 4,427,783; 4,444,887; 4,451,570; 4,466,917; 4,472,500; 4,491,632; 4,493,890.

Uses of Polynucleotides

Diagnostics

Polynucleotides containing noncoding regions of SEQ ID NOS:5, 6, 7 or 8 may be used as probes for detecting mutations from samples from a patient. Genomic DNA may be isolated from the patient. A mutation(s) may be detected by Southern blot analysis, specifically by hybridizing restriction digested genomic DNA to various probes and subjecting to agarose electrophoresis.

Polynucleotides containing noncoding regions may be used as PCR primers and may be used to amplify the genomic DNA isolated from the patients. Additionally, primers may be obtained by routine or long range PCR, that can yield products containing more than one exon and intervening intron. The sequence of the amplified genomic DNA from the patient may be determined using methods known in the art. Such probes may be between 10-100 nucleotides in length and may preferably be between 20-50 nucleotides in length.

Thus the invention is thus directed to kits comprising these polynucleotide probes. In a specific embodiment, these probes are labeled with a detectable substance.

Antisense Oligonucleotides and Mimetics

The invention is further directed to antisense oligonucleotides and mimetics to these polynucleotide sequences. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription or RNA processing (triple helix (see Lee et al., Nucl. Acids Res., 6:3073 (1979); Cooney et al, Science, 241:456 (1988); and Dervan et al., Science, 251: 1360 (1991)), thereby preventing transcription and the production of said polypeptides.

The antisense oligonucleotides or mimetics of the present invention may be used to decrease levels of a polypeptide. For example, SNARE YKT6 has been found to be essential for vesicle-associated endoplasmic reticulum-Golgi transport and cell growth. Therefore, the SNARE YKT6 antisense oligonucleotides of the present invention could be used to inhibit cell growth and in particular, to treat or prevent tumor growth. POLD2 is necessary for DNA replication. POLD2 antisense sequences could also be used to inhibit cell growth. Glucokinase and AEBP1 antisense sequences may be used to treat hyperglycemia.

The antisense oligonucleotides of the present invention may be formulated into pharmaceutical compositions. These compositions may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

(including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention, the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC50 as found to be effective in in vitro and in vivo animal models.

In general, dosage is from 0.01 ug to 10 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 10 g per kg of body weight, once or more daily, to once every 20 years.

Gene Therapy

As noted above, SNARE YKT6 is necessary for cell growth, POLD2 is involved in DNA replication and repair, AEBP1 is involved in repressing adipogenesis and glucokinase is involved in glucose sensing in pancreatic islet beta cells and liver. Therefore, the SNARE YKT6 gene may be used to modulate or prevent cell apoptosis and treat such disorders as virus-induced lymphocyte depletion (AIDS); cell death in neurodegenerative disorders characterized by the gradual loss of specific sets of neurons (e.g., Alzheimer's Disease, Parkinson's disease, ALS, retinitis pigmentosa, spinal muscular atrophy and various forms of cerebellar degeneration), cell death in blood cell disorders resulting from deprivation of growth factors (anemia associated with chronic disease, aplastic anemia, chronic neutropenia and myelodysplastic syndromes) and disorders arising out of an acute loss of blood flow (e.g., myocardial infarctions and stroke). The glucokinase gene may be used to treat diabetes mellitus. The AEBP1 gene may be used to modulate or inhibit adipogenesis and treat obesity, diabetes mellitus and/or osteopenic disorders. POLD2 may be used to treat defects in DNA repair such as xeroderma pigmentosum, progeria and ataxia telangiectasia.

As described herein, the polynucleotide of the present invention may be introduced into a patient's cells for therapeutic uses. As will be discussed in further detail below, cells can be transfected using any appropriate means, including viral vectors, as shown by the example, chemical transfectants, or physico-mechanical methods such as electroporation and direct diffusion of DNA. See, for example,

Wolff, Jon A, et al., "Direct gene transfer into mouse muscle in vivo," *Science*, 247, 1465-1468, 1990; and Wolff, Jon A, "Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs," *Nature*, 352, 815-818, 1991. As used herein, vectors are agents that transport the gene into the cell without degradation and include a promoter yielding expression of the gene in the cells into which it is delivered. As will be discussed in further detail below, promoters can be general promoters, yielding expression in a variety of mammalian cells, or cell specific, or even nuclear versus cytoplasmic specific. These are known to those skilled in the art and can be constructed using standard molecular biology protocols. Vectors have been divided into two classes:

- a) Biological agents derived from viral, bacterial or other sources.
- b) Chemical physical methods that increase the potential for gene uptake, directly introduce the gene into the nucleus or target the gene to a cell receptor.

Biological Vectors

Viral vectors have higher transaction (ability to introduce genes) abilities than do most chemical or physical methods to introduce genes into cells. Vectors that may be used in the present invention include viruses, such as adenoviruses, adeno associated virus (AAV), vaccinia, herpesviruses, baculoviruses and retroviruses, bacteriophages, cosmid, plasmids, fungal vectors and other recombination vehicles typically used in the art which have been described for expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple protein expression. Polynucleotides are inserted into vector genomes using methods well known in the art.

Retroviral vectors are the vectors most commonly used in clinical trials, since they carry a larger genetic payload than other viral vectors. However, they are not useful in non-proliferating cells. Adenovirus vectors are relatively stable and easy to work with, have high titers, and can be delivered in aerosol formulation. Pox viral vectors are large and have several sites for inserting genes, they are thermostable and can be stored at room temperature.

Examples of promoters are SP6, T4, T7, SV40 early promoter, cytomegalovirus (CMV) promoter, mouse mammary tumor virus (MMTV) steroid-inducible promoter, Moloney murine leukemia virus (MMLV) promoter, phosphoglycerate kinase (PGK) promoter, and the like. Alternatively, the promoter may be an endogenous adenovirus promoter, for example the E1 a promoter or the Ad2 major late promoter (MLP). Similarly, those of ordinary skill in the art can construct adenoviral vectors utilizing endogenous or heterologous poly A addition signals.

Plasmids are not integrated into the genome and the vast majority of them are present only from a few weeks to several months, so they are typically very safe. However, they have lower expression levels than retroviruses and since cells have the ability to identify and eventually shut down foreign gene expression, the continuous release of DNA from the polymer to the target cells

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

substantially increases the duration of functional expression while maintaining the benefit of the safety associated with non-viral transfections.

Chemical/physical vectors

Other methods to directly introduce genes into cells or exploit receptors on the surface of cells include the use of liposomes and lipids, ligands for specific cell surface receptors, cell receptors, and calcium phosphate and other chemical mediators, microinjections directly to single cells, electroporation and homologous recombination. Liposomes are commercially available from Gibco BRL, for example, as LIPOFECTIN™ and LIPOFECTACE™, which are formed of cationic lipids such as N-[1-(2,3 dioleyloxy)-propyl]-n,n,n-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Numerous methods are also published for making liposomes, known to those skilled in the art.

For example, Nucleic acid-Lipid Complexes--Lipid carriers can be associated with naked nucleic acids (e.g., plasmid DNA) to facilitate passage through cellular membranes. Cationic, anionic, or neutral lipids can be used for this purpose. However, cationic lipids are preferred because they have been shown to associate better with DNA which, generally, has a negative charge. Cationic lipids have also been shown to mediate intracellular delivery of plasmid DNA (Felgner and Ringold, *Nature* 337:387 (1989)). Intravenous injection of cationic lipid-plasmid complexes into mice has been shown to result in expression of the DNA in lung (Brigham et al., *Am. J. Med. Sci.* 298:278 (1989)). See also, Osaka et al., *J. Pharm. Sci.* 85(6):612-618 (1996); San et al., *Human Gene Therapy* 4:781-788 (1993); Senior et al., *Biochimica et Biophysica Acta* 1070:173-179 (1991); Kabanov and Kabanov, *Bioconjugate Chem.* 6:7-20 (1995); Remy et al., *Bioconjugate Chem.* 5:647-654 (1994); Behr, J-P., *Bioconjugate Chem* 5:382-389 (1994); Behr et al., *Proc. Natl. Acad. Sci., USA* 86:6982-6986 (1989); and Wyman et al., *Biochem.* 36:3008-3017 (1997).

Cationic lipids are known to those of ordinary skill in the art. Representative cationic lipids include those disclosed, for example, in U.S. Pat. No. 5,283,185; and e.g., U.S. Pat. No. 5,767,099. In a preferred embodiment, the cationic lipid is N4 -spermine cholesteryl carbamate (GL-67) disclosed in U.S. Pat. No. 5,767,099. Additional preferred lipids include N4 -spermidine cholesteryl carbamate (GL-53) and 1-(N4 -spermind) -2,3-dilaurylglycerol carbamate (GL-89).

The vectors of the invention may be targeted to specific cells by linking a targeting molecule to the vector. A targeting molecule is any agent that is specific for a cell or tissue type of interest, including for example, a ligand, antibody, sugar, receptor, or other binding molecule.

Invention vectors may be delivered to the target cells in a suitable composition, either alone, or complexed, as provided above, comprising the vector and a suitably acceptable carrier. The vector may

SUBSTITUTE SPECIFICATION-MARKED UP VERSION

be delivered to target cells by methods known in the art, for example, intravenous, intramuscular, intranasal, subcutaneous, intubation, lavage, and the like. The vectors may be delivered via *in vivo* or *ex vivo* applications. *In vivo* applications involve the direct administration of an adenoviral vector of the invention formulated into a composition to the cells of an individual. *Ex vivo* applications involve the transfer of the adenoviral vector directly to harvested autologous cells which are maintained *in vitro*, followed by readministration of the transduced cells to a recipient.

In a specific embodiment, the vector is transfected into antigen-presenting cells. Suitable sources of antigen-presenting cells (APCs) include, but are not limited to, whole cells such as dendritic cells or macrophages; purified MHC class I molecule complexed to β 2-microglobulin and foster antigen-presenting cells. In a specific embodiment, the vectors of the present invention may be introduced into T cells or B cells using methods known in the art (see, for example, Tsokos and Nepom, 2000, J. Clin. Invest. 106:181-183).

The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed, since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

Various references are cited herein, the disclosure of which are incorporated by reference in their entireties.

WHAT IS CLAIMED IS:

1. (currently amended) An isolated genomic ~~polynucleotide~~nucleic acid molecule, said ~~polynucleotide~~nucleic acid molecule obtainable from human chromosome 7 having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a ~~polynucleotide~~nucleic acid molecule encoding a polypeptide selected from the group consisting of human SNARE YKT6 depicted in SEQ ID NO:1, human liver glucokinase depicted in SEQ ID NO:2, human adipocyte enhancer binding protein 1 depicted in SEQ ID NO:3 and DNA directed 50kD regulatory subunit (POLD2) depicted in SEQ ID NO:4 and variants thereof;

~~(c)~~a ~~polynucleotide~~nucleic acid molecule selected from the group consisting of SEQ ID NO:5 which encodes human SNARE YKT6 depicted in SEQ ID NO:1, SEQ ID NO:6 which encodes human liver glucokinase depicted in SEQ ID NO:2, SEQ ID NO:8 which encodes human adipocyte enhancer binding protein 1 depicted in SEQ ID NO:3 and SEQ ID NO:7 which encodes DNA directed 50kD regulatory subunit (POLD2) depicted in SEQ ID NO:4 and variants thereof;

(c) a nucleic acid molecule extending from the 5'-end of SEQ ID NO:5 to the 3'-end of SEQ ID NO:8 that comprises the contiguous coding sequences for SNARE YKT6, glucokinase, POLD2 and the adipocyte enhancer binding protein 1;

~~(c)~~——a ~~polynucleotide~~ which is a variant of SEQ ID NOS:5, 6, 7, or 8;

——~~(d)~~——a ~~polynucleotide~~ which is an allelic variant of SEQ ID NOS:5, 6, 7, or 8;

——~~(e)~~——a ~~polynucleotide~~ which encodes a variant of SEQ ID NOS:1, 2, 3, or 4;

~~(fd)~~ a ~~polynucleotide~~nucleic acid molecule which hybridizes to any one of the polynucleotides specified in (a)-~~(ec)~~

~~(e)~~ a ~~polynucleotide~~nucleic acid molecule which is a reverse complement of the polynucleotides specified in (a)-~~(fc)~~;

2. (currently amended) A nucleic acid construct comprising the ~~polynucleotide~~nucleic acid molecule of claim 1.

3. (currently amended) An expression vector comprising the ~~polynucleotide~~nucleic acid molecule of claim 1.

4. (original) A recombinant host cell comprising the nucleic acid ~~construct~~molecule of claim 12.

Claim 5 (cancelled)

6. (currently amended) A method for obtaining a polypeptide encoded by a ~~polynucleotide~~ nucleic acid molecule obtainable from human chromosome 7, said polypeptide selected from the group consisting of human SNARE YKT6, human liver glucokinase, human adipocyte enhancer binding protein 1 and DNA directed 50kD regulatory subunit (POLD2) comprising:

(a) culturing the recombinant host cell of claim ~~54~~ under conditions that provide for the expression of said polypeptide and

(b) recovering said expressed polypeptide.

7. (currently amended) A method for preparing an antibody specific to a polypeptide selected from the group consisting of human SNARE YKT6, human liver glucokinase, human adipocyte enhancer binding protein 1 and DNA directed 50kD regulatory subunit (POLD2) comprising:

(a) obtaining a polypeptide according to the method of claim 6;

(b) optionally conjugating said polypeptide to a carrier protein;

(c) immunizing a host animal with said polypeptide or polypeptide-carrier protein conjugate of step (b) with an adjuvant and

(d) obtaining antibody from said immunized host animal.

8. (currently amended) An ~~antisense oligonucleotide or mimetic to an isolated polynucleotide~~ isolated nucleic acid molecule of at least 15 nucleotides or mimetic which hybridizes at high stringency to a non-coding region of ~~specific to SEQ ID NOS:5, 6, 7 or 8~~ the nucleic acid molecule of claim 1, which non-coding region is selected from the group consisting of an intron, a splice junction, a 5' non-coding region, a transcription factor binding region, an expression control region and a 3' non-coding region.

9. (currently amended) A method of diagnosing a pathological condition or susceptibility to a pathological condition in a subject comprising:

~~— (a) determining the presence or absence of a mutation in the polynucleotide of claim 1 and~~

~~— (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation~~

- (a) isolating genomic DNA from a subject;
- (b) determining the presence or absence of a variant in said genomic DNA using the nucleic acid molecule of claim 8 and
- (c) -diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said variant.

10. (currently amended) A composition comprising the ~~polynucleotide~~nucleic acid molecule of claim 1 and a carrier.

11. (currently amended) A composition comprising the ~~antisense oligonucleotide~~nucleic acid molecule of claim 8 and a carrier.

12. (original) A method for preventing, treating or ameliorating a medical condition, comprising administering to a subject an amount of the composition of claim 10 effective to prevent, treat or ameliorate said medical condition.

13. (original) A method for preventing, treating or ameliorating a medical condition, comprising administering to a subject an amount of the composition of claim 11 effective to prevent, treat or ameliorate said medical condition.

14. (currently amended) A kit comprising the ~~polynucleotide~~nucleic acid molecule of claim ~~18~~.

15. (original) The kit according to claim 14, in which the polynucleotide is labeled with a detectable substance.

16. (currently amended) ~~A kit comprising the antisense oligonucleotide or mimetic of claim 8.~~The kit according to claim 14, which comprises a plurality of nucleic acid molecules.

Claims 17-22 are cancelled.

23. (new) A method for modulating levels of human SNARE YKT6, human glucokinase, human adipocyte enhancer binding protein 1 or DNA directed 50kD regulatory subunit (POLD2) in a subject in need thereof comprising administering to said subject an amount of the nucleic acid molecule of claim 1 effective to modulate said human SNARE YKT6, human glucokinase, human adipocyte enhancer binding protein 1 or DNA directed 50kD regulatory subunit (POLD2) levels.

24. (new) A method for modulating levels of human SNARE YKT6, human glucokinase, human adipocyte enhancer binding protein 1 or DNA directed 50kD regulatory subunit (POLD2) in a subject in need thereof comprising administering to said subject an amount of the nucleic acid molecule of claim 8 effective to modulate said human SNARE YKT6, human glucokinase, human adipocyte enhancer binding protein 1 or DNA directed 50kD regulatory subunit (POLD2) levels.

25. (new) A method of identifying variants of SEQ ID NOS: 5, 6, 7 or 8 comprising
(a) isolating genomic DNA from a subject and
(b) determining the presence or absence of a variant in said genomic DNA using the nucleic acid molecule of claim 8.

26. (new) A method for detecting the presence or absence of a non-coding nucleic acid sequence specific to the nucleic acid molecule of claim 1 in a sample, said method comprising contacting the sample with a nucleic acid molecule of at least 15 nucleotides which hybridizes at high stringency to a non-coding region specific to the nucleic acid molecule of claim 1, which non-coding region is selected from the group consisting of an intron, a splice junction, a 5' non-coding region, a transcription factor binding region, an expression control region and a 3' non-coding region.

ABSTRACT

The invention is directed to isolated genomic polynucleotide fragments that encode human SNARE YKT6, human ~~liver~~-glucokinase, human adipocyte enhancer binding protein (AEBP1) and DNA directed 50kD regulatory subunit (POLD2), vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain SNARE YKT6, human ~~liver~~-glucokinase, AEBP1 protein and POLD2 and to diagnose, treat, prevent and/or ameliorate a pathological disorder.